Sign In

Login

Password

Forgot Password ? Sign Up

Rak jelita grubego (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rak jelita grubego" in Polish language version.

refsWebsite
Global rank Polish rank
468nih.gov
4th place
7th place
347doi.org
2nd place
6th place
31google.pl
low place
557th place
11web.archive.org
1st place
1st place
8ascopubs.org
low place
8,458th place
5wiley.com
222nd place
228th place
3nejm.org
2,374th place
2,071st place
3czytelniamedyczna.pl
low place
1,047th place
3researchgate.net
120th place
180th place
3aacrjournals.org
8,869th place
9,541st place
2zalecenia.med.pl
low place
low place
2termedia.pl
low place
624th place
2mp.pl
8,738th place
165th place
2iiarjournals.org
low place
low place
2oup.com
485th place
620th place
1wcrf.org
low place
low place
1archive.is
87th place
5th place
1mayoclinic.org
1,610th place
4,301st place
1phie.pl
low place
2,260th place
1who.int
195th place
256th place
1onkologia.org.pl
low place
8,813th place
1viamedica.pl
low place
585th place
1pharmacopola.pl
low place
763rd place
1asge.org
low place
low place
1esge.com
low place
low place
1nature.com
234th place
204th place
1biomedcentral.com
2,747th place
1,537th place
1keepeek.com
low place
low place
1cancer.org
3,680th place
6,345th place
1indexcopernicus.com
low place
9,781st place
1cancernetwork.com
low place
low place
1sciencedirect.com
149th place
235th place
1springer.com
274th place
376th place
1vetpol.org.pl
low place
3,193rd place

aacrjournals.org

cancerres.aacrjournals.org

clincancerres.aacrjournals.org

archive.is

ascopubs.org

ascopubs.org

jco.ascopubs.org

asge.org

biomedcentral.com

cancer.org

cancernetwork.com

czytelniamedyczna.pl

doi.org

  • J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser i inni. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. „Int J Cancer”. 136 (5), s. E359-86, marzec 2015. DOI: 10.1002/ijc.29210. PMID: 25220842. 
  • S.R. Majumdar, R.H. Fletcher, A.T. Evans. How does colorectal cancer present? Symptoms, duration, and clues to location. „Am J Gastroenterol”. 94 (10), s. 3039–3045, październik 1999. DOI: 10.1111/j.1572-0241.1999.01454.x. PMID: 10520866. 
  • C.M. Johnson, C. Wei, J.E. Ensor, D.J. Smolenski i inni. Meta-analyses of colorectal cancer risk factors. „Cancer Causes Control”. 24 (6), s. 1207–1222, czerwiec 2013. DOI: 10.1007/s10552-013-0201-5. PMID: 23563998. 
  • F.A. Haggar, R.P. Boushey. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. „Clin Colon Rectal Surg”. 22 (4), s. 191–197, listopad 2009. DOI: 10.1055/s-0029-1242458. PMID: 21037809. 
  • M. Pericleous, D. Mandair, M.E. Caplin. Diet and supplements and their impact on colorectal cancer. „J Gastrointest Oncol”. 4 (4), s. 409–423, grudzień 2013. DOI: 10.3978/j.issn.2078-6891.2013.003. PMID: 24294513. 
  • D.D. Alexander, A.J. Miller, C.A. Cushing, K.A. Lowe. Processed meat and colorectal cancer: a quantitative review of prospective epidemiologic studies. „Eur J Cancer Prev”. 19 (5), s. 328–341, wrzesień 2010. DOI: 10.1097/CEJ.0b013e32833b48fa. PMID: 20495462. 
  • D.D. Alexander, C.A. Cushing. Red meat and colorectal cancer: a critical summary of prospective epidemiologic studies. „Obes Rev”. 12 (5), s. e472–e493, maj 2011. DOI: 10.1111/j.1467-789X.2010.00785.x. PMID: 20663065. 
  • W.C. Willett, M.J. Stampfer, G.A. Colditz, B.A. Rosner i inni. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. „N Engl J Med”. 323 (24), s. 1664–1672, grudzień 1990. DOI: 10.1056/NEJM199012133232404. PMID: 2172820. 
  • T.T. Fung, F.B. Hu, K. Wu, S.E. Chiuve i inni. The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer. „Am J Clin Nutr”. 92 (6), s. 1429–1435, grudzień 2010. DOI: 10.3945/ajcn.2010.29242. PMID: 21097651. 
  • D.D. Alexander, C.A. Cushing, K.A. Lowe, B. Sceurman i inni. Meta-analysis of animal fat or animal protein intake and colorectal cancer. „Am J Clin Nutr”. 89 (5), s. 1402–1409, maj 2009. DOI: 10.3945/ajcn.2008.26838. PMID: 19261724. 
  • S. Sasazuki, M. Inoue, M. Iwasaki, N. Sawada i inni. Intake of n-3 and n-6 polyunsaturated fatty acids and development of colorectal cancer by subsite: Japan Public Health Center-based prospective study. „Int J Cancer”. 129 (7), s. 1718–1729, październik 2011. DOI: 10.1002/ijc.25802. PMID: 21120874. 
  • Y. Kimura, S. Kono, K. Toyomura, J. Nagano i inni. Meat, fish and fat intake in relation to subsite-specific risk of colorectal cancer: The Fukuoka Colorectal Cancer Study. „Cancer Sci”. 98 (4), s. 590–597, kwiecień 2007. DOI: 10.1111/j.1349-7006.2007.00425.x. PMID: 17425596. 
  • E. Theodoratou, G. McNeill, R. Cetnarskyj, S.M. Farrington i inni. Dietary fatty acids and colorectal cancer: a case-control study. „Am J Epidemiol”. 166 (2), s. 181–195, lipiec 2007. DOI: 10.1093/aje/kwm063. PMID: 17493949. 
  • S. Kim, D.P. Sandler, J. Galanko, C. Martin i inni. Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. „Am J Epidemiol”. 171 (9), s. 969–979, maj 2010. DOI: 10.1093/aje/kwq032. PMID: 20392864. 
  • S. Wu, B. Feng, K. Li, X. Zhu i inni. Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. „Am J Med”. 125 (6), s. 551–559.e5, czerwiec 2012. DOI: 10.1016/j.amjmed.2012.01.022. PMID: 22513196. 
  • C.R. Daniel, M.L. McCullough, R.C. Patel, E.J. Jacobs i inni. Dietary intake of omega-6 and omega-3 fatty acids and risk of colorectal cancer in a prospective cohort of U.S. men and women. „Cancer Epidemiol Biomarkers Prev”. 18 (2), s. 516–525, luty 2009. DOI: 10.1158/1055-9965.EPI-08-0750. PMID: 19190143. 
  • X.J. Shen, J.D. Zhou, J.Y. Dong, W.Q. Ding i inni. Dietary intake of n-3 fatty acids and colorectal cancer risk: a meta-analysis of data from 489 000 individuals. „Br J Nutr”. 108 (9), s. 1550–1556, listopad 2012. DOI: 10.1017/S0007114512003546. PMID: 22906228. 
  • C.H. MacLean, S.J. Newberry, W.A. Mojica, P. Khanna i inni. Effects of omega-3 fatty acids on cancer risk: a systematic review. „JAMA”. 295 (4), s. 403–415, styczeń 2006. DOI: 10.1001/jama.295.4.403. PMID: 16434631. 
  • F.J. van Duijnhoven, H.B. Bueno-De-Mesquita, P. Ferrari, M. Jenab i inni. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. „Am J Clin Nutr”. 89 (5), s. 1441–1452, maj 2009. DOI: 10.3945/ajcn.2008.27120. PMID: 19339391. 
  • K.B. Michels, E. Giovannucci, A.T. Chan, R. Singhania i inni. Fruit and vegetable consumption and colorectal adenomas in the Nurses’ Health Study. „Cancer Res”. 66 (7), s. 3942–3953, kwiecień 2006. DOI: 10.1158/0008-5472.CAN-05-3637. PMID: 16585224. 
  • D.S. Alberts, M.E. Martínez, D.J. Roe, J.M. Guillén-Rodríguez i inni. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. „N Engl J Med”. 342 (16), s. 1156–1162, kwiecień 2000. DOI: 10.1056/NEJM200004203421602. PMID: 10770980. 
  • Y. Park, D.J. Hunter, D. Spiegelman, L. Bergkvist i inni. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. „JAMA”. 294 (22), s. 2849–2857, grudzień 2005. DOI: 10.1001/jama.294.22.2849. PMID: 16352792. 
  • I. Kato, A. Akhmedkhanov, K. Koenig, P.G. Toniolo i inni. Prospective study of diet and female colorectal cancer: the New York University Women’s Health Study. „Nutr Cancer”. 28 (3), s. 276–281, 1997. DOI: 10.1080/01635589709514588. PMID: 9343837. 
  • E.D. Gorham, C.F. Garland, F.C. Garland, W.B. Grant i inni. Vitamin D and prevention of colorectal cancer. „J Steroid Biochem Mol Biol”. 97 (1–2), s. 179–194, październik 2005. DOI: 10.1016/j.jsbmb.2005.06.018. PMID: 16236494. 
  • J. Wactawski-Wende, J.M. Kotchen, G.L. Anderson, A.R. Assaf i inni. Calcium plus vitamin D supplementation and the risk of colorectal cancer. „N Engl J Med”. 354 (7), s. 684–696, luty 2006. DOI: 10.1056/NEJMoa055222. PMID: 16481636. 
  • A.A. Moghaddam, M. Woodward, R. Huxley. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. „Cancer Epidemiol Biomarkers Prev”. 16 (12), s. 2533–2547, grudzień 2007. DOI: 10.1158/1055-9965.EPI-07-0708. PMID: 18086756. 
  • L.C. Thygesen, M. Grønbaek, C. Johansen, C.S. Fuchs i inni. Prospective weight change and colon cancer risk in male US health professionals. „Int J Cancer”. 123 (5), s. 1160–1165, wrzesień 2008. DOI: 10.1002/ijc.23612. PMID: 18546286. 
  • N. Khan, F. Afaq, H. Mukhtar. Lifestyle as risk factor for cancer: Evidence from human studies. „Cancer Lett”. 293 (2), s. 133–143, lipiec 2010. DOI: 10.1016/j.canlet.2009.12.013. PMID: 20080335. 
  • Y. Kim, Y. Kim, S. Lee. An association between colonic adenoma and abdominal obesity: a cross-sectional study. „BMC Gastroenterol”. 9, s. 4, 2009. DOI: 10.1186/1471-230X-9-4. PMID: 19144203. 
  • S.C. Larsson, N. Orsini, A. Wolk. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. „J Natl Cancer Inst”. 97 (22), s. 1679–1687, listopad 2005. DOI: 10.1093/jnci/dji375. PMID: 16288121. 
  • L. Deng, Z. Gui, L. Zhao, J. Wang i inni. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. „Dig Dis Sci”. 57 (6), s. 1576–1585, czerwiec 2012. DOI: 10.1007/s10620-012-2055-1. PMID: 22350783. 
  • H. Yuhara, C. Steinmaus, S.E. Cohen, D.A. Corley i inni. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. „Am J Gastroenterol”. 106 (11), s. 1911–1921; quiz 1922, listopad 2011. DOI: 10.1038/ajg.2011.301. PMID: 21912438. 
  • S. Jarvandi, N.O. Davidson, M. Schootman. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. „PLoS One”. 8 (9), s. e74616, 2013. DOI: 10.1371/journal.pone.0074616. PMID: 24069323. 
  • J.M. Berster, B. Göke. Type 2 diabetes mellitus as risk factor for colorectal cancer. „Arch Physiol Biochem”. 114 (1), s. 84–98, luty 2008. DOI: 10.1080/13813450802008455. PMID: 18465362. 
  • K.T. Mills, C.F. Bellows, A.E. Hoffman, T.N. Kelly i inni. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. „Dis Colon Rectum”. 56 (11), s. 1304–1319, listopad 2013. DOI: 10.1097/DCR.0b013e3182a479f9. PMID: 24105007. 
  • Y. Mao, S. Pan, S.W. Wen, K.C. Johnson. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. „Int J Cancer”. 105 (6), s. 831–837, lipiec 2003. DOI: 10.1002/ijc.11159. PMID: 12767070. 
  • T.I. Nilsen, L.J. Vatten. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. „Br J Cancer”. 84 (3), s. 417–422, luty 2001. DOI: 10.1054/bjoc.2000.1582. PMID: 11161410. 
  • K.J. Lee, M. Inoue, T. Otani, M. Iwasaki i inni. Physical activity and risk of colorectal cancer in Japanese men and women: the Japan Public Health Center-based prospective study. „Cancer Causes Control”. 18 (2), s. 199–209, marzec 2007. DOI: 10.1007/s10552-006-0098-3. PMID: 17206529. 
  • A.L. Zisman, A. Nickolov, R.E. Brand, A. Gorchow i inni. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. „Arch Intern Med”. 166 (6), s. 629–634, marzec 2006. DOI: 10.1001/archinte.166.6.629. PMID: 16567601. 
  • E. Botteri, S. Iodice, V. Bagnardi, S. Raimondi i inni. Smoking and colorectal cancer: a meta-analysis. „JAMA”. 300 (23), s. 2765–2778, grudzień 2008. DOI: 10.1001/jama.2008.839. PMID: 19088354. 
  • P.S. Liang, T.Y. Chen, E. Giovannucci. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. „Int J Cancer”. 124 (10), s. 2406–2415, maj 2009. DOI: 10.1002/ijc.24191. PMID: 19142968. 
  • M. Lüchtenborg, K.K. White, L. Wilkens, L.N. Kolonel i inni. Smoking and colorectal cancer: different effects by type of cigarettes?. „Cancer Epidemiol Biomarkers Prev”. 16 (7), s. 1341–1347, lipiec 2007. DOI: 10.1158/1055-9965.EPI-06-0519. PMID: 17626999. 
  • E. Botteri, S. Iodice, S. Raimondi, P. Maisonneuve i inni. Cigarette smoking and adenomatous polyps: a meta-analysis. „Gastroenterology”. 134 (2), s. 388–395, luty 2008. DOI: 10.1053/j.gastro.2007.11.007. PMID: 18242207. 
  • L.M. Hannan, E.J. Jacobs, M.J. Thun. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. „Cancer Epidemiol Biomarkers Prev”. 18 (12), s. 3362–3367, grudzień 2009. DOI: 10.1158/1055-9965.EPI-09-0661. PMID: 19959683. 
  • E.R. Kim, D.K. Chang. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. „World J Gastroenterol”. 20 (29), s. 9872–9881, sierpień 2014. DOI: 10.3748/wjg.v20.i29.9872. PMID: 25110418. 
  • L. Lakatos, G. Mester, Z. Erdelyi, G. David i inni. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. „Inflamm Bowel Dis”. 12 (3), s. 205–211, marzec 2006. DOI: 10.1097/01.MIB.0000217770.21261.ce. PMID: 16534422. 
  • C. Canavan, K.R. Abrams, J. Mayberry. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. „Aliment Pharmacol Ther”. 23 (8), s. 1097–1104, kwiecień 2006. DOI: 10.1111/j.1365-2036.2006.02854.x. PMID: 16611269. 
  • A. Ekbom, C. Helmick, M. Zack, H.O. Adami. Ulcerative colitis and colorectal cancer. A population-based study. „N Engl J Med”. 323 (18), s. 1228–1233, listopad 1990. DOI: 10.1056/NEJM199011013231802. PMID: 2215606. 
  • J. Potack, S.H. Itzkowitz. Colorectal cancer in inflammatory bowel disease. „Gut Liver”. 2 (2), s. 61–73, wrzesień 2008. DOI: 10.5009/gnl.2008.2.2.61. PMID: 20485613. 
  • P. Ferrari, M. Jenab, T. Norat, A. Moskal i inni. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). „Int J Cancer”. 121 (9), s. 2065–2072, listopad 2007. DOI: 10.1002/ijc.22966. PMID: 17640039. 
  • T. Mizoue, M. Inoue, K. Wakai, C. Nagata i inni. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. „Am J Epidemiol”. 167 (12), s. 1397–1406, czerwiec 2008. DOI: 10.1093/aje/kwn073. PMID: 18420544. 
  • B. Delhougne, C. Deneux, R. Abs, P. Chanson i inni. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. „J Clin Endocrinol Metab”. 80 (11), s. 3223–3226, listopad 1995. DOI: 10.1210/jcem.80.11.7593429. PMID: 7593429. 
  • A.G. Renehan, J. O’Connell, D. O’Halloran, F. Shanahan i inni. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. „Horm Metab Res”. 35 (11–12). s. 712–725. DOI: 10.1055/s-2004-814150. PMID: 14710350. 
  • F. Kastrinos, S. Syngal. Inherited colorectal cancer syndromes. „Cancer J”. 17 (6). s. 405–415. DOI: 10.1097/PPO.0b013e318237e408. PMID: 22157284. 
  • E.M. Stoffel, F. Kastrinos. Familial colorectal cancer, beyond Lynch syndrome. „Clin Gastroenterol Hepatol”. 12 (7), s. 1059–1068, lipiec 2014. DOI: 10.1016/j.cgh.2013.08.015. PMID: 23962553. 
  • J.M. Carethers, E.M. Stoffel. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. „World J Gastroenterol”. 21 (31), s. 9253–9261, sierpień 2015. DOI: 10.3748/wjg.v21.i31.9253. PMID: 26309352. 
  • K.E. Resnick, H. Hampel, R. Fishel, D.E. Cohn. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. „Gynecol Oncol”. 114 (1), s. 128–134, lipiec 2009. DOI: 10.1016/j.ygyno.2009.03.003. PMID: 19375789. 
  • A. de la Chapelle. The incidence of Lynch syndrome. „Fam Cancer”. 4 (3), s. 233–237, 2005. DOI: 10.1007/s10689-004-5811-3. PMID: 16136383. 
  • H. Hampel, W.L. Frankel, E. Martin, M. Arnold i inni. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). „N Engl J Med”. 352 (18), s. 1851–1860, maj 2005. DOI: 10.1056/NEJMoa043146. PMID: 15872200. 
  • V. Steinke, C. Engel, R. Büttner, H.K. Schackert i inni. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. „Dtsch Arztebl Int”. 110 (3), s. 32–38, styczeń 2013. DOI: 10.3238/arztebl.2013.0032. PMID: 23413378. 
  • G.L. Baiocchi, N. Portolani, W. Vermi, C. Baronchelli i inni. Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. „BMC Surg”. 14, s. 9, 2014. DOI: 10.1186/1471-2482-14-9. PMID: 24533633. 
  • J. Balmaña, F. Balaguer, A. Cervantes, D. Arnold. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. „Ann Oncol”. 24 Suppl 6, s. vi73-80, październik 2013. DOI: 10.1093/annonc/mdt209. PMID: 23813931. 
  • S. Shiovitz, W.K. Copeland, M.N. Passarelli, A.N. Burnett-Hartman i inni. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. „Br J Cancer”. 111 (3), s. 598–602, lipiec 2014. DOI: 10.1038/bjc.2014.309. PMID: 24918813. 
  • F.G. Campos, M. Sulbaran, A.V. Safatle-Ribeiro, C.A. Martinez. Duodenal adenoma surveillance in patients with familial adenomatous polyposis. „World J Gastrointest Endosc”. 7 (10), s. 950–959, sierpień 2015. DOI: 10.4253/wjge.v7.i10.950. PMID: 26265988. 
  • M.L. Leoz, S. Carballal, L. Moreira, T. Ocaña i inni. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. „Appl Clin Genet”. 8, s. 95–107, 2015. DOI: 10.2147/TACG.S51484. PMID: 25931827. 
  • A.M. Jelsig, N. Qvist, K. Brusgaard, C.B. Nielsen i inni. Hamartomatous polyposis syndromes: a review. „Orphanet J Rare Dis”. 9, s. 101, 2014. DOI: 10.1186/1750-1172-9-101. PMID: 25022750. 
  • N. Hearle, V. Schumacher, F.H. Menko, S. Olschwang i inni. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. „Clin Cancer Res”. 12 (10), s. 3209–3215, maj 2006. DOI: 10.1158/1078-0432.CCR-06-0083. PMID: 16707622. 
  • F.G. Campos, M.N. Figueiredo, C.A. Martinez. Colorectal cancer risk in hamartomatous polyposis syndromes. „World J Gastrointest Surg”. 7 (3), s. 25–32, marzec 2015. DOI: 10.4240/wjgs.v7.i3.25. PMID: 25848489. 
  • E. Chow, F. Macrae. A review of juvenile polyposis syndrome. „J Gastroenterol Hepatol”. 20 (11), s. 1634–1640, listopad 2005. DOI: 10.1111/j.1440-1746.2005.03865.x. PMID: 16246179. 
  • N. Mishra, J. Hall. Identification of patients at risk for hereditary colorectal cancer. „Clin Colon Rectal Surg”. 25 (2), s. 67–82, czerwiec 2012. DOI: 10.1055/s-0032-1313777. PMID: 23730221. 
  • M.L. Poulsen, M.L. Bisgaard. MUTYH Associated Polyposis (MAP). „Curr Genomics”. 9 (6), s. 420–435, wrzesień 2008. DOI: 10.2174/138920208785699562. PMID: 19506731. 
  • A.T. Chan, E.L. Giovannucci. Primary prevention of colorectal cancer. „Gastroenterology”. 138 (6), s. 2029–2043.e10, czerwiec 2010. DOI: 10.1053/j.gastro.2010.01.057. PMID: 20420944. 
  • P.J. Tárraga López, J.S. Albero, J.A. Rodríguez-Montes. Primary and secondary prevention of colorectal cancer. „Clin Med Insights Gastroenterol”. 7, s. 33–46, 2014. DOI: 10.4137/CGast.S14039. PMID: 25093007. 
  • S.J. Winawer, A.G. Zauber, M.J. O’Brien, M.N. Ho i inni. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. „N Engl J Med”. 328 (13), s. 901–906, kwiecień 1993. DOI: 10.1056/NEJM199304013281301. PMID: 8446136. 
  • G.P. Young, E.L. Symonds, J.E. Allison, S.R. Cole i inni. Advances in Fecal Occult Blood Tests: the FIT revolution. „Dig Dis Sci”. 60 (3), s. 609–622, marzec 2015. DOI: 10.1007/s10620-014-3445-3. PMID: 25492500. 
  • P. Hewitson, P. Glasziou, L. Irwig, B. Towler i inni. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. „Cochrane Database Syst Rev”, s. CD001216, 2007. DOI: 10.1002/14651858.CD001216.pub2. PMID: 17253456. 
  • F. Stracci, M. Zorzi, G. Grazzini. Colorectal cancer screening: tests, strategies, and perspectives. „Front Public Health”. 2, s. 210, 2014. DOI: 10.3389/fpubh.2014.00210. PMID: 25386553. 
  • E. Flossmann, P.M. Rothwell. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. „Lancet”. 369 (9573), s. 1603–1613, maj 2007. DOI: 10.1016/S0140-6736(07)60747-8. PMID: 17499602. 
  • T.K. Asano, R.S. McLeod. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. „Cochrane Database Syst Rev”, s. CD004079, 2004. DOI: 10.1002/14651858.CD004079.pub2. PMID: 15106236. 
  • A.T. Chan, E.L. Giovannucci, J.A. Meyerhardt, E.S. Schernhammer i inni. Aspirin dose and duration of use and risk of colorectal cancer in men. „Gastroenterology”. 134 (1), s. 21–28, styczeń 2008. DOI: 10.1053/j.gastro.2007.09.035. PMID: 18005960. 
  • N. Arber, C.J. Eagle, J. Spicak, I. Rácz i inni. Celecoxib for the prevention of colorectal adenomatous polyps. „N Engl J Med”. 355 (9), s. 885–895, sierpień 2006. DOI: 10.1056/NEJMoa061652. PMID: 16943401. 
  • M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston i inni. Celecoxib for the prevention of sporadic colorectal adenomas. „N Engl J Med”. 355 (9), s. 873–884, sierpień 2006. DOI: 10.1056/NEJMoa061355. PMID: 16943400. 
  • J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan i inni. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. „Gastroenterology”. 131 (6), s. 1674–1682, grudzień 2006. DOI: 10.1053/j.gastro.2006.08.079. PMID: 17087947. 
  • S.D. Solomon, M.A. Pfeffer, J.J. McMurray, R. Fowler i inni. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. „Circulation”. 114 (10), s. 1028–1035, wrzesień 2006. DOI: 10.1161/CIRCULATIONAHA.106.636746. PMID: 16943394. 
  • R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese i inni. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. „N Engl J Med”. 352 (11), s. 1092–1102, marzec 2005. DOI: 10.1056/NEJMoa050493. PMID: 15713943. 
  • F.M. Giardiello, S.R. Hamilton, A.J. Krush, S. Piantadosi i inni. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. „N Engl J Med”. 328 (18), s. 1313–1316, maj 1993. DOI: 10.1056/NEJM199305063281805. PMID: 8385741. 
  • S. Bonovas, K. Filioussi, C.S. Flordellis, N.M. Sitaras. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. „J Clin Oncol”. 25 (23), s. 3462–3468, sierpień 2007. DOI: 10.1200/JCO.2007.10.8936. PMID: 17687150. 
  • S. Liu, R. Zheng, M. Zhang, S. Zhang i inni. Incidence and mortality of colorectal cancer in China, 2011. „Chin J Cancer Res”. 27 (1), s. 22–28, luty 2015. DOI: 10.3978/j.issn.1000-9604.2015.02.01. PMID: 25717222. 
  • J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso i inni. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. „Eur J Cancer”. 49 (6), s. 1374–1403, kwiecień 2013. DOI: 10.1016/j.ejca.2012.12.027. PMID: 23485231. 
  • R. Siegel, C. Desantis, A. Jemal. Colorectal cancer statistics, 2014. „CA Cancer J Clin”. 64 (2). s. 104–117. DOI: 10.3322/caac.21220. PMID: 24639052. 
  • F. Amersi, M. Agustin, C.Y. Ko. Colorectal cancer: epidemiology, risk factors, and health services. „Clin Colon Rectal Surg”. 18 (3), s. 133–140, sierpień 2005. DOI: 10.1055/s-2005-916274. PMID: 20011296. 
  • G. Murphy, S.S. Devesa, A.J. Cross, P.D. Inskip i inni. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. „Int J Cancer”. 128 (7), s. 1668–1675, kwiecień 2011. DOI: 10.1002/ijc.25481. PMID: 20503269. 
  • R.J. Wong. Marked variations in proximal colon cancer survival by race/ethnicity within the United States. „J Clin Gastroenterol”. 44 (9), s. 625–630, październik 2010. DOI: 10.1097/MCG.0b013e3181c64a7a. PMID: 19996985. 
  • M. Fleming, S. Ravula, S.F. Tatishchev, H.L. Wang. Colorectal carcinoma: Pathologic aspects. „J Gastrointest Oncol”. 3 (3), s. 153–173, wrzesień 2012. DOI: 10.3978/j.issn.2078-6891.2012.030. PMID: 22943008. 
  • L. Cheng, C. Eng, L.Z. Nieman, A.S. Kapadia i inni. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. „Am J Clin Oncol”. 34 (6), s. 573–580, grudzień 2011. DOI: 10.1097/COC.0b013e3181fe41ed. PMID: 21217399. 
  • N. Savas, U. Dagli, S. Akbulut, O. Yuksel i inni. Colorectal cancer localization in young patients: should we expand the screening program?. „Dig Dis Sci”. 52 (3), s. 798–802, marzec 2007. DOI: 10.1007/s10620-006-9432-6. PMID: 17245629. 
  • R.A. Meguid, M.B. Slidell, C.L. Wolfgang, D.C. Chang i inni. Is there a difference in survival between right- versus left-sided colon cancers?. „Ann Surg Oncol”. 15 (9), s. 2388–2394, wrzesień 2008. DOI: 10.1245/s10434-008-0015-y. PMID: 18622647. 
  • A.K. Lam, S.S. Chan, M. Leung. Synchronous colorectal cancer: clinical, pathological and molecular implications. „World J Gastroenterol”. 20 (22), s. 6815–6820, czerwiec 2014. DOI: 10.3748/wjg.v20.i22.6815. PMID: 24944471. 
  • J. Munding, A. Tannapfel. Epidemiology of Colorectal Adenomas and Histopathological Assessment of Endoscopic Specimens in the Colorectum. „Viszeralmedizin”. 30 (1), s. 10–16, luty 2014. DOI: 10.1159/000357744. PMID: 26288577. 
  • D.K. Rex, D.J. Ahnen, J.A. Baron, K.P. Batts i inni. Serrated lesions of the colorectum: review and recommendations from an expert panel. „Am J Gastroenterol”. 107 (9), s. 1315–1329; quiz 1314, 1330, wrzesień 2012. DOI: 10.1038/ajg.2012.161. PMID: 22710576. 
  • V.P. Bauer, H.T. Papaconstantinou. Management of serrated adenomas and hyperplastic polyps. „Clin Colon Rectal Surg”. 21 (4), s. 273–279, listopad 2008. DOI: 10.1055/s-0028-1089942. PMID: 20011438. 
  • J.J. Centelles. General aspects of colorectal cancer. „ISRN Oncol”. 2012, s. 139268, 2012. DOI: 10.5402/2012/139268. PMID: 23209942. 
  • N. Shussman, S.D. Wexner. Colorectal polyps and polyposis syndromes. „Gastroenterol Rep (Oxf)”. 2 (1), s. 1–15, luty 2014. DOI: 10.1093/gastro/got041. PMID: 24760231. 
  • H. Raskov, H.C. Pommergaard, J. Burcharth, J. Rosenberg. Colorectal carcinogenesis-update and perspectives. „World J Gastroenterol”. 20 (48), s. 18151–18164, grudzień 2014. DOI: 10.3748/wjg.v20.i48.18151. PMID: 25561783. 
  • A.M. Joosen, G.G. Kuhnle, S.M. Aspinall, T.M. Barrow i inni. Effect of processed and red meat on endogenous nitrosation and DNA damage. „Carcinogenesis”. 30 (8), s. 1402–1407, sierpień 2009. DOI: 10.1093/carcin/bgp130. PMID: 19498009. 
  • R.L. Santarelli, F. Pierre, D.E. Corpet. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. „Nutr Cancer”. 60 (2), s. 131–144, 2008. DOI: 10.1080/01635580701684872. PMID: 18444144. 
  • C.T. Dellavalle, Q. Xiao, G. Yang, X.O. Shu i inni. Dietary nitrate and nitrite intake and risk of colorectal cancer in the Shanghai Women’s Health Study. „Int J Cancer”. 134 (12), s. 2917–2926, czerwiec 2014. DOI: 10.1002/ijc.28612. PMID: 24242755. 
  • M. Scarpa, I. Castagliuolo, C. Castoro, A. Pozza i inni. Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. „World J Gastroenterol”. 20 (22), s. 6774–6785, czerwiec 2014. DOI: 10.3748/wjg.v20.i22.6774. PMID: 24944468. 
  • B. Yan, H. Wang, Z.N. Rabbani, Y. Zhao i inni. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. „Cancer Res”. 66 (24), s. 11565–11570, grudzień 2006. DOI: 10.1158/0008-5472.CAN-06-2540. PMID: 17178846. 
  • M.M. Derry, K. Raina, C. Agarwal, R. Agarwal. Identifying molecular targets of lifestyle modifications in colon cancer prevention. „Front Oncol”. 3, s. 119, 2013. DOI: 10.3389/fonc.2013.00119. PMID: 23675573. 
  • F. Arvelo, F. Sojo, C. Cotte. Biology of colorectal cancer. „Ecancermedicalscience”. 9, s. 520, 2015. DOI: 10.3332/ecancer.2015.520. PMID: 25932044. 
  • L. Yamane, C. Scapulatempo-Neto, R.M. Reis, D.P. Guimarães. Serrated pathway in colorectal carcinogenesis. „World J Gastroenterol”. 20 (10), s. 2634–2640, marzec 2014. DOI: 10.3748/wjg.v20.i10.2634. PMID: 24627599. 
  • E. Vilar, S.B. Gruber. Microsatellite instability in colorectal cancer-the stable evidence. „Nat Rev Clin Oncol”. 7 (3), s. 153–162, marzec 2010. DOI: 10.1038/nrclinonc.2009.237. PMID: 20142816. 
  • D. Kedrin, M.K. Gala. Genetics of the serrated pathway to colorectal cancer. „Clin Transl Gastroenterol”. 6, s. e84, 2015. DOI: 10.1038/ctg.2015.12. PMID: 25856207. 
  • Ł. Szylberg, M. Janiczek, A. Popiel, A. Marszałek. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. „Gastroenterol Res Pract”. 2015, s. 573814, 2015. DOI: 10.1155/2015/573814. PMID: 25945086. 
  • P. Alberici, R. Fodde. The role of the APC tumor suppressor in chromosomal instability. „Genome Dyn”. 1, s. 149–170, 2006. DOI: 10.1159/000092506. PMID: 18724059. 
  • K. Aoki, M.M. Taketo. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. „J Cell Sci”. 120 (Pt 19), s. 3327–3335, październik 2007. DOI: 10.1242/jcs.03485. PMID: 17881494. 
  • X.L. Li, J. Zhou, Z.R. Chen, W.J. Chng. P53 mutations in colorectal cancer – molecular pathogenesis and pharmacological reactivation. „World J Gastroenterol”. 21 (1), s. 84–93, styczeń 2015. DOI: 10.3748/wjg.v21.i1.84. PMID: 25574081. 
  • A. Russo, V. Bazan, B. Iacopetta, D. Kerr i inni. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. „J Clin Oncol”. 23 (30), s. 7518–7528, październik 2005. DOI: 10.1200/JCO.2005.00.471. PMID: 16172461. 
  • B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern i inni. Genetic alterations during colorectal-tumor development. „N Engl J Med”. 319 (9), s. 525–532, wrzesień 1988. DOI: 10.1056/NEJM198809013190901. PMID: 2841597. 
  • C. Forcet, X. Ye, L. Granger, V. Corset i inni. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. „Proc Natl Acad Sci U S A”. 98 (6), s. 3416–3421, marzec 2001. DOI: 10.1073/pnas.051378298. PMID: 11248093. 
  • A.M. Krasinskas. EGFR Signaling in Colorectal Carcinoma. „Patholog Res Int”. 2011, s. 932932, 2011. DOI: 10.4061/2011/932932. PMID: 21403829. 
  • J.P. Spano, R. Fagard, J.C. Soria, O. Rixe i inni. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. „Ann Oncol”. 16 (2), s. 189–194, luty 2005. DOI: 10.1093/annonc/mdi057. PMID: 15668269. 
  • C. Tan, X. Du. KRAS mutation testing in metastatic colorectal cancer. „World J Gastroenterol”. 18 (37), s. 5171–5180, październik 2012. DOI: 10.3748/wjg.v18.i37.5171. PMID: 23066310. 
  • C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O’Callaghan i inni. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. „N Engl J Med”. 359 (17), s. 1757–1765, październik 2008. DOI: 10.1056/NEJMoa0804385. PMID: 18946061. 
  • R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem i inni. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. „J Clin Oncol”. 26 (10), s. 1626–1634, kwiecień 2008. DOI: 10.1200/JCO.2007.14.7116. PMID: 18316791. 
  • M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero i inni. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. „J Clin Oncol”. 28 (31), s. 4706–4713, listopad 2010. DOI: 10.1200/JCO.2009.27.6055. PMID: 20921462. 
  • E. Van Cutsem, C.H. Köhne, I. Láng, G. Folprecht i inni. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. „J Clin Oncol”. 29 (15), s. 2011–2019, maj 2011. DOI: 10.1200/JCO.2010.33.5091. PMID: 21502544. 
  • J. Colicelli. Human RAS superfamily proteins and related GTPases. „Sci STKE”. 2004 (250), s. RE13, wrzesień 2004. DOI: 10.1126/stke.2502004re13. PMID: 15367757. 
  • D. Vigil, J. Cherfils, K.L. Rossman, C.J. Der. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. „Nat Rev Cancer”. 10 (12), s. 842–857, grudzień 2010. DOI: 10.1038/nrc2960. PMID: 21102635. 
  • X. Liu, M. Jakubowski, J.L. Hunt. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. „Am J Clin Pathol”. 135 (2), s. 245–252, luty 2011. DOI: 10.1309/AJCP7FO2VAXIVSTP. PMID: 21228365. 
  • D. Barras. BRAF Mutation in Colorectal Cancer: An Update. „Biomark Cancer”. 7 (Suppl 1), s. 9–12, 2015. DOI: 10.4137/BIC.S25248. PMID: 26396549. 
  • F.A. Sinicrope, Q. Shi, T.C. Smyrk, S.N. Thibodeau i inni. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. „Gastroenterology”. 148 (1), s. 88–99, styczeń 2015. DOI: 10.1053/j.gastro.2014.09.041. PMID: 25305506. 
  • B. Tran, S. Kopetz, J. Tie, P. Gibbs i inni. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. „Cancer”. 117 (20), s. 4623–4632, październik 2011. DOI: 10.1002/cncr.26086. PMID: 21456008. 
  • C.R. Boland, A. Goel. Microsatellite instability in colorectal cancer. „Gastroenterology”. 138 (6), s. 2073–2087.e3, czerwiec 2010. DOI: 10.1053/j.gastro.2009.12.064. PMID: 20420947. 
  • R. Jover, A. Payá, C. Alenda, M.J. Poveda i inni. Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. „Am J Clin Pathol”. 122 (3), s. 389–394, wrzesień 2004. DOI: 10.1309/V9PG-K2Y2-60VF-VULR. PMID: 15362369. 
  • M. Pinheiro, T. Ahlquist, S.A. Danielsen, G.E. Lind i inni. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. „BMC Cancer”. 10, s. 587, 2010. DOI: 10.1186/1471-2407-10-587. PMID: 20979647. 
  • D. Cao, M. Hou, Y.S. Guan, M. Jiang i inni. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. „BMC Cancer”. 9, s. 432, 2009. DOI: 10.1186/1471-2407-9-432. PMID: 20003271. 
  • M. Mathonnet, A. Perraud, N. Christou, H. Akil i inni. Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. „World J Gastroenterol”. 20 (15), s. 4189–4196, kwiecień 2014. DOI: 10.3748/wjg.v20.i15.4189. PMID: 24764657. 
  • R.G. Landmann, M.R. Weiser. Surgical management of locally advanced and locally recurrent colon cancer. „Clin Colon Rectal Surg”. 18 (3), s. 182–189, sierpień 2005. DOI: 10.1055/s-2005-916279. PMID: 20011301. 
  • C. Liebig, G. Ayala, J.A. Wilks, D.H. Berger i inni. Perineural invasion in cancer: a review of the literature. „Cancer”. 115 (15), s. 3379–3391, sierpień 2009. DOI: 10.1002/cncr.24396. PMID: 19484787. 
  • N. Knijn, S.C. Mogk, S. Teerenstra, F. Simmer i inni. Perineural Invasion Is a Strong Prognostic Factor in Colorectal Cancer: A Systematic Review. „Am J Surg Pathol”, wrzesień 2015. DOI: 10.1097/PAS.0000000000000518. PMID: 26426380. 
  • M. Qiu, J. Hu, D. Yang, D.P. Cosgrove i inni. Pattern of distant metastases in colorectal cancer: a SEER based study. „Oncotarget”, październik 2015. DOI: 10.18632/oncotarget.6130. PMID: 26484417. 
  • P. Gervaz, P. Bucher, I. Neyroud-Caspar, C. Soravia i inni. Proximal location of colon cancer is a risk factor for development of metachronous colorectal cancer: a population-based study. „Dis Colon Rectum”. 48 (2), s. 227–232, luty 2005. DOI: 10.1007/s10350-004-0805-7. PMID: 15711864. 
  • J. Kaplan, A. Strongin, D.G. Adler, A.A. Siddiqui. Enteral stents for the management of malignant colorectal obstruction. „World J Gastroenterol”. 20 (37), s. 13239–13245, październik 2014. DOI: 10.3748/wjg.v20.i37.13239. PMID: 25309061. 
  • S.P. Hong, T.I. Kim. Colorectal stenting: an advanced approach to malignant colorectal obstruction. „World J Gastroenterol”. 20 (43), s. 16020–16028, listopad 2014. DOI: 10.3748/wjg.v20.i43.16020. PMID: 25473154. 
  • X.F. Yang, K. Pan. Diagnosis and management of acute complications in patients with colon cancer: bleeding, obstruction, and perforation. „Chin J Cancer Res”. 26 (3), s. 331–340, czerwiec 2014. DOI: 10.3978/j.issn.1000-9604.2014.06.11. PMID: 25035661. 
  • M. Świderska, B. Choromańska, E. Dąbrowska, E. Konarzewska-Duchnowska i inni. The diagnostics of colorectal cancer. „Contemp Oncol (Pozn)”. 18 (1), s. 1–6, 2014. DOI: 10.5114/wo.2013.39995. PMID: 24876814. 
  • D.A. Fisher, A.K. Shergill, D.S. Early, R.D. Acosta i inni. Role of endoscopy in the staging and management of colorectal cancer. „Gastrointest Endosc”. 78 (1), s. 8–12, lipiec 2013. DOI: 10.1016/j.gie.2013.04.163. PMID: 23664162. 
  • R.J. Loffeld, M. Flens, G. Fransen, F.C. den Boer i inni. The localisation of cancer in the sigmoid, rectum or rectosigmoid junction using endoscopy or radiology-What is the most accurate method?. „J Gastrointest Oncol”. 5 (6), s. 469–473, grudzień 2014. DOI: 10.3978/j.issn.2078-6891.2014.087. PMID: 25436127. 
  • A. Laghi. Computed tomography colonography in 2014: an update on technique and indications. „World J Gastroenterol”. 20 (45), s. 16858–16867, grudzień 2014. DOI: 10.3748/wjg.v20.i45.16858. PMID: 25492999. 
  • S. Bipat, A.S. Glas, F.J. Slors, A.H. Zwinderman i inni. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. „Radiology”. 232 (3), s. 773–783, wrzesień 2004. DOI: 10.1148/radiol.2323031368. PMID: 15273331. 
  • S.R. Puli, M.L. Bechtold, J.B. Reddy, A. Choudhary i inni. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. „Dig Dis Sci”. 55 (5), s. 1221–1229, maj 2010. DOI: 10.1007/s10620-009-0862-9. PMID: 19517233. 
  • S.R. Puli, M.L. Bechtold, J.B. Reddy, A. Choudhary i inni. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. „Ann Surg Oncol”. 16 (2), s. 254–265, luty 2009. DOI: 10.1245/s10434-008-0231-5. PMID: 19018597. 
  • M.E. Riccioni, R. Urgesi, R. Cianci, A. Bizzotto i inni. Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?. „World J Gastrointest Endosc”. 4 (4), s. 99–107, kwiecień 2012. DOI: 10.4253/wjge.v4.i4.99. PMID: 22523610. 
  • C. Spada, F. Barbaro, G. Andrisani, L. Minelli Grazioli i inni. Colon capsule endoscopy: What we know and what we would like to know. „World J Gastroenterol”. 20 (45), s. 16948–16955, grudzień 2014. DOI: 10.3748/wjg.v20.i45.16948. PMID: 25493007. 
  • M.F. Hale, R. Sidhu, M.E. McAlindon. Capsule endoscopy: current practice and future directions. „World J Gastroenterol”. 20 (24), s. 7752–7759, czerwiec 2014. DOI: 10.3748/wjg.v20.i24.7752. PMID: 24976712. 
  • R. Eliakim, K. Yassin, Y. Niv, Y. Metzger i inni. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. „Endoscopy”. 41 (12), s. 1026–1031, grudzień 2009. DOI: 10.1055/s-0029-1215360. PMID: 19967618. 
  • C. Spada, C. Hassan, M. Munoz-Navas, H. Neuhaus i inni. Second-generation colon capsule endoscopy compared with colonoscopy. „Gastrointest Endosc”. 74 (3), s. 581–589.e1, wrzesień 2011. DOI: 10.1016/j.gie.2011.03.1125. PMID: 21601200. 
  • C. Spada, C. Hassan, J.P. Galmiche, H. Neuhaus i inni. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. „Endoscopy”. 44 (5), s. 527–536, maj 2012. DOI: 10.1055/s-0031-1291717. PMID: 22389230. 
  • P.J. Pickhardt, C. Hassan, S. Halligan, R. Marmo. Colorectal cancer: CT colonography and colonoscopy for detection-systematic review and meta-analysis. „Radiology”. 259 (2), s. 393–405, maj 2011. DOI: 10.1148/radiol.11101887. PMID: 21415247. 
  • M. Kekelidze, L. D’Errico, M. Pansini, A. Tyndall i inni. Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. „World J Gastroenterol”. 19 (46), s. 8502–8514, grudzień 2013. DOI: 10.3748/wjg.v19.i46.8502. PMID: 24379567. 
  • F.M. Zijta, S. Bipat, J. Stoker. Magnetic resonance (MR) colonography in the detection of colorectal lesions: a systematic review of prospective studies. „Eur Radiol”. 20 (5), s. 1031–1046, maj 2010. DOI: 10.1007/s00330-009-1663-4. PMID: 19936754. 
  • M. Mulla, R. Deb, R. Singh. MRI in T staging of rectal cancer: How effective is it?. „Indian J Radiol Imaging”. 20 (2), s. 118–121, maj 2010. DOI: 10.4103/0971-3026.63055. PMID: 20607023. 
  • U. Tapan, M. Ozbayrak, S. Tatlı. MRI in local staging of rectal cancer: an update. „Diagn Interv Radiol”. 20 (5). s. 390–398. DOI: 10.5152/dir.2014.13265. PMID: 25010367. 
  • C. Klessen, P. Rogalla, M. Taupitz. Local staging of rectal cancer: the current role of MRI. „Eur Radiol”. 17 (2), s. 379–389, luty 2007. DOI: 10.1007/s00330-006-0388-x. PMID: 17008990. 
  • M.C. Niekel, S. Bipat, J. Stoker. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. „Radiology”. 257 (3), s. 674–684, grudzień 2010. DOI: 10.1148/radiol.10100729. PMID: 20829538. 
  • D. Delbeke, W.H. Martin. FDG PET and PET/CT for colorectal cancer. „Methods Mol Biol”. 727, s. 77–103, 2011. DOI: 10.1007/978-1-61779-062-1_6. PMID: 21331930. 
  • F.U. Chowdhury, N. Shah, A.F. Scarsbrook, K.M. Bradley. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. „Postgrad Med J”. 86 (1013), s. 174–182, marzec 2010. DOI: 10.1136/pgmj.2009.079087. PMID: 20237012. 
  • L.F. de Geus-Oei, T.J. Ruers, C.J. Punt, J.W. Leer i inni. FDG-PET in colorectal cancer. „Cancer Imaging”. 6, s. S71-81, 2006. DOI: 10.1102/1470-7330.2006.9014. PMID: 17114081. 
  • Z. Vukobrat-Bijedic, A. Husic-Selimovic, A. Sofic, N. Bijedic i inni. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. „Med Arch”. 67 (6), s. 397–401, grudzień 2013. DOI: 10.5455/medarh.2013.67.397-401. PMID: 25568506. 
  • J. Stiksma, D.C. Grootendorst, P.W. van der Linden. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. „Clin Colorectal Cancer”. 13 (4), s. 239–244, grudzień 2014. DOI: 10.1016/j.clcc.2014.09.004. PMID: 25442815. 
  • Y. Narita, H. Taniguchi, A. Komori, S. Nitta i inni. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. „Cancer Chemother Pharmacol”. 73 (2), s. 409–416, luty 2014. DOI: 10.1007/s00280-013-2367-7. PMID: 24322376. 
  • J. Louhimo, M. Carpelan-Holmström, H. Alfthan, U.H. Stenman i inni. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. „Int J Cancer”. 101 (6), s. 545–548, październik 2002. DOI: 10.1002/ijc.90009. PMID: 12237895. 
  • D. Ayude, F.J. Rodríguez-Berrocal, J. Ayude, S. Blanco-Prieto i inni. Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer. „BMC Cancer”. 13, s. 543, 2013. DOI: 10.1186/1471-2407-13-543. PMID: 24215576. 
  • H.Y. Kim, S.J. Lee, G. Lee, L. Song i inni. Should preoperative chest CT be recommended to all colon cancer patients?. „Ann Surg”. 259 (2), s. 323–328, luty 2014. DOI: 10.1097/SLA.0b013e3182865080. PMID: 23426347. 
  • I. Zlobec, A. Lugli. Prognostic and predictive factors in colorectal cancer. „Postgrad Med J”. 84 (994), s. 403–411, sierpień 2008. DOI: 10.1136/jcp.2007.054858. PMID: 18832400. 
  • O. Marzouk, J. Schofield. Review of histopathological and molecular prognostic features in colorectal cance. „Cancers (Basel)”. 3 (2), s. 2767–2810, 2011. DOI: 10.3390/cancers3022767. PMID: 24212832. 
  • C.C. Compton. Colorectal carcinoma: diagnostic, prognostic, and molecular features. „Mod Pathol”. 16 (4), s. 376–388, kwiecień 2003. DOI: 10.1097/01.MP.0000062859.46942.93. PMID: 12692203. 
  • C.C. Compton, L.P. Fielding, L.J. Burgart, B. Conley i inni. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. „Arch Pathol Lab Med”. 124 (7), s. 979–994, lipiec 2000. DOI: <0979:PFICC>2.0.CO;2 10.1043/0003-9985(2000)124<0979:PFICC>2.0.CO;2. PMID: 10888773. 
  • V.H. Koelzer, A. Lugli. The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. „Front Oncol”. 4, s. 29, 2014. DOI: 10.3389/fonc.2014.00029. PMID: 24600585. 
  • J. Betge, M.J. Pollheimer, R.A. Lindtner, P. Kornprat i inni. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. „Cancer”. 118 (3), s. 628–638, luty 2012. DOI: 10.1002/cncr.26310. PMID: 21751188. 
  • C. Liebig, G. Ayala, J. Wilks, G. Verstovsek i inni. Perineural invasion is an independent predictor of outcome in colorectal cancer. „J Clin Oncol”. 27 (31), s. 5131–5137, listopad 2009. DOI: 10.1200/JCO.2009.22.4949. PMID: 19738119. 
  • T. Sakamoto, G. Mori, M. Yamada, Y. Kinjo i inni. Endoscopic submucosal dissection for colorectal neoplasms: a review. „World J Gastroenterol”. 20 (43), s. 16153–16158, listopad 2014. DOI: 10.3748/wjg.v20.i43.16153. PMID: 25473168. 
  • S.L. Bosch, S. Teerenstra, J.H. de Wilt, C. Cunningham i inni. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. „Endoscopy”. 45 (10), s. 827–834, październik 2013. DOI: 10.1055/s-0033-1344238. PMID: 23884793. 
  • T.A. Heafner, S.C. Glasgow. A critical review of the role of local excision in the treatment of early (T1 and T2) rectal tumors. „J Gastrointest Oncol”. 5 (5), s. 345–352, październik 2014. DOI: 10.3978/j.issn.2078-6891.2014.066. PMID: 25276407. 
  • D. Hahnloser, B.G. Wolff, D.W. Larson, J. Ping i inni. Immediate radical resection after local excision of rectal cancer: an oncologic compromise?. „Dis Colon Rectum”. 48 (3), s. 429–437, marzec 2005. DOI: 10.1007/s10350-004-0900-9. PMID: 15747069. 
  • Y.N. You, N.N. Baxter, A. Stewart, H. Nelson. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. „Ann Surg”. 245 (5), s. 726–733, maj 2007. DOI: 10.1097/01.sla.0000252590.95116.4f. PMID: 17457165. 
  • G.M. Nash, M.R. Weiser, J.G. Guillem, L.K. Temple i inni. Long-term survival after transanal excision of T1 rectal cancer. „Dis Colon Rectum”. 52 (4), s. 577–582, kwiecień 2009. DOI: 10.1007/DCR.0b013e3181a0adbd. PMID: 19404055. 
  • K.B. Stitzenberg, H.K. Sanoff, D.C. Penn, M.O. Meyers i inni. Practice patterns and long-term survival for early-stage rectal cancer. „J Clin Oncol”. 31 (34), s. 4276–4282, grudzień 2013. DOI: 10.1200/JCO.2013.49.1860. PMID: 24166526. 
  • M. den Dulk, H. Putter, L. Collette, C.A. Marijnen i inni. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. „Eur J Cancer”. 45 (7), s. 1175–1183, maj 2009. DOI: 10.1016/j.ejca.2008.11.039. PMID: 19128956. 
  • L. Påhlman, M. Bohe, B. Cedermark, M. Dahlberg i inni. The Swedish rectal cancer registry. „Br J Surg”. 94 (10), s. 1285–1292, październik 2007. DOI: 10.1002/bjs.5679. PMID: 17661309. 
  • A. Martling, T. Holm, L.E. Rutqvist, H. Johansson i inni. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. „Br J Surg”. 92 (2), s. 225–229, luty 2005. DOI: 10.1002/bjs.4834. PMID: 15609382. 
  • A.M. Lacy, J.C. García-Valdecasas, S. Delgado, A. Castells i inni. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. „Lancet”. 359 (9325), s. 2224–2229, czerwiec 2002. DOI: 10.1016/S0140-6736(02)09290-5. PMID: 12103285. 
  • M. Buunen, R. Veldkamp, W.C. Hop, E. Kuhry i inni. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. „Lancet Oncol”. 10 (1), s. 44–52, styczeń 2009. DOI: 10.1016/S1470-2045(08)70310-3. PMID: 19071061. 
  • B.L. Green, H.C. Marshall, F. Collinson, P. Quirke i inni. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. „Br J Surg”. 100 (1), s. 75–82, styczeń 2013. DOI: 10.1002/bjs.8945. PMID: 23132548. 
  • H. Ohtani, Y. Tamamori, Y. Arimoto, Y. Nishiguchi i inni. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and open colectomy for colon cancer. „J Cancer”. 3, s. 49–57, 2012. DOI: 10.7150/jca.3621. PMID: 22315650. 
  • B. Di, Y. Li, K. Wei, X. Xiao i inni. Laparoscopic versus open surgery for colon cancer: a meta-analysis of 5-year follow-up outcomes. „Surg Oncol”. 22 (3), s. e39-43, wrzesień 2013. DOI: 10.1016/j.suronc.2013.03.002. PMID: 23643698. 
  • E. Kuhry, W. Schwenk, R. Gaupset, U. Romild i inni. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. „Cancer Treat Rev”. 34 (6), s. 498–504, październik 2008. DOI: 10.1016/j.ctrv.2008.03.011. PMID: 18468803. 
  • F. Rondelli, S. Trastulli, N. Avenia, G. Schillaci i inni. Is laparoscopic right colectomy more effective than open resection? A meta-analysis of randomized and nonrandomized studies. „Colorectal Dis”. 14 (8), s. e447-69, sierpień 2012. DOI: 10.1111/j.1463-1318.2012.03054.x. PMID: 22540533. 
  • D.G. Jayne, H.C. Thorpe, J. Copeland, P. Quirke i inni. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. „Br J Surg”. 97 (11), s. 1638–1645, listopad 2010. DOI: 10.1002/bjs.7160. PMID: 20629110. 
  • D.G. Jayne, P.J. Guillou, H. Thorpe, P. Quirke i inni. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. „J Clin Oncol”. 25 (21), s. 3061–3068, lipiec 2007. DOI: 10.1200/JCO.2006.09.7758. PMID: 17634484. 
  • D.P. Nussbaum, P.J. Speicher, A.M. Ganapathi, B.R. Englum i inni. Laparoscopic versus open low anterior resection for rectal cancer: results from the national cancer data base. „J Gastrointest Surg”. 19 (1), s. 124–131; discussion 131-2, styczeń 2015. DOI: 10.1007/s11605-014-2614-1. PMID: 25091847. 
  • S. Gill, C.L. Loprinzi, D.J. Sargent, S.D. Thomé i inni. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. „J Clin Oncol”. 22 (10), s. 1797–1806, maj 2004. DOI: 10.1200/JCO.2004.09.059. PMID: 15067028. 
  • R. Gray, J. Barnwell, C. McConkey, R.K. Hills i inni. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. „Lancet”. 370 (9604), s. 2020–2029, grudzień 2007. DOI: 10.1016/S0140-6736(07)61866-2. PMID: 18083404. 
  • X. Wu, J. Zhang, X. He, C. Wang i inni. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. „J Gastrointest Surg”. 16 (3), s. 646–655, marzec 2012. DOI: 10.1007/s11605-011-1682-8. PMID: 22194062. 
  • E.S. O’Connor, D.Y. Greenblatt, N.K. LoConte, R.E. Gangnon i inni. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. „J Clin Oncol”. 29 (25), s. 3381–3388, wrzesień 2011. DOI: 10.1200/JCO.2010.34.3426. PMID: 21788561. 
  • J.J. Biagi, M.J. Raphael, W.J. Mackillop, W. Kong i inni. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. „JAMA”. 305 (22), s. 2335–2342, czerwiec 2011. DOI: 10.1001/jama.2011.749. PMID: 21642686. 
  • T. André, C. Boni, M. Navarro, J. Tabernero i inni. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. „J Clin Oncol”. 27 (19), s. 3109–3116, lipiec 2009. DOI: 10.1200/JCO.2008.20.6771. PMID: 19451431. 
  • H.K. Sanoff, W.R. Carpenter, C.F. Martin, D.J. Sargent i inni. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. „J Natl Cancer Inst”. 104 (3), s. 211–227, luty 2012. DOI: 10.1093/jnci/djr524. PMID: 22266473. 
  • H.K. Sanoff, W.R. Carpenter, J. Freburger, L. Li i inni. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. „Cancer”. 118 (17), s. 4309–4320, wrzesień 2012. DOI: 10.1002/cncr.27422. PMID: 22294436. 
  • J.P. Kuebler, H.S. Wieand, M.J. O’Connell, R.E. Smith i inni. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. „J Clin Oncol”. 25 (16), s. 2198–2204, czerwiec 2007. DOI: 10.1200/JCO.2006.08.2974. PMID: 17470851. 
  • G. Yothers, M.J. O’Connell, C.J. Allegra, J.P. Kuebler i inni. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. „J Clin Oncol”. 29 (28), s. 3768–3774, październik 2011. DOI: 10.1200/JCO.2011.36.4539. PMID: 21859995. 
  • S. Sharif, M.J. O’Connell, G. Yothers, S. Lopa i inni. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. „Cancer Invest”. 26 (9), s. 956–963, listopad 2008. DOI: 10.1080/07357900802132550. PMID: 18798075. 
  • C. Twelves, A. Wong, M.P. Nowacki, M. Abt i inni. Capecitabine as adjuvant treatment for stage III colon cancer. „N Engl J Med”. 352 (26), s. 2696–2704, czerwiec 2005. DOI: 10.1056/NEJMoa043116. PMID: 15987918. 
  • C. Twelves, W. Scheithauer, J. McKendrick, J.F. Seitz i inni. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. „Ann Oncol”. 23 (5), s. 1190–1197, maj 2012. DOI: 10.1093/annonc/mdr366. PMID: 21896539. 
  • D.G. Haller, J. Tabernero, J. Maroun, F. de Braud i inni. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. „J Clin Oncol”. 29 (11), s. 1465–1471, kwiecień 2011. DOI: 10.1200/JCO.2010.33.6297. PMID: 21383294. 
  • L.L. Gunderson, D.J. Sargent, J.E. Tepper, N. Wolmark i inni. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. „J Clin Oncol”. 22 (10), s. 1785–1796, maj 2004. DOI: 10.1200/JCO.2004.08.173. PMID: 15067027. 
  • R. Sauer, H. Becker, W. Hohenberger, C. Rödel i inni. Preoperative versus postoperative chemoradiotherapy for rectal cancer. „N Engl J Med”. 351 (17), s. 1731–1740, październik 2004. DOI: 10.1056/NEJMoa040694. PMID: 15496622. 
  • R. Sauer, T. Liersch, S. Merkel, R. Fietkau i inni. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. „J Clin Oncol”. 30 (16), s. 1926–1933, czerwiec 2012. DOI: 10.1200/JCO.2011.40.1836. PMID: 22529255. 
  • L.C. Peng, J. Milsom, K. Garrett, G. Nandakumar i inni. Surveillance, epidemiology, and end results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer. „Cancer Epidemiol”. 38 (1), s. 73–78, luty 2014. DOI: 10.1016/j.canep.2013.12.008. PMID: 24491755. 
  • J.P. Gérard, T. Conroy, F. Bonnetain, O. Bouché i inni. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. „J Clin Oncol”. 24 (28), s. 4620–4625, październik 2006. DOI: 10.1200/JCO.2006.06.7629. PMID: 17008704. 
  • J.F. Bosset, G. Calais, L. Mineur, P. Maingon i inni. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. „J Clin Oncol”. 23 (24), s. 5620–5627, sierpień 2005. DOI: 10.1200/JCO.2005.02.113. PMID: 16009958. 
  • J.F. Bosset, L. Collette, G. Calais, L. Mineur i inni. Chemotherapy with preoperative radiotherapy in rectal cancer. „N Engl J Med”. 355 (11), s. 1114–1123, wrzesień 2006. DOI: 10.1056/NEJMoa060829. PMID: 16971718. 
  • W.P. Ceelen, Y. Van Nieuwenhove, K. Fierens. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. „Cochrane Database Syst Rev”, s. CD006041, 2009. DOI: 10.1002/14651858.CD006041.pub2. PMID: 19160264. 
  • K. McCarthy, K. Pearson, R. Fulton, J. Hewitt. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. „Cochrane Database Syst Rev”. 12, s. CD008368, 2012. DOI: 10.1002/14651858.CD008368.pub2. PMID: 23235660. 
  • N.N. Rahbari, H. Elbers, V. Askoxylakis, E. Motschall i inni. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. „Ann Surg Oncol”. 20 (13), s. 4169–4182, grudzień 2013. DOI: 10.1245/s10434-013-3198-9. PMID: 24002536. 
  • M.J. O’Connell, L.H. Colangelo, R.W. Beart, N.J. Petrelli i inni. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. „J Clin Oncol”. 32 (18), s. 1927–1934, czerwiec 2014. DOI: 10.1200/JCO.2013.53.7753. PMID: 24799484. 
  • R.D. Hofheinz, F. Wenz, S. Post, A. Matzdorff i inni. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. „Lancet Oncol”. 13 (6), s. 579–588, czerwiec 2012. DOI: 10.1016/S1470-2045(12)70116-X. PMID: 22503032. 
  • C. Aschele, L. Cionini, S. Lonardi, C. Pinto i inni. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. „J Clin Oncol”. 29 (20), s. 2773–2780, lipiec 2011. DOI: 10.1200/JCO.2010.34.4911. PMID: 21606427. 
  • C. Rödel, T. Liersch, H. Becker, R. Fietkau i inni. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. „Lancet Oncol”. 13 (7), s. 679–687, lipiec 2012. DOI: 10.1016/S1470-2045(12)70187-0. PMID: 22627104. 
  • J.P. Gérard, D. Azria, S. Gourgou-Bourgade, I. Martel-Lafay i inni. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. „J Clin Oncol”. 30 (36), s. 4558–4565, grudzień 2012. DOI: 10.1200/JCO.2012.42.8771. PMID: 23109696. 
  • K. Bujko, M.P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski i inni. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. „Br J Surg”. 93 (10), s. 1215–1223, październik 2006. DOI: 10.1002/bjs.5506. PMID: 16983741. 
  • S.Y. Ngan, B. Burmeister, R.J. Fisher, M. Solomon i inni. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. „J Clin Oncol”. 30 (31), s. 3827–3833, listopad 2012. DOI: 10.1200/JCO.2012.42.9597. PMID: 23008301. 
  • T. Latkauskas, H. Pauzas, I. Gineikiene, R. Janciauskiene i inni. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. „Colorectal Dis”. 14 (3), s. 294–298, marzec 2012. DOI: 10.1111/j.1463-1318.2011.02815.x. PMID: 21899712. 
  • C. Fernández-Martos, C. Pericay, J. Aparicio, A. Salud i inni. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. „J Clin Oncol”. 28 (5), s. 859–865, luty 2010. DOI: 10.1200/JCO.2009.25.8541. PMID: 20065174. 
  • R. Maréchal, B. Vos, M. Polus, T. Delaunoit i inni. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. „Ann Oncol”. 23 (6), s. 1525–1530, czerwiec 2012. DOI: 10.1093/annonc/mdr473. PMID: 22039087. 
  • J.F. Bosset, G. Calais, L. Mineur, P. Maingon i inni. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. „Lancet Oncol”. 15 (2), s. 184–190, luty 2014. DOI: 10.1016/S1470-2045(13)70599-0. PMID: 24440473. 
  • S.H. Petersen, H. Harling, L.T. Kirkeby, P. Wille-Jørgensen i inni. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. „Cochrane Database Syst Rev”. 3, s. CD004078, 2012. DOI: 10.1002/14651858.CD004078.pub2. PMID: 22419291. 
  • Y.S. Hong, B.H. Nam, K.P. Kim, J.E. Kim i inni. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. „Lancet Oncol”. 15 (11), s. 1245–1253, październik 2014. DOI: 10.1016/S1470-2045(14)70377-8. PMID: 25201358. 
  • M.D. Hellinger, C.A. Santiago. Reoperation for recurrent colorectal cancer. „Clin Colon Rectal Surg”. 19 (4), s. 228–236, listopad 2006. DOI: 10.1055/s-2006-956445. PMID: 20011326. 
  • D. Sargent, A. Sobrero, A. Grothey, M.J. O’Connell i inni. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. „J Clin Oncol”. 27 (6), s. 872–877, luty 2009. DOI: 10.1200/JCO.2008.19.5362. PMID: 19124803. 
  • D.J. Sargent, H.S. Wieand, D.G. Haller, R. Gray i inni. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. „J Clin Oncol”. 23 (34), s. 8664–8670, grudzień 2005. DOI: 10.1200/JCO.2005.01.6071. PMID: 16260700. 
  • Ö. Akgül, E. Çetinkaya, Ş. Ersöz, M. Tez. Role of surgery in colorectal cancer liver metastases. „World J Gastroenterol”. 20 (20), s. 6113–6122, maj 2014. DOI: 10.3748/wjg.v20.i20.6113. PMID: 24876733. 
  • F.I. Macedo, T. Makarawo. Colorectal hepatic metastasis: Evolving therapies. „World J Hepatol”. 6 (7), s. 453–463, lipiec 2014. DOI: 10.4254/wjh.v6.i7.453. PMID: 25067997. 
  • S. Vatandoust, T.J. Price, C.S. Karapetis. Colorectal cancer: Metastases to a single organ. „World J Gastroenterol”. 21 (41), s. 11767–11776, listopad 2015. DOI: 10.3748/wjg.v21.i41.11767. PMID: 26557001. 
  • G.P. Kanas, A. Taylor, J.N. Primrose, W.J. Langeberg i inni. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. „Clin Epidemiol”. 4, s. 283–301, 2012. DOI: 10.2147/CLEP.S34285. PMID: 23152705. 
  • T.A. Aloia, J.N. Vauthey, E.M. Loyer, D. Ribero i inni. Solitary colorectal liver metastasis: resection determines outcome. „Arch Surg”. 141 (5), s. 460–466; discussion 466-7, maj 2006. DOI: 10.1001/archsurg.141.5.460. PMID: 16702517. 
  • W.S. Lee, S.H. Yun, H.K. Chun, W.Y. Lee i inni. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. „J Clin Gastroenterol”. 42 (8), s. 945–949, wrzesień 2008. DOI: 10.1097/MCG.0b013e318064e752. PMID: 18438208. 
  • H. Hur, Y.T. Ko, B.S. Min, K.S. Kim i inni. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. „Am J Surg”. 197 (6), s. 728–736, czerwiec 2009. DOI: 10.1016/j.amjsurg.2008.04.013. PMID: 18789428. 
  • H.K. Kim, J.H. Cho, H.Y. Lee, J. Lee i inni. Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times?. „World J Gastroenterol”. 20 (20), s. 6133–6145, maj 2014. DOI: 10.3748/wjg.v20.i20.6133. PMID: 24876735. 
  • T. Treasure. Pulmonary Metastasectomy for Colorectal Cancer: Recent Reports Prompt a Review of the Available Evidence. „Curr Colorectal Cancer Rep”. 10 (3), s. 296–302, 2014. DOI: 10.1007/s11888-014-0234-5. PMID: 25191154. 
  • C. Pulitanò, M. Bodingbauer, L. Aldrighetti, M.C. de Jong i inni. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. „Ann Surg Oncol”. 18 (5), s. 1380–1388, maj 2011. DOI: 10.1245/s10434-010-1459-4. PMID: 21136180. 
  • T.C. Chua, A. Saxena, W. Liauw, F. Chu i inni. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases-a systematic review. „Eur J Cancer”. 48 (12), s. 1757–1765, sierpień 2012. DOI: 10.1016/j.ejca.2011.10.034. PMID: 22153217. 
  • D.R. Carpizo, M. D’Angelica. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. „Ann Surg Oncol”. 16 (9), s. 2411–2421, wrzesień 2009. DOI: 10.1245/s10434-009-0493-6. PMID: 19554376. 
  • D.R. Carpizo, C. Are, W. Jarnagin, R. Dematteo i inni. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. „Ann Surg Oncol”. 16 (8), s. 2138–2146, sierpień 2009. DOI: 10.1245/s10434-009-0521-6. PMID: 19495884. 
  • S.R. Alberts, W.L. Horvath, W.C. Sternfeld, R.M. Goldberg i inni. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. „J Clin Oncol”. 23 (36), s. 9243–9249, grudzień 2005. DOI: 10.1200/JCO.2005.07.740. PMID: 16230673. 
  • A. Falcone, S. Ricci, I. Brunetti, E. Pfanner i inni. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. „J Clin Oncol”. 25 (13), s. 1670–1676, maj 2007. DOI: 10.1200/JCO.2006.09.0928. PMID: 17470860. 
  • J. Souglakos, N. Androulakis, K. Syrigos, A. Polyzos i inni. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). „Br J Cancer”. 94 (6), s. 798–805, marzec 2006. DOI: 10.1038/sj.bjc.6603011. PMID: 16508637. 
  • G. Masi, E. Vasile, F. Loupakis, S. Cupini i inni. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. „J Natl Cancer Inst”. 103 (1), s. 21–30, styczeń 2011. DOI: 10.1093/jnci/djq456. PMID: 21123833. 
  • G. Folprecht, T. Gruenberger, W.O. Bechstein, H.R. Raab i inni. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. „Lancet Oncol”. 11 (1), s. 38–47, styczeń 2010. DOI: 10.1016/S1470-2045(09)70330-4. PMID: 19942479. 
  • G. Folprecht, T. Gruenberger, W. Bechstein, H.R. Raab i inni. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). „Ann Oncol”. 25 (5), s. 1018–1025, maj 2014. DOI: 10.1093/annonc/mdu088. PMID: 24585720. 
  • L.C. Ye, T.S. Liu, L. Ren, Y. Wei i inni. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. „J Clin Oncol”. 31 (16), s. 1931–1938, czerwiec 2013. DOI: 10.1200/JCO.2012.44.8308. PMID: 23569301. 
  • F. Petrelli, S. Barni. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. „Int J Colorectal Dis”. 27 (8), s. 997–1004, sierpień 2012. DOI: 10.1007/s00384-012-1438-2. PMID: 22358385. 
  • C.S. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki i inni. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. „J Clin Oncol”. 25 (30), s. 4779–4786, październik 2007. DOI: 10.1200/JCO.2007.11.3357. PMID: 17947725. 
  • H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright i inni. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. „N Engl J Med”. 350 (23), s. 2335–2342, czerwiec 2004. DOI: 10.1056/NEJMoa032691. PMID: 15175435. 
  • L.B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. „J Clin Oncol”. 26 (12), s. 2013–2019, kwiecień 2008. DOI: 10.1200/JCO.2007.14.9930. PMID: 18421054. 
  • B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston i inni. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. „Lancet”. 371 (9617), s. 1007–1016, marzec 2008. DOI: 10.1016/S0140-6736(08)60455-9. PMID: 18358928. 
  • B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston i inni. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. „Lancet Oncol”. 14 (12), s. 1208–1215, listopad 2013. DOI: 10.1016/S1470-2045(13)70447-9. PMID: 24120480. 
  • Tomas Buchler, Tomas Pavlik, Bohuslav Melichar, Zbynek Bortlicek i inni. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. „BMC Cancer”, 2014. DOI: 10.1186/1471-2407-14-323. 
  • J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. „J Clin Oncol”. 26 (12), s. 2006–2012, kwiecień 2008. DOI: 10.1200/JCO.2007.14.9898. PMID: 18421053. 
  • J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. „Br J Cancer”. 105 (1), s. 58–64, czerwiec 2011. DOI: 10.1038/bjc.2011.201. PMID: 21673685. 
  • C. Zhang, J. Wang, H. Gu, D. Zhu i inni. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. „Oncol Lett”. 3 (4), s. 831–838, kwiecień 2012. DOI: 10.3892/ol.2012.567. PMID: 22741002. 
  • C. Tournigand, T. André, E. Achille, G. Lledo i inni. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. „J Clin Oncol”. 22 (2), s. 229–237, styczeń 2004. DOI: 10.1200/JCO.2004.05.113. PMID: 14657227. 
  • G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani i inni. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. „J Clin Oncol”. 23 (22), s. 4866–4875, sierpień 2005. DOI: 10.1200/JCO.2005.07.113. PMID: 15939922. 
  • E. Mitry, A.L. Fields, H. Bleiberg, R. Labianca i inni. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. „J Clin Oncol”. 26 (30), s. 4906–4911, październik 2008. DOI: 10.1200/JCO.2008.17.3781. PMID: 18794541. 
  • D. Cunningham, I. Lang, E. Marcuello, V. Lorusso i inni. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. „Lancet Oncol”. 14 (11), s. 1077–1085, październik 2013. DOI: 10.1016/S1470-2045(13)70154-2. PMID: 24028813. 
  • F.F. Kabbinavar, J. Schulz, M. McCleod, T. Patel i inni. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. „J Clin Oncol”. 23 (16), s. 3697–3705, czerwiec 2005. DOI: 10.1200/JCO.2005.05.112. PMID: 15738537. 
  • F.F. Kabbinavar, J. Hambleton, R.D. Mass, H.I. Hurwitz i inni. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. „J Clin Oncol”. 23 (16), s. 3706–3712, czerwiec 2005. DOI: 10.1200/JCO.2005.00.232. PMID: 15867200. 
  • F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi i inni. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. „Clin Colorectal Cancer”. 12 (3), s. 145–151, wrzesień 2013. DOI: 10.1016/j.clcc.2013.04.006. PMID: 23763824. 
  • L.T. Macedo, A.B. da Costa Lima, A.D. Sasse. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. „BMC Cancer”. 12, s. 89, 2012. DOI: 10.1186/1471-2407-12-89. PMID: 22414244. 
  • J.A. Meyerhardt, L. Li, H.K. Sanoff, W. Carpenter i inni. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. „J Clin Oncol”. 30 (6), s. 608–615, luty 2012. DOI: 10.1200/JCO.2011.38.9650. PMID: 22253466. 
  • H.I. Hurwitz, N.C. Tebbutt, F. Kabbinavar, B.J. Giantonio i inni. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. „Oncologist”. 18 (9), s. 1004–1012, 2013. DOI: 10.1634/theoncologist.2013-0107. PMID: 23881988. 
  • Y. Cao, A. Tan, F. Gao, L. Liu i inni. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. „Int J Colorectal Dis”. 24 (6), s. 677–685, czerwiec 2009. DOI: 10.1007/s00384-009-0655-9. PMID: 19184059. 
  • S. Welch, K. Spithoff, R.B. Rumble, J. Maroun. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. „Ann Oncol”. 21 (6), s. 1152–1162, czerwiec 2010. DOI: 10.1093/annonc/mdp533. PMID: 19942597. 
  • V. Ranpura, S. Hapani, S. Wu. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. „JAMA”. 305 (5), s. 487–494, luty 2011. DOI: 10.1001/jama.2011.51. PMID: 21285426. 
  • D. Miles, N. Harbeck, B. Escudier, H. Hurwitz i inni. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. „J Clin Oncol”. 29 (1), s. 83–88, styczeń 2011. DOI: 10.1200/JCO.2010.30.2794. PMID: 21098326. 
  • D. Cunningham, Y. Humblet, S. Siena, D. Khayat i inni. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. „N Engl J Med”. 351 (4), s. 337–345, lipiec 2004. DOI: 10.1056/NEJMoa033025. PMID: 15269313. 
  • E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet i inni. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. „J Clin Oncol”. 25 (13), s. 1658–1664, maj 2007. DOI: 10.1200/JCO.2006.08.1620. PMID: 17470858. 
  • J.P. Spano, C. Lagorce, D. Atlan, G. Milano i inni. Impact of EGFR expression on colorectal cancer patient prognosis and survival. „Ann Oncol”. 16 (1), s. 102–108, styczeń 2005. DOI: 10.1093/annonc/mdi006. PMID: 15598946. 
  • J.R. Hecht, E. Mitchell, M.A. Neubauer, H.A. Burris i inni. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. „Clin Cancer Res”. 16 (7), s. 2205–2213, kwiecień 2010. DOI: 10.1158/1078-0432.CCR-09-2017. PMID: 20332321. 
  • K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah i inni. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. „J Clin Oncol”. 23 (9), s. 1803–1810, marzec 2005. DOI: 10.1200/JCO.2005.08.037. PMID: 15677699. 
  • H.O. Al-Shamsi, W. Alhazzani, R.A. Wolff. Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. „J Gastrointest Oncol”. 6 (3), s. 314–321, czerwiec 2015. DOI: 10.3978/j.issn.2078-6891.2015.016. PMID: 26029459. 
  • C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann i inni. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. „J Clin Oncol”. 27 (5), s. 663–671, luty 2009. DOI: 10.1200/JCO.2008.20.8397. PMID: 19114683. 
  • T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade i inni. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. „Lancet”. 377 (9783), s. 2103–2114, czerwiec 2011. DOI: 10.1016/S0140-6736(11)60613-2. PMID: 21641636. 
  • E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski i inni. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. „N Engl J Med”. 360 (14), s. 1408–1417, kwiecień 2009. DOI: 10.1056/NEJMoa0805019. PMID: 19339720. 
  • I. Láng, C.H. Köhne, G. Folprecht, P. Rougier i inni. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. „Eur J Cancer”. 49 (2), s. 439–448, styczeń 2013. DOI: 10.1016/j.ejca.2012.08.023. PMID: 23116683. 
  • V. Heinemann, L.F. von Weikersthal, T. Decker, A. Kiani i inni. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. „Lancet Oncol”. 15 (10), s. 1065–1075, wrzesień 2014. DOI: 10.1016/S1470-2045(14)70330-4. PMID: 25088940. 
  • J.Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero i inni. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. „N Engl J Med”. 369 (11), s. 1023–1034, wrzesień 2013. DOI: 10.1056/NEJMoa1305275. PMID: 24024839. 
  • L.S. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola i inni. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. „J Clin Oncol”. 32 (21), s. 2240–2247, lipiec 2014. DOI: 10.1200/JCO.2013.53.2473. PMID: 24687833. 
  • E.P. Mitchell, B. Piperdi, M.E. Lacouture, H. Shearer i inni. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. „Clin Colorectal Cancer”. 10 (4), s. 333–339, grudzień 2011. DOI: 10.1016/j.clcc.2011.06.004. PMID: 22000810. 
  • P. Rougier, E. Van Cutsem, E. Bajetta, N. Niederle i inni. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. „Lancet”. 352 (9138), s. 1407–1412, październik 1998. DOI: 10.1016/S0140-6736(98)03085-2. PMID: 9807986. 
  • G.P. Kim, D.J. Sargent, M.R. Mahoney, K.M. Rowland i inni. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. „J Clin Oncol”. 27 (17), s. 2848–2854, czerwiec 2009. DOI: 10.1200/JCO.2008.20.4552. PMID: 19380443. 
  • E. Segelov, D. Chan, J. Shapiro, T.J. Price i inni. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. „Br J Cancer”. 111 (6), s. 1122–1131, wrzesień 2014. DOI: 10.1038/bjc.2014.404. PMID: 25072258. 
  • M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero i inni. Final results from a randomized phase 3 study of FOLFIRI {±} panitumumab for second-line treatment of metastatic colorectal cancer. „Ann Oncol”. 25 (1), s. 107–116, styczeń 2014. DOI: 10.1093/annonc/mdt523. PMID: 24356622. 
  • D.J. Jonker, C.J. O’Callaghan, C.S. Karapetis, J.R. Zalcberg i inni. Cetuximab for the treatment of colorectal cancer. „N Engl J Med”. 357 (20), s. 2040–2048, listopad 2007. DOI: 10.1056/NEJMoa071834. PMID: 18003960. 
  • Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer Sr, Michael N. Needle i inni. Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. „Journal of Clinical Oncology”, 2004. DOI: 10.1200/JCO.2004.10.182. 
  • J. Bennouna, J. Sastre, D. Arnold, P. Österlund i inni. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. „Lancet Oncol”. 14 (1), s. 29–37, styczeń 2013. DOI: 10.1016/S1470-2045(12)70477-1. PMID: 23168366. 
  • S. Kubicka, R. Greil, T. André, J. Bennouna i inni. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. „Ann Oncol”. 24 (9), s. 2342–2349, wrzesień 2013. DOI: 10.1093/annonc/mdt231. PMID: 23852309. 
  • T.H. Cartwright, Y.M. Yim, E. Yu, H. Chung i inni. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. „Clin Colorectal Cancer”. 11 (4), s. 238–246, grudzień 2012. DOI: 10.1016/j.clcc.2012.05.005. PMID: 22658457. 
  • A. Patel, W. Sun. Ziv-aflibercept in metastatic colorectal cancer. „Biologics”. 8, s. 13–25, 2014. DOI: 10.2147/BTT.S39360. PMID: 24368879. 
  • E. Van Cutsem, J. Tabernero, R. Lakomy, H. Prenen i inni. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. „J Clin Oncol”. 30 (28), s. 3499–3506, październik 2012. DOI: 10.1200/JCO.2012.42.8201. PMID: 22949147. 
  • G. Goel, W. Sun. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting-its impact on clinical practice. „J Hematol Oncol”. 8, s. 92, 2015. DOI: 10.1186/s13045-015-0183-8. PMID: 26215324. 
  • J. Tabernero, T. Yoshino, A.L. Cohn, R. Obermannova i inni. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. „Lancet Oncol”. 16 (5), s. 499–508, maj 2015. DOI: 10.1016/S1470-2045(15)70127-0. PMID: 25877855. 
  • S.M. Ronnekleiv-Kelly, G.D. Kennedy. Management of stage IV rectal cancer: palliative options. „World J Gastroenterol”. 17 (7), s. 835–847, luty 2011. DOI: 10.3748/wjg.v17.i7.835. PMID: 21412493. 
  • R. Costi, F. Leonardi, D. Zanoni, V. Violi i inni. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. „World J Gastroenterol”. 20 (24), s. 7602–7621, czerwiec 2014. DOI: 10.3748/wjg.v20.i24.7602. PMID: 24976699. 
  • A. Tuca, E. Guell, E. Martinez-Losada, N. Codorniu. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. „Cancer Manag Res”. 4, s. 159–169, 2012. DOI: 10.2147/CMAR.S29297. PMID: 22904637. 
  • M. Winner, S.J. Mooney, D.L. Hershman, D.L. Feingold i inni. Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. „JAMA Surg”. 148 (8), s. 715–722, sierpień 2013. DOI: 10.1001/jamasurg.2013.1. PMID: 23740130. 
  • M.A. Mohd Suan, W.L. Tan, S.A. Soelar, I. Ismail i inni. Intestinal obstruction: predictor of poor prognosis in colorectal carcinoma?. „Epidemiol Health”. 37, s. e2015017, 2015. DOI: 10.4178/epih/e2015017. PMID: 25868638. 
  • L. Ansaloni, R.E. Andersson, F. Bazzoli, F. Catena i inni. Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. „World J Emerg Surg”. 5, s. 29, 2010. DOI: 10.1186/1749-7922-5-29. PMID: 21189148. 
  • A.M. Watt, I.G. Faragher, T.T. Griffin, N.A. Rieger i inni. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. „Ann Surg”. 246 (1), s. 24–30, lipiec 2007. DOI: 10.1097/01.sla.0000261124.72687.72. PMID: 17592286. 
  • X.D. Zhao, B.B. Cai, R.S. Cao, R.H. Shi. Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis. „World J Gastroenterol”. 19 (33), s. 5565–5574, wrzesień 2013. DOI: 10.3748/wjg.v19.i33.5565. PMID: 24023502. 
  • H. Ptok, F. Marusch, R. Steinert, L. Meyer i inni. Incurable stenosing colorectal carcinoma: endoscopic stent implantation or palliative surgery?. „World J Surg”. 30 (8), s. 1481–1487, sierpień 2006. DOI: 10.1007/s00268-005-0513-z. PMID: 16850152. 
  • H. Huhtinen, P. Varpe, J. Karvonen, A. Rantala i inni. Late complications related to palliative stenting in patients with obstructing colorectal cancer. „Minim Invasive Ther Allied Technol”. 22 (6), s. 352–358, grudzień 2013. DOI: 10.3109/13645706.2013.797911. PMID: 23758091. 
  • A.M. Nitschke, C.E. Ray. Percutaneous neurolytic celiac plexus block. „Semin Intervent Radiol”. 30 (3), s. 318–321, wrzesień 2013. DOI: 10.1055/s-0033-1353485. PMID: 24436554. 
  • D.P. Seamans, G.Y. Wong, J.L. Wilson. Interventional pain therapy for intractable abdominal cancer pain. „J Clin Oncol”. 21 (9 Suppl), s. 92s-94s, maj 2003. DOI: 10.1200/JCO.2003.01.184. PMID: 12743207. 
  • C. Granda-Cameron, D. DeMille, M.P. Lynch, C. Huntzinger i inni. An interdisciplinary approach to manage cancer cachexia. „Clin J Oncol Nurs”. 14 (1), s. 72–80, luty 2010. DOI: 10.1188/10.CJON.72-80. PMID: 20118029. 
  • J.N. Gordon, S.R. Green, P.M. Goggin. Cancer cachexia. „QJM”. 98 (11), s. 779–788, listopad 2005. DOI: 10.1093/qjmed/hci127. PMID: 16214835. 
  • R. Dhanapal, T. Saraswathi, R.N. Govind. Cancer cachexia. „J Oral Maxillofac Pathol”. 15 (3), s. 257–260, wrzesień 2011. DOI: 10.4103/0973-029X.86670. PMID: 22144825. 
  • N.B. Kumar, A. Kazi, T. Smith, T. Crocker i inni. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. „Curr Treat Options Oncol”. 11 (3–4), s. 107–117, grudzień 2010. DOI: 10.1007/s11864-010-0127-z. PMID: 21128029. 
  • C.L. Donohoe, A.M. Ryan, J.V. Reynolds. Cancer cachexia: mechanisms and clinical implications. „Gastroenterol Res Pract”. 2011, s. 601434, 2011. DOI: 10.1155/2011/601434. PMID: 21760776. 
  • T. Aoyagi, K.P. Terracina, A. Raza, H. Matsubara i inni. Cancer cachexia, mechanism and treatment. „World J Gastrointest Oncol”. 7 (4), s. 17–29, kwiecień 2015. DOI: 10.4251/wjgo.v7.i4.17. PMID: 25897346. 
  • D.C. McMillan, S.J. Wigmore, K.C. Fearon, P. O’Gorman i inni. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. „Br J Cancer”. 79 (3–4), s. 495–500, luty 1999. DOI: 10.1038/sj.bjc.6690077. PMID: 10027319. 
  • L.C. Cerchietti, A.H. Navigante, M.A. Castro. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. „Nutr Cancer”. 59 (1), s. 14–20, 2007. DOI: 10.1080/01635580701365068. PMID: 17927497. 
  • C. Gridelli, C. Gallo, A. Ceribelli, V. Gebbia i inni. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. „Lancet Oncol”. 8 (6), s. 500–512, czerwiec 2007. DOI: 10.1016/S1470-2045(07)70146-8. PMID: 17513173. 
  • J. Reid, C.M. Hughes, L.J. Murray, C. Parsons i inni. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. „Palliat Med”. 27 (4), s. 295–303, kwiecień 2013. DOI: 10.1177/0269216312441382. PMID: 22450159. 
  • M.D. DeBoer, D.L. Marks. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. „Nat Clin Pract Endocrinol Metab”. 2 (8), s. 459–466, sierpień 2006. DOI: 10.1038/ncpendmet0221. PMID: 16932335. 
  • J.M. Scarlett, D.L. Marks. The use of melanocortin antagonists in cachexia of chronic disease. „Expert Opin Investig Drugs”. 14 (10), s. 1233–1239, październik 2005. DOI: 10.1517/13543784.14.10.1233. PMID: 16185165. 
  • S. Busquets, M.T. Figueras, G. Fuster, V. Almendro i inni. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. „Cancer Res”. 64 (18), s. 6725–6731, wrzesień 2004. DOI: 10.1158/0008-5472.CAN-04-0425. PMID: 15374990. 
  • J.N. Gordon, T.M. Trebble, R.D. Ellis, H.D. Duncan i inni. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. „Gut”. 54 (4), s. 540–545, kwiecień 2005. DOI: 10.1136/gut.2004.047563. PMID: 15753541. 
  • Health at a Glance 2015 OECD Indicators. Organization for Economic Cooperation and Development, 2015, s. 154. DOI: 10.1787/health_glance-2015-en. ISBN 978-92-64-23257-0.
  • F.G. Campos, A. Habr-Gama, S.C. Nahas, R.O. Perez i inni. Abdominoperineal excision: evolution of a centenary operation. „Dis Colon Rectum”. 55 (8), s. 844–853, sierpień 2012. DOI: 10.1097/DCR.0b013e31825ab0f7. PMID: 22810469. 
  • B. Gustavsson, G. Carlsson, D. Machover, N. Petrelli i inni. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. „Clin Colorectal Cancer”. 14 (1), s. 1–10, marzec 2015. DOI: 10.1016/j.clcc.2014.11.002. PMID: 25579803. 
  • L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen i inni. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. „N Engl J Med”. 343 (13), s. 905–914, wrzesień 2000. DOI: 10.1056/NEJM200009283431302. PMID: 11006366. 
  • R.M. Goldberg, D.J. Sargent, R.F. Morton, C.S. Fuchs i inni. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. „J Clin Oncol”. 22 (1), s. 23–30, styczeń 2004. DOI: 10.1200/JCO.2004.09.046. PMID: 14665611. 
  • R.L. Johnson, J.C. Fleet. Animal models of colorectal cancer. „Cancer Metastasis Rev”. 32 (1–2), s. 39–61, czerwiec 2013. DOI: 10.1007/s10555-012-9404-6. PMID: 23076650. 
  • A. Velcich, W. Yang, J. Heyer, A. Fragale i inni. Colorectal cancer in mice genetically deficient in the mucin Muc2. „Science”. 295 (5560), s. 1726–1729, marzec 2002. DOI: 10.1126/science.1069094. PMID: 11872843. 

esge.com

google.pl

books.google.pl

iiarjournals.org

ar.iiarjournals.org

indexcopernicus.com

journals.indexcopernicus.com

keepeek.com

mayoclinic.org

mp.pl

nature.com

nejm.org

nih.gov

ncbi.nlm.nih.gov

  • J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser i inni. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. „Int J Cancer”. 136 (5), s. E359-86, marzec 2015. DOI: 10.1002/ijc.29210. PMID: 25220842. 
  • H.S. Saidi, D. Karuri, E.O. Nyaim. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. „East Afr Med J”. 85 (6), s. 259–262, czerwiec 2008. PMID: 18817021. 
  • S.R. Majumdar, R.H. Fletcher, A.T. Evans. How does colorectal cancer present? Symptoms, duration, and clues to location. „Am J Gastroenterol”. 94 (10), s. 3039–3045, październik 1999. DOI: 10.1111/j.1572-0241.1999.01454.x. PMID: 10520866. 
  • C.M. Johnson, C. Wei, J.E. Ensor, D.J. Smolenski i inni. Meta-analyses of colorectal cancer risk factors. „Cancer Causes Control”. 24 (6), s. 1207–1222, czerwiec 2013. DOI: 10.1007/s10552-013-0201-5. PMID: 23563998. 
  • F.A. Haggar, R.P. Boushey. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. „Clin Colon Rectal Surg”. 22 (4), s. 191–197, listopad 2009. DOI: 10.1055/s-0029-1242458. PMID: 21037809. 
  • P. Boyle, J.S. Langman. ABC of colorectal cancer: Epidemiology. „BMJ”. 321 (7264), s. 805–808, wrzesień 2000. PMID: 11009523. 
  • M. Pericleous, D. Mandair, M.E. Caplin. Diet and supplements and their impact on colorectal cancer. „J Gastrointest Oncol”. 4 (4), s. 409–423, grudzień 2013. DOI: 10.3978/j.issn.2078-6891.2013.003. PMID: 24294513. 
  • T. Norat, A. Lukanova, P. Ferrari, E. Riboli. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. „Int J Cancer”. 98 (2), s. 241–256, marzec 2002. PMID: 11857415. 
  • M.S. Sandhu, I.R. White, K. McPherson. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. „Cancer Epidemiol Biomarkers Prev”. 10 (5), s. 439–446, maj 2001. PMID: 11352852. 
  • R. Sinha, W.H. Chow, M. Kulldorff, J. Denobile i inni. Well-done, grilled red meat increases the risk of colorectal adenomas. „Cancer Res”. 59 (17), s. 4320–4324, wrzesień 1999. PMID: 10485479. 
  • N.M. Probst-Hensch, R. Sinha, M.P. Longnecker, J.S. Witte i inni. Meat preparation and colorectal adenomas in a large sigmoidoscopy-based case-control study in California (United States). „Cancer Causes Control”. 8 (2), s. 175–183, marzec 1997. PMID: 9134241. 
  • D.D. Alexander, A.J. Miller, C.A. Cushing, K.A. Lowe. Processed meat and colorectal cancer: a quantitative review of prospective epidemiologic studies. „Eur J Cancer Prev”. 19 (5), s. 328–341, wrzesień 2010. DOI: 10.1097/CEJ.0b013e32833b48fa. PMID: 20495462. 
  • D.D. Alexander, C.A. Cushing. Red meat and colorectal cancer: a critical summary of prospective epidemiologic studies. „Obes Rev”. 12 (5), s. e472–e493, maj 2011. DOI: 10.1111/j.1467-789X.2010.00785.x. PMID: 20663065. 
  • S. Franceschi, C. La Vecchia, A. Russo, A. Favero i inni. Macronutrient intake and risk of colorectal cancer in Italy. „Int J Cancer”. 76 (3), s. 321–324, maj 1998. PMID: 9579566. 
  • W.C. Willett, M.J. Stampfer, G.A. Colditz, B.A. Rosner i inni. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. „N Engl J Med”. 323 (24), s. 1664–1672, grudzień 1990. DOI: 10.1056/NEJM199012133232404. PMID: 2172820. 
  • T.T. Fung, F.B. Hu, K. Wu, S.E. Chiuve i inni. The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer. „Am J Clin Nutr”. 92 (6), s. 1429–1435, grudzień 2010. DOI: 10.3945/ajcn.2010.29242. PMID: 21097651. 
  • D.D. Alexander, C.A. Cushing, K.A. Lowe, B. Sceurman i inni. Meta-analysis of animal fat or animal protein intake and colorectal cancer. „Am J Clin Nutr”. 89 (5), s. 1402–1409, maj 2009. DOI: 10.3945/ajcn.2008.26838. PMID: 19261724. 
  • S. Sasazuki, M. Inoue, M. Iwasaki, N. Sawada i inni. Intake of n-3 and n-6 polyunsaturated fatty acids and development of colorectal cancer by subsite: Japan Public Health Center-based prospective study. „Int J Cancer”. 129 (7), s. 1718–1729, październik 2011. DOI: 10.1002/ijc.25802. PMID: 21120874. 
  • Y. Kimura, S. Kono, K. Toyomura, J. Nagano i inni. Meat, fish and fat intake in relation to subsite-specific risk of colorectal cancer: The Fukuoka Colorectal Cancer Study. „Cancer Sci”. 98 (4), s. 590–597, kwiecień 2007. DOI: 10.1111/j.1349-7006.2007.00425.x. PMID: 17425596. 
  • E. Theodoratou, G. McNeill, R. Cetnarskyj, S.M. Farrington i inni. Dietary fatty acids and colorectal cancer: a case-control study. „Am J Epidemiol”. 166 (2), s. 181–195, lipiec 2007. DOI: 10.1093/aje/kwm063. PMID: 17493949. 
  • S. Kim, D.P. Sandler, J. Galanko, C. Martin i inni. Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. „Am J Epidemiol”. 171 (9), s. 969–979, maj 2010. DOI: 10.1093/aje/kwq032. PMID: 20392864. 
  • S. Wu, B. Feng, K. Li, X. Zhu i inni. Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. „Am J Med”. 125 (6), s. 551–559.e5, czerwiec 2012. DOI: 10.1016/j.amjmed.2012.01.022. PMID: 22513196. 
  • C.R. Daniel, M.L. McCullough, R.C. Patel, E.J. Jacobs i inni. Dietary intake of omega-6 and omega-3 fatty acids and risk of colorectal cancer in a prospective cohort of U.S. men and women. „Cancer Epidemiol Biomarkers Prev”. 18 (2), s. 516–525, luty 2009. DOI: 10.1158/1055-9965.EPI-08-0750. PMID: 19190143. 
  • X.J. Shen, J.D. Zhou, J.Y. Dong, W.Q. Ding i inni. Dietary intake of n-3 fatty acids and colorectal cancer risk: a meta-analysis of data from 489 000 individuals. „Br J Nutr”. 108 (9), s. 1550–1556, listopad 2012. DOI: 10.1017/S0007114512003546. PMID: 22906228. 
  • C.H. MacLean, S.J. Newberry, W.A. Mojica, P. Khanna i inni. Effects of omega-3 fatty acids on cancer risk: a systematic review. „JAMA”. 295 (4), s. 403–415, styczeń 2006. DOI: 10.1001/jama.295.4.403. PMID: 16434631. 
  • F.J. van Duijnhoven, H.B. Bueno-De-Mesquita, P. Ferrari, M. Jenab i inni. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. „Am J Clin Nutr”. 89 (5), s. 1441–1452, maj 2009. DOI: 10.3945/ajcn.2008.27120. PMID: 19339391. 
  • A.E. Millen, A.F. Subar, B.I. Graubard, U. Peters i inni. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. „Am J Clin Nutr”. 86 (6), s. 1754–1764, grudzień 2007. PMID: 18065596. 
  • K.B. Michels, E. Giovannucci, A.T. Chan, R. Singhania i inni. Fruit and vegetable consumption and colorectal adenomas in the Nurses’ Health Study. „Cancer Res”. 66 (7), s. 3942–3953, kwiecień 2006. DOI: 10.1158/0008-5472.CAN-05-3637. PMID: 16585224. 
  • J.S. Witte, M.P. Longnecker, C.L. Bird, E.R. Lee i inni. Relation of vegetable, fruit, and grain consumption to colorectal adenomatous polyps. „Am J Epidemiol”. 144 (11), s. 1015–1025, grudzień 1996. PMID: 8942431. 
  • D.S. Alberts, M.E. Martínez, D.J. Roe, J.M. Guillén-Rodríguez i inni. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. „N Engl J Med”. 342 (16), s. 1156–1162, kwiecień 2000. DOI: 10.1056/NEJM200004203421602. PMID: 10770980. 
  • E. Bidoli, S. Franceschi, R. Talamini, S. Barra i inni. Food consumption and cancer of the colon and rectum in north-eastern Italy. „Int J Cancer”. 50 (2), s. 223–229, styczeń 1992. PMID: 1730516. 
  • G.R. Howe, E. Benito, R. Castelleto, J. Cornée i inni. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. „J Natl Cancer Inst”. 84 (24), s. 1887–1896, grudzień 1992. PMID: 1334153. 
  • B. Trock, E. Lanza, P. Greenwald. Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. „J Natl Cancer Inst”. 82 (8), s. 650–661, kwiecień 1990. PMID: 2157027. 
  • Y. Park, D.J. Hunter, D. Spiegelman, L. Bergkvist i inni. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. „JAMA”. 294 (22), s. 2849–2857, grudzień 2005. DOI: 10.1001/jama.294.22.2849. PMID: 16352792. 
  • D. Aune, D.S. Chan, R. Lau, R. Vieira i inni. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. „BMJ”. 343, s. d6617, 2011. PMID: 22074852. 
  • C.F. Garland, F.C. Garland. Do sunlight and vitamin D reduce the likelihood of colon cancer?. „Int J Epidemiol”. 9 (3), s. 227–231, wrzesień 1980. PMID: 7440046. 
  • I. Kato, A. Akhmedkhanov, K. Koenig, P.G. Toniolo i inni. Prospective study of diet and female colorectal cancer: the New York University Women’s Health Study. „Nutr Cancer”. 28 (3), s. 276–281, 1997. DOI: 10.1080/01635589709514588. PMID: 9343837. 
  • E.D. Gorham, C.F. Garland, F.C. Garland, W.B. Grant i inni. Vitamin D and prevention of colorectal cancer. „J Steroid Biochem Mol Biol”. 97 (1–2), s. 179–194, październik 2005. DOI: 10.1016/j.jsbmb.2005.06.018. PMID: 16236494. 
  • F. Levi, C. Pasche, F. Lucchini, C. La Vecchia. Selected micronutrients and colorectal cancer. a case-control study from the canton of Vaud, Switzerland. „Eur J Cancer”. 36 (16), s. 2115–2119, październik 2000. PMID: 11044650. 
  • J. Wactawski-Wende, J.M. Kotchen, G.L. Anderson, A.R. Assaf i inni. Calcium plus vitamin D supplementation and the risk of colorectal cancer. „N Engl J Med”. 354 (7), s. 684–696, luty 2006. DOI: 10.1056/NEJMoa055222. PMID: 16481636. 
  • M.L. McCullough, A.S. Robertson, C. Rodriguez, E.J. Jacobs i inni. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). „Cancer Causes Control”. 14 (1), s. 1–12, luty 2003. PMID: 12708719. 
  • P. Pietinen, N. Malila, M. Virtanen, T.J. Hartman i inni. Diet and risk of colorectal cancer in a cohort of Finnish men. „Cancer Causes Control”. 10 (5), s. 387–396, październik 1999. PMID: 10530608. 
  • M.E. Martínez, E.L. Giovannucci, G.A. Colditz, M.J. Stampfer i inni. Calcium, vitamin D, and the occurrence of colorectal cancer among women. „J Natl Cancer Inst”. 88 (19), s. 1375–1382, październik 1996. PMID: 8827015. 
  • E. Kampman, R.A. Goldbohm, P.A. van den Brandt, P. van 't Veer. Fermented dairy products, calcium, and colorectal cancer in The Netherlands Cohort Study. „Cancer Res”. 54 (12), s. 3186–3190, czerwiec 1994. PMID: 8205538. 
  • E. Cho, S.A. Smith-Warner, D. Spiegelman, W.L. Beeson i inni. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. „J Natl Cancer Inst”. 96 (13), s. 1015–1022, lipiec 2004. PMID: 15240785. 
  • A.A. Moghaddam, M. Woodward, R. Huxley. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. „Cancer Epidemiol Biomarkers Prev”. 16 (12), s. 2533–2547, grudzień 2007. DOI: 10.1158/1055-9965.EPI-07-0708. PMID: 18086756. 
  • L.C. Thygesen, M. Grønbaek, C. Johansen, C.S. Fuchs i inni. Prospective weight change and colon cancer risk in male US health professionals. „Int J Cancer”. 123 (5), s. 1160–1165, wrzesień 2008. DOI: 10.1002/ijc.23612. PMID: 18546286. 
  • S.C. Larsson, A. Wolk. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. „Am J Clin Nutr”. 86 (3), s. 556–565, wrzesień 2007. PMID: 17823417. 
  • N. Khan, F. Afaq, H. Mukhtar. Lifestyle as risk factor for cancer: Evidence from human studies. „Cancer Lett”. 293 (2), s. 133–143, lipiec 2010. DOI: 10.1016/j.canlet.2009.12.013. PMID: 20080335. 
  • Y. Kim, Y. Kim, S. Lee. An association between colonic adenoma and abdominal obesity: a cross-sectional study. „BMC Gastroenterol”. 9, s. 4, 2009. DOI: 10.1186/1471-230X-9-4. PMID: 19144203. 
  • S.H. Davoodi, T. Malek-Shahabi, A. Malekshahi-Moghadam, R. Shahbazi i inni. Obesity as an important risk factor for certain types of cancer. „Iran J Cancer Prev”. 6 (4), s. 186–194, 2013. PMID: 25250133. 
  • S.C. Larsson, N. Orsini, A. Wolk. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. „J Natl Cancer Inst”. 97 (22), s. 1679–1687, listopad 2005. DOI: 10.1093/jnci/dji375. PMID: 16288121. 
  • L. Deng, Z. Gui, L. Zhao, J. Wang i inni. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. „Dig Dis Sci”. 57 (6), s. 1576–1585, czerwiec 2012. DOI: 10.1007/s10620-012-2055-1. PMID: 22350783. 
  • H. Yuhara, C. Steinmaus, S.E. Cohen, D.A. Corley i inni. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. „Am J Gastroenterol”. 106 (11), s. 1911–1921; quiz 1922, listopad 2011. DOI: 10.1038/ajg.2011.301. PMID: 21912438. 
  • S. Jarvandi, N.O. Davidson, M. Schootman. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. „PLoS One”. 8 (9), s. e74616, 2013. DOI: 10.1371/journal.pone.0074616. PMID: 24069323. 
  • Y.X. Yang, S. Hennessy, J.D. Lewis. Type 2 diabetes mellitus and the risk of colorectal cancer. „Clin Gastroenterol Hepatol”. 3 (6), s. 587–594, czerwiec 2005. PMID: 15952101. 
  • J.M. Berster, B. Göke. Type 2 diabetes mellitus as risk factor for colorectal cancer. „Arch Physiol Biochem”. 114 (1), s. 84–98, luty 2008. DOI: 10.1080/13813450802008455. PMID: 18465362. 
  • K.T. Mills, C.F. Bellows, A.E. Hoffman, T.N. Kelly i inni. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. „Dis Colon Rectum”. 56 (11), s. 1304–1319, listopad 2013. DOI: 10.1097/DCR.0b013e3182a479f9. PMID: 24105007. 
  • Y. Mao, S. Pan, S.W. Wen, K.C. Johnson. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. „Int J Cancer”. 105 (6), s. 831–837, lipiec 2003. DOI: 10.1002/ijc.11159. PMID: 12767070. 
  • G.A. Colditz, C.C. Cannuscio, A.L. Frazier. Physical activity and reduced risk of colon cancer: implications for prevention. „Cancer Causes Control”. 8 (4), s. 649–667, lipiec 1997. PMID: 9242482. 
  • T.I. Nilsen, L.J. Vatten. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. „Br J Cancer”. 84 (3), s. 417–422, luty 2001. DOI: 10.1054/bjoc.2000.1582. PMID: 11161410. 
  • K.J. Lee, M. Inoue, T. Otani, M. Iwasaki i inni. Physical activity and risk of colorectal cancer in Japanese men and women: the Japan Public Health Center-based prospective study. „Cancer Causes Control”. 18 (2), s. 199–209, marzec 2007. DOI: 10.1007/s10552-006-0098-3. PMID: 17206529. 
  • A.L. Zisman, A. Nickolov, R.E. Brand, A. Gorchow i inni. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. „Arch Intern Med”. 166 (6), s. 629–634, marzec 2006. DOI: 10.1001/archinte.166.6.629. PMID: 16567601. 
  • E. Botteri, S. Iodice, V. Bagnardi, S. Raimondi i inni. Smoking and colorectal cancer: a meta-analysis. „JAMA”. 300 (23), s. 2765–2778, grudzień 2008. DOI: 10.1001/jama.2008.839. PMID: 19088354. 
  • P.S. Liang, T.Y. Chen, E. Giovannucci. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. „Int J Cancer”. 124 (10), s. 2406–2415, maj 2009. DOI: 10.1002/ijc.24191. PMID: 19142968. 
  • M. Lüchtenborg, K.K. White, L. Wilkens, L.N. Kolonel i inni. Smoking and colorectal cancer: different effects by type of cigarettes?. „Cancer Epidemiol Biomarkers Prev”. 16 (7), s. 1341–1347, lipiec 2007. DOI: 10.1158/1055-9965.EPI-06-0519. PMID: 17626999. 
  • E. Botteri, S. Iodice, S. Raimondi, P. Maisonneuve i inni. Cigarette smoking and adenomatous polyps: a meta-analysis. „Gastroenterology”. 134 (2), s. 388–395, luty 2008. DOI: 10.1053/j.gastro.2007.11.007. PMID: 18242207. 
  • L.M. Hannan, E.J. Jacobs, M.J. Thun. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. „Cancer Epidemiol Biomarkers Prev”. 18 (12), s. 3362–3367, grudzień 2009. DOI: 10.1158/1055-9965.EPI-09-0661. PMID: 19959683. 
  • E.R. Kim, D.K. Chang. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. „World J Gastroenterol”. 20 (29), s. 9872–9881, sierpień 2014. DOI: 10.3748/wjg.v20.i29.9872. PMID: 25110418. 
  • J.A. Eaden, K.R. Abrams, J.F. Mayberry. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. „Gut”. 48 (4), s. 526–535, kwiecień 2001. PMID: 11247898. 
  • L. Lakatos, G. Mester, Z. Erdelyi, G. David i inni. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. „Inflamm Bowel Dis”. 12 (3), s. 205–211, marzec 2006. DOI: 10.1097/01.MIB.0000217770.21261.ce. PMID: 16534422. 
  • C. Canavan, K.R. Abrams, J. Mayberry. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. „Aliment Pharmacol Ther”. 23 (8), s. 1097–1104, kwiecień 2006. DOI: 10.1111/j.1365-2036.2006.02854.x. PMID: 16611269. 
  • A. Ekbom, C. Helmick, M. Zack, H.O. Adami. Ulcerative colitis and colorectal cancer. A population-based study. „N Engl J Med”. 323 (18), s. 1228–1233, listopad 1990. DOI: 10.1056/NEJM199011013231802. PMID: 2215606. 
  • J. Potack, S.H. Itzkowitz. Colorectal cancer in inflammatory bowel disease. „Gut Liver”. 2 (2), s. 61–73, wrzesień 2008. DOI: 10.5009/gnl.2008.2.2.61. PMID: 20485613. 
  • R.M. Soetikno, O.S. Lin, P.A. Heidenreich, H.S. Young i inni. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. „Gastrointest Endosc”. 56 (1), s. 48–54, lipiec 2002. PMID: 12085034. 
  • K.W. Nuako, D.A. Ahlquist, D.W. Mahoney, D.J. Schaid i inni. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. „Gastroenterology”. 115 (5), s. 1079–1083, listopad 1998. PMID: 9797361. 
  • J. Askling, P.W. Dickman, P. Karlén, O. Broström i inni. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. „Gastroenterology”. 120 (6), s. 1356–1362, maj 2001. PMID: 11313305. 
  • P. Ferrari, M. Jenab, T. Norat, A. Moskal i inni. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). „Int J Cancer”. 121 (9), s. 2065–2072, listopad 2007. DOI: 10.1002/ijc.22966. PMID: 17640039. 
  • T. Mizoue, M. Inoue, K. Wakai, C. Nagata i inni. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. „Am J Epidemiol”. 167 (12), s. 1397–1406, czerwiec 2008. DOI: 10.1093/aje/kwn073. PMID: 18420544. 
  • E. Cho, S.A. Smith-Warner, J. Ritz, P.A. van den Brandt i inni. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. „Ann Intern Med”. 140 (8), s. 603–613, kwiecień 2004. PMID: 15096331. 
  • N.N. Baxter, J.E. Tepper, S.B. Durham, D.A. Rothenberger i inni. Increased risk of rectal cancer after prostate radiation: a population-based study. „Gastroenterology”. 128 (4), s. 819–824, kwiecień 2005. PMID: 15825064. 
  • B. Delhougne, C. Deneux, R. Abs, P. Chanson i inni. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. „J Clin Endocrinol Metab”. 80 (11), s. 3223–3226, listopad 1995. DOI: 10.1210/jcem.80.11.7593429. PMID: 7593429. 
  • A.G. Renehan, J. O’Connell, D. O’Halloran, F. Shanahan i inni. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. „Horm Metab Res”. 35 (11–12). s. 712–725. DOI: 10.1055/s-2004-814150. PMID: 14710350. 
  • F. Kastrinos, S. Syngal. Inherited colorectal cancer syndromes. „Cancer J”. 17 (6). s. 405–415. DOI: 10.1097/PPO.0b013e318237e408. PMID: 22157284. 
  • W.M. Grady. Genetic testing for high-risk colon cancer patients. „Gastroenterology”. 124 (6), s. 1574–1594, maj 2003. PMID: 12761718. 
  • E.M. Stoffel, F. Kastrinos. Familial colorectal cancer, beyond Lynch syndrome. „Clin Gastroenterol Hepatol”. 12 (7), s. 1059–1068, lipiec 2014. DOI: 10.1016/j.cgh.2013.08.015. PMID: 23962553. 
  • J.M. Carethers, E.M. Stoffel. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. „World J Gastroenterol”. 21 (31), s. 9253–9261, sierpień 2015. DOI: 10.3748/wjg.v21.i31.9253. PMID: 26309352. 
  • K.E. Resnick, H. Hampel, R. Fishel, D.E. Cohn. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. „Gynecol Oncol”. 114 (1), s. 128–134, lipiec 2009. DOI: 10.1016/j.ygyno.2009.03.003. PMID: 19375789. 
  • A. de la Chapelle. The incidence of Lynch syndrome. „Fam Cancer”. 4 (3), s. 233–237, 2005. DOI: 10.1007/s10689-004-5811-3. PMID: 16136383. 
  • H. Hampel, W.L. Frankel, E. Martin, M. Arnold i inni. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). „N Engl J Med”. 352 (18), s. 1851–1860, maj 2005. DOI: 10.1056/NEJMoa043146. PMID: 15872200. 
  • D.C. Chung, A.K. Rustgi. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. „Ann Intern Med”. 138 (7), s. 560–570, kwiecień 2003. PMID: 12667026. 
  • V. Steinke, C. Engel, R. Büttner, H.K. Schackert i inni. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. „Dtsch Arztebl Int”. 110 (3), s. 32–38, styczeń 2013. DOI: 10.3238/arztebl.2013.0032. PMID: 23413378. 
  • G.L. Baiocchi, N. Portolani, W. Vermi, C. Baronchelli i inni. Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. „BMC Surg”. 14, s. 9, 2014. DOI: 10.1186/1471-2482-14-9. PMID: 24533633. 
  • M. Aarnio, R. Sankila, E. Pukkala, R. Salovaara i inni. Cancer risk in mutation carriers of DNA-mismatch-repair genes. „Int J Cancer”. 81 (2), s. 214–218, kwiecień 1999. PMID: 10188721. 
  • H.T. Lynch, T.C. Smyrk, P.M. Lynch, S.J. Lanspa i inni. Adenocarcinoma of the small bowel in lynch syndrome II. „Cancer”. 64 (10), s. 2178–2183, listopad 1989. PMID: 2804907. 
  • H.F. Vasen, J.T. Wijnen, F.H. Menko, J.H. Kleibeuker i inni. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. „Gastroenterology”. 110 (4), s. 1020–1027, kwiecień 1996. PMID: 8612988. 
  • Y. Parc, C. Boisson, G. Thomas, S. Olschwang. Cancer risk in 348 French MSH2 or MLH1 gene carriers. „J Med Genet”. 40 (3), s. 208–213, marzec 2003. PMID: 12624141. 
  • J. Balmaña, F. Balaguer, A. Cervantes, D. Arnold. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. „Ann Oncol”. 24 Suppl 6, s. vi73-80, październik 2013. DOI: 10.1093/annonc/mdt209. PMID: 23813931. 
  • S. Shiovitz, W.K. Copeland, M.N. Passarelli, A.N. Burnett-Hartman i inni. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. „Br J Cancer”. 111 (3), s. 598–602, lipiec 2014. DOI: 10.1038/bjc.2014.309. PMID: 24918813. 
  • F.G. Campos, M. Sulbaran, A.V. Safatle-Ribeiro, C.A. Martinez. Duodenal adenoma surveillance in patients with familial adenomatous polyposis. „World J Gastrointest Endosc”. 7 (10), s. 950–959, sierpień 2015. DOI: 10.4253/wjge.v7.i10.950. PMID: 26265988. 
  • M.L. Leoz, S. Carballal, L. Moreira, T. Ocaña i inni. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. „Appl Clin Genet”. 8, s. 95–107, 2015. DOI: 10.2147/TACG.S51484. PMID: 25931827. 
  • A.M. Jelsig, N. Qvist, K. Brusgaard, C.B. Nielsen i inni. Hamartomatous polyposis syndromes: a review. „Orphanet J Rare Dis”. 9, s. 101, 2014. DOI: 10.1186/1750-1172-9-101. PMID: 25022750. 
  • F.M. Giardiello, J.D. Brensinger, A.C. Tersmette, S.N. Goodman i inni. Very high risk of cancer in familial Peutz-Jeghers syndrome. „Gastroenterology”. 119 (6), s. 1447–1453, grudzień 2000. PMID: 11113065. 
  • N. Hearle, V. Schumacher, F.H. Menko, S. Olschwang i inni. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. „Clin Cancer Res”. 12 (10), s. 3209–3215, maj 2006. DOI: 10.1158/1078-0432.CCR-06-0083. PMID: 16707622. 
  • F.G. Campos, M.N. Figueiredo, C.A. Martinez. Colorectal cancer risk in hamartomatous polyposis syndromes. „World J Gastrointest Surg”. 7 (3), s. 25–32, marzec 2015. DOI: 10.4240/wjgs.v7.i3.25. PMID: 25848489. 
  • M.G. Dunlop. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. „Gut”. 51 Suppl 5, s. V21-7, październik 2002. PMID: 12221036. 
  • E. Chow, F. Macrae. A review of juvenile polyposis syndrome. „J Gastroenterol Hepatol”. 20 (11), s. 1634–1640, listopad 2005. DOI: 10.1111/j.1440-1746.2005.03865.x. PMID: 16246179. 
  • N. Mishra, J. Hall. Identification of patients at risk for hereditary colorectal cancer. „Clin Colon Rectal Surg”. 25 (2), s. 67–82, czerwiec 2012. DOI: 10.1055/s-0032-1313777. PMID: 23730221. 
  • M.L. Poulsen, M.L. Bisgaard. MUTYH Associated Polyposis (MAP). „Curr Genomics”. 9 (6), s. 420–435, wrzesień 2008. DOI: 10.2174/138920208785699562. PMID: 19506731. 
  • A.T. Chan, E.L. Giovannucci. Primary prevention of colorectal cancer. „Gastroenterology”. 138 (6), s. 2029–2043.e10, czerwiec 2010. DOI: 10.1053/j.gastro.2010.01.057. PMID: 20420944. 
  • P.J. Tárraga López, J.S. Albero, J.A. Rodríguez-Montes. Primary and secondary prevention of colorectal cancer. „Clin Med Insights Gastroenterol”. 7, s. 33–46, 2014. DOI: 10.4137/CGast.S14039. PMID: 25093007. 
  • S.J. Winawer, A.G. Zauber, M.J. O’Brien, M.N. Ho i inni. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. „N Engl J Med”. 328 (13), s. 901–906, kwiecień 1993. DOI: 10.1056/NEJM199304013281301. PMID: 8446136. 
  • F. Citarda, G. Tomaselli, R. Capocaccia, S. Barcherini i inni. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. „Gut”. 48 (6), s. 812–815, czerwiec 2001. PMID: 11358901. 
  • N.N. Baxter, M.A. Goldwasser, L.F. Paszat, R. Saskin i inni. Association of colonoscopy and death from colorectal cancer. „Ann Intern Med”. 150 (1), s. 1–8, styczeń 2009. PMID: 19075198. 
  • G.P. Young, E.L. Symonds, J.E. Allison, S.R. Cole i inni. Advances in Fecal Occult Blood Tests: the FIT revolution. „Dig Dis Sci”. 60 (3), s. 609–622, marzec 2015. DOI: 10.1007/s10620-014-3445-3. PMID: 25492500. 
  • P. Hewitson, P. Glasziou, L. Irwig, B. Towler i inni. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. „Cochrane Database Syst Rev”, s. CD001216, 2007. DOI: 10.1002/14651858.CD001216.pub2. PMID: 17253456. 
  • F. Stracci, M. Zorzi, G. Grazzini. Colorectal cancer screening: tests, strategies, and perspectives. „Front Public Health”. 2, s. 210, 2014. DOI: 10.3389/fpubh.2014.00210. PMID: 25386553. 
  • E. Flossmann, P.M. Rothwell. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. „Lancet”. 369 (9573), s. 1603–1613, maj 2007. DOI: 10.1016/S0140-6736(07)60747-8. PMID: 17499602. 
  • T.K. Asano, R.S. McLeod. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. „Cochrane Database Syst Rev”, s. CD004079, 2004. DOI: 10.1002/14651858.CD004079.pub2. PMID: 15106236. 
  • Y.P. Wang, Q. Wang, T. Gan, T. Pan i inni. Non-steroidal anti-inflammatory agents for chemoprevention of colorectal polyps: a meta-analysis. „Zhonghua Nei Ke Za Zhi”. 43 (1), s. 10–12, styczeń 2004. PMID: 14990012. 
  • A.T. Chan, E.L. Giovannucci, J.A. Meyerhardt, E.S. Schernhammer i inni. Aspirin dose and duration of use and risk of colorectal cancer in men. „Gastroenterology”. 134 (1), s. 21–28, styczeń 2008. DOI: 10.1053/j.gastro.2007.09.035. PMID: 18005960. 
  • N. Arber, C.J. Eagle, J. Spicak, I. Rácz i inni. Celecoxib for the prevention of colorectal adenomatous polyps. „N Engl J Med”. 355 (9), s. 885–895, sierpień 2006. DOI: 10.1056/NEJMoa061652. PMID: 16943401. 
  • M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston i inni. Celecoxib for the prevention of sporadic colorectal adenomas. „N Engl J Med”. 355 (9), s. 873–884, sierpień 2006. DOI: 10.1056/NEJMoa061355. PMID: 16943400. 
  • J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan i inni. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. „Gastroenterology”. 131 (6), s. 1674–1682, grudzień 2006. DOI: 10.1053/j.gastro.2006.08.079. PMID: 17087947. 
  • S.D. Solomon, M.A. Pfeffer, J.J. McMurray, R. Fowler i inni. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. „Circulation”. 114 (10), s. 1028–1035, wrzesień 2006. DOI: 10.1161/CIRCULATIONAHA.106.636746. PMID: 16943394. 
  • R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese i inni. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. „N Engl J Med”. 352 (11), s. 1092–1102, marzec 2005. DOI: 10.1056/NEJMoa050493. PMID: 15713943. 
  • F.M. Giardiello, S.R. Hamilton, A.J. Krush, S. Piantadosi i inni. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. „N Engl J Med”. 328 (18), s. 1313–1316, maj 1993. DOI: 10.1056/NEJM199305063281805. PMID: 8385741. 
  • D. Labayle, D. Fischer, P. Vielh, F. Drouhin i inni. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. „Gastroenterology”. 101 (3), s. 635–639, wrzesień 1991. PMID: 1650315. 
  • S. Bonovas, K. Filioussi, C.S. Flordellis, N.M. Sitaras. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. „J Clin Oncol”. 25 (23), s. 3462–3468, sierpień 2007. DOI: 10.1200/JCO.2007.10.8936. PMID: 17687150. 
  • S. Liu, R. Zheng, M. Zhang, S. Zhang i inni. Incidence and mortality of colorectal cancer in China, 2011. „Chin J Cancer Res”. 27 (1), s. 22–28, luty 2015. DOI: 10.3978/j.issn.1000-9604.2015.02.01. PMID: 25717222. 
  • J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso i inni. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. „Eur J Cancer”. 49 (6), s. 1374–1403, kwiecień 2013. DOI: 10.1016/j.ejca.2012.12.027. PMID: 23485231. 
  • R. Siegel, C. Desantis, A. Jemal. Colorectal cancer statistics, 2014. „CA Cancer J Clin”. 64 (2). s. 104–117. DOI: 10.3322/caac.21220. PMID: 24639052. 
  • F. Amersi, M. Agustin, C.Y. Ko. Colorectal cancer: epidemiology, risk factors, and health services. „Clin Colon Rectal Surg”. 18 (3), s. 133–140, sierpień 2005. DOI: 10.1055/s-2005-916274. PMID: 20011296. 
  • G. Murphy, S.S. Devesa, A.J. Cross, P.D. Inskip i inni. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. „Int J Cancer”. 128 (7), s. 1668–1675, kwiecień 2011. DOI: 10.1002/ijc.25481. PMID: 20503269. 
  • R.J. Wong. Marked variations in proximal colon cancer survival by race/ethnicity within the United States. „J Clin Gastroenterol”. 44 (9), s. 625–630, październik 2010. DOI: 10.1097/MCG.0b013e3181c64a7a. PMID: 19996985. 
  • M. Fleming, S. Ravula, S.F. Tatishchev, H.L. Wang. Colorectal carcinoma: Pathologic aspects. „J Gastrointest Oncol”. 3 (3), s. 153–173, wrzesień 2012. DOI: 10.3978/j.issn.2078-6891.2012.030. PMID: 22943008. 
  • L. Cheng, C. Eng, L.Z. Nieman, A.S. Kapadia i inni. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. „Am J Clin Oncol”. 34 (6), s. 573–580, grudzień 2011. DOI: 10.1097/COC.0b013e3181fe41ed. PMID: 21217399. 
  • M.A. Jafarabadi, S.M. Mohammadi, E. Hajizadeh, A. Kazemnejad i inni. Does the prognosis of colorectal cancer vary with tumor site?. „Gastroenterol Hepatol Bed Bench”. 4 (4), s. 199–209, 2011. PMID: 24834183. 
  • N. Savas, U. Dagli, S. Akbulut, O. Yuksel i inni. Colorectal cancer localization in young patients: should we expand the screening program?. „Dig Dis Sci”. 52 (3), s. 798–802, marzec 2007. DOI: 10.1007/s10620-006-9432-6. PMID: 17245629. 
  • R.A. Meguid, M.B. Slidell, C.L. Wolfgang, D.C. Chang i inni. Is there a difference in survival between right- versus left-sided colon cancers?. „Ann Surg Oncol”. 15 (9), s. 2388–2394, wrzesień 2008. DOI: 10.1245/s10434-008-0015-y. PMID: 18622647. 
  • A.K. Lam, S.S. Chan, M. Leung. Synchronous colorectal cancer: clinical, pathological and molecular implications. „World J Gastroenterol”. 20 (22), s. 6815–6820, czerwiec 2014. DOI: 10.3748/wjg.v20.i22.6815. PMID: 24944471. 
  • N.S. Goldstein. Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. „Am J Clin Pathol”. 125 (1), s. 146–153, styczeń 2006. PMID: 16483003. 
  • J. Munding, A. Tannapfel. Epidemiology of Colorectal Adenomas and Histopathological Assessment of Endoscopic Specimens in the Colorectum. „Viszeralmedizin”. 30 (1), s. 10–16, luty 2014. DOI: 10.1159/000357744. PMID: 26288577. 
  • D.K. Rex, D.J. Ahnen, J.A. Baron, K.P. Batts i inni. Serrated lesions of the colorectum: review and recommendations from an expert panel. „Am J Gastroenterol”. 107 (9), s. 1315–1329; quiz 1314, 1330, wrzesień 2012. DOI: 10.1038/ajg.2012.161. PMID: 22710576. 
  • V.P. Bauer, H.T. Papaconstantinou. Management of serrated adenomas and hyperplastic polyps. „Clin Colon Rectal Surg”. 21 (4), s. 273–279, listopad 2008. DOI: 10.1055/s-0028-1089942. PMID: 20011438. 
  • J.J. Centelles. General aspects of colorectal cancer. „ISRN Oncol”. 2012, s. 139268, 2012. DOI: 10.5402/2012/139268. PMID: 23209942. 
  • N. Shussman, S.D. Wexner. Colorectal polyps and polyposis syndromes. „Gastroenterol Rep (Oxf)”. 2 (1), s. 1–15, luty 2014. DOI: 10.1093/gastro/got041. PMID: 24760231. 
  • D.L. Worthley, V.L. Whitehall, K.J. Spring, B.A. Leggett. Colorectal carcinogenesis: road maps to cancer. „World J Gastroenterol”. 13 (28), s. 3784–3791, lipiec 2007. PMID: 17657831. 
  • H. Raskov, H.C. Pommergaard, J. Burcharth, J. Rosenberg. Colorectal carcinogenesis-update and perspectives. „World J Gastroenterol”. 20 (48), s. 18151–18164, grudzień 2014. DOI: 10.3748/wjg.v20.i48.18151. PMID: 25561783. 
  • A.M. Joosen, G.G. Kuhnle, S.M. Aspinall, T.M. Barrow i inni. Effect of processed and red meat on endogenous nitrosation and DNA damage. „Carcinogenesis”. 30 (8), s. 1402–1407, sierpień 2009. DOI: 10.1093/carcin/bgp130. PMID: 19498009. 
  • R.L. Santarelli, F. Pierre, D.E. Corpet. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. „Nutr Cancer”. 60 (2), s. 131–144, 2008. DOI: 10.1080/01635580701684872. PMID: 18444144. 
  • W. Lijinsky. N-Nitroso compounds in the diet. „Mutat Res”. 443 (1–2), s. 129–138, lipiec 1999. PMID: 10415436. 
  • C.T. Dellavalle, Q. Xiao, G. Yang, X.O. Shu i inni. Dietary nitrate and nitrite intake and risk of colorectal cancer in the Shanghai Women’s Health Study. „Int J Cancer”. 134 (12), s. 2917–2926, czerwiec 2014. DOI: 10.1002/ijc.28612. PMID: 24242755. 
  • S.A. Bingham, R. Hughes, A.J. Cross. Effect of white versus red meat on endogenous N-nitrosation in the human colon and further evidence of a dose response. „J Nutr”. 132 (11 Suppl), s. 3522S-3525S, listopad 2002. PMID: 12421881. 
  • A.J. Cross, J.R. Pollock, S.A. Bingham. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. „Cancer Res”. 63 (10), s. 2358–2360, maj 2003. PMID: 12750250. 
  • A.L. Sesink, D.S. Termont, J.H. Kleibeuker, R. Van der Meer. Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. „Cancer Res”. 59 (22), s. 5704–5709, listopad 1999. PMID: 10582688. 
  • T. Sawa, T. Akaike, K. Kida, Y. Fukushima i inni. Lipid peroxyl radicals from oxidized oils and heme-iron: implication of a high-fat diet in colon carcinogenesis. „Cancer Epidemiol Biomarkers Prev”. 7 (11), s. 1007–1012, listopad 1998. PMID: 9829709. 
  • S. Nowell, B. Coles, R. Sinha, S. MacLeod i inni. Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk. „Mutat Res”. 506–507, s. 175–185, wrzesień 2002. PMID: 12351157. 
  • M. Scarpa, I. Castagliuolo, C. Castoro, A. Pozza i inni. Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. „World J Gastroenterol”. 20 (22), s. 6774–6785, czerwiec 2014. DOI: 10.3748/wjg.v20.i22.6774. PMID: 24944468. 
  • J.K. Triantafillidis, G. Nasioulas, P.A. Kosmidis. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. „Anticancer Res”. 29 (7), s. 2727–2737, lipiec 2009. PMID: 19596953. 
  • B. Yan, H. Wang, Z.N. Rabbani, Y. Zhao i inni. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. „Cancer Res”. 66 (24), s. 11565–11570, grudzień 2006. DOI: 10.1158/0008-5472.CAN-06-2540. PMID: 17178846. 
  • A.J. Schottelius, H. Dinter. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. „Cancer Treat Res”. 130, s. 67–87, 2006. PMID: 16610703. 
  • M.M. Derry, K. Raina, C. Agarwal, R. Agarwal. Identifying molecular targets of lifestyle modifications in colon cancer prevention. „Front Oncol”. 3, s. 119, 2013. DOI: 10.3389/fonc.2013.00119. PMID: 23675573. 
  • F. Arvelo, F. Sojo, C. Cotte. Biology of colorectal cancer. „Ecancermedicalscience”. 9, s. 520, 2015. DOI: 10.3332/ecancer.2015.520. PMID: 25932044. 
  • B. Li, X.Y. Shi, D.X. Liao, B.R. Cao i inni. Advanced colorectal adenoma related gene expression signature may predict prognostic for colorectal cancer patients with adenoma-carcinoma sequence. „Int J Clin Exp Med”. 8 (4), s. 4883–4898, 2015. PMID: 26131062. 
  • T. Armaghany, J.D. Wilson, Q. Chu, G. Mills. Genetic alterations in colorectal cancer. „Gastrointest Cancer Res”. 5 (1), s. 19–27, styczeń 2012. PMID: 22574233. 
  • L. Yamane, C. Scapulatempo-Neto, R.M. Reis, D.P. Guimarães. Serrated pathway in colorectal carcinogenesis. „World J Gastroenterol”. 20 (10), s. 2634–2640, marzec 2014. DOI: 10.3748/wjg.v20.i10.2634. PMID: 24627599. 
  • E. Vilar, S.B. Gruber. Microsatellite instability in colorectal cancer-the stable evidence. „Nat Rev Clin Oncol”. 7 (3), s. 153–162, marzec 2010. DOI: 10.1038/nrclinonc.2009.237. PMID: 20142816. 
  • D. Kedrin, M.K. Gala. Genetics of the serrated pathway to colorectal cancer. „Clin Transl Gastroenterol”. 6, s. e84, 2015. DOI: 10.1038/ctg.2015.12. PMID: 25856207. 
  • Ł. Szylberg, M. Janiczek, A. Popiel, A. Marszałek. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. „Gastroenterol Res Pract”. 2015, s. 573814, 2015. DOI: 10.1155/2015/573814. PMID: 25945086. 
  • P. Alberici, R. Fodde. The role of the APC tumor suppressor in chromosomal instability. „Genome Dyn”. 1, s. 149–170, 2006. DOI: 10.1159/000092506. PMID: 18724059. 
  • R.H. Giles, J.H. van Es, H. Clevers. Caught up in a Wnt storm: Wnt signaling in cancer. „Biochim Biophys Acta”. 1653 (1), s. 1–24, czerwiec 2003. PMID: 12781368. 
  • T. Takayama, M. Ohi, T. Hayashi, K. Miyanishi i inni. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. „Gastroenterology”. 121 (3), s. 599–611, wrzesień 2001. PMID: 11522744. 
  • K. Aoki, M.M. Taketo. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. „J Cell Sci”. 120 (Pt 19), s. 3327–3335, październik 2007. DOI: 10.1242/jcs.03485. PMID: 17881494. 
  • X.L. Li, J. Zhou, Z.R. Chen, W.J. Chng. P53 mutations in colorectal cancer – molecular pathogenesis and pharmacological reactivation. „World J Gastroenterol”. 21 (1), s. 84–93, styczeń 2015. DOI: 10.3748/wjg.v21.i1.84. PMID: 25574081. 
  • A. Russo, V. Bazan, B. Iacopetta, D. Kerr i inni. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. „J Clin Oncol”. 23 (30), s. 7518–7528, październik 2005. DOI: 10.1200/JCO.2005.00.471. PMID: 16172461. 
  • B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern i inni. Genetic alterations during colorectal-tumor development. „N Engl J Med”. 319 (9), s. 525–532, wrzesień 1988. DOI: 10.1056/NEJM198809013190901. PMID: 2841597. 
  • M. Duman-Scheel. Deleted in Colorectal Cancer (DCC) pathfinding: axon guidance gene finally turned tumor suppressor. „Curr Drug Targets”. 13 (11), s. 1445–1453, październik 2012. PMID: 22876889. 
  • C. Forcet, X. Ye, L. Granger, V. Corset i inni. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. „Proc Natl Acad Sci U S A”. 98 (6), s. 3416–3421, marzec 2001. DOI: 10.1073/pnas.051378298. PMID: 11248093. 
  • A.M. Krasinskas. EGFR Signaling in Colorectal Carcinoma. „Patholog Res Int”. 2011, s. 932932, 2011. DOI: 10.4061/2011/932932. PMID: 21403829. 
  • J.P. Spano, R. Fagard, J.C. Soria, O. Rixe i inni. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. „Ann Oncol”. 16 (2), s. 189–194, luty 2005. DOI: 10.1093/annonc/mdi057. PMID: 15668269. 
  • C. Tan, X. Du. KRAS mutation testing in metastatic colorectal cancer. „World J Gastroenterol”. 18 (37), s. 5171–5180, październik 2012. DOI: 10.3748/wjg.v18.i37.5171. PMID: 23066310. 
  • C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O’Callaghan i inni. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. „N Engl J Med”. 359 (17), s. 1757–1765, październik 2008. DOI: 10.1056/NEJMoa0804385. PMID: 18946061. 
  • R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem i inni. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. „J Clin Oncol”. 26 (10), s. 1626–1634, kwiecień 2008. DOI: 10.1200/JCO.2007.14.7116. PMID: 18316791. 
  • M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero i inni. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. „J Clin Oncol”. 28 (31), s. 4706–4713, listopad 2010. DOI: 10.1200/JCO.2009.27.6055. PMID: 20921462. 
  • E. Van Cutsem, C.H. Köhne, I. Láng, G. Folprecht i inni. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. „J Clin Oncol”. 29 (15), s. 2011–2019, maj 2011. DOI: 10.1200/JCO.2010.33.5091. PMID: 21502544. 
  • J. Colicelli. Human RAS superfamily proteins and related GTPases. „Sci STKE”. 2004 (250), s. RE13, wrzesień 2004. DOI: 10.1126/stke.2502004re13. PMID: 15367757. 
  • D. Vigil, J. Cherfils, K.L. Rossman, C.J. Der. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. „Nat Rev Cancer”. 10 (12), s. 842–857, grudzień 2010. DOI: 10.1038/nrc2960. PMID: 21102635. 
  • X. Liu, M. Jakubowski, J.L. Hunt. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. „Am J Clin Pathol”. 135 (2), s. 245–252, luty 2011. DOI: 10.1309/AJCP7FO2VAXIVSTP. PMID: 21228365. 
  • D. Barras. BRAF Mutation in Colorectal Cancer: An Update. „Biomark Cancer”. 7 (Suppl 1), s. 9–12, 2015. DOI: 10.4137/BIC.S25248. PMID: 26396549. 
  • F.A. Sinicrope, Q. Shi, T.C. Smyrk, S.N. Thibodeau i inni. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. „Gastroenterology”. 148 (1), s. 88–99, styczeń 2015. DOI: 10.1053/j.gastro.2014.09.041. PMID: 25305506. 
  • B. Tran, S. Kopetz, J. Tie, P. Gibbs i inni. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. „Cancer”. 117 (20), s. 4623–4632, październik 2011. DOI: 10.1002/cncr.26086. PMID: 21456008. 
  • C.R. Boland, A. Goel. Microsatellite instability in colorectal cancer. „Gastroenterology”. 138 (6), s. 2073–2087.e3, czerwiec 2010. DOI: 10.1053/j.gastro.2009.12.064. PMID: 20420947. 
  • P. Peltomäki. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. „Hum Mol Genet”. 10 (7), s. 735–740, kwiecień 2001. PMID: 11257106. 
  • R. Jover, A. Payá, C. Alenda, M.J. Poveda i inni. Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. „Am J Clin Pathol”. 122 (3), s. 389–394, wrzesień 2004. DOI: 10.1309/V9PG-K2Y2-60VF-VULR. PMID: 15362369. 
  • M. Pinheiro, T. Ahlquist, S.A. Danielsen, G.E. Lind i inni. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. „BMC Cancer”. 10, s. 587, 2010. DOI: 10.1186/1471-2407-10-587. PMID: 20979647. 
  • L.M. Ellis, Y. Takahashi, W. Liu, R.M. Shaheen. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. „Oncologist”. 5 Suppl 1, s. 11–15, 2000. PMID: 10804085. 
  • R. Bendardaf, A. Buhmeida, M. Hilska, M. Laato i inni. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. „Anticancer Res”. 28 (6B). s. 3865–3870. PMID: 19192642. 
  • D. Cao, M. Hou, Y.S. Guan, M. Jiang i inni. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. „BMC Cancer”. 9, s. 432, 2009. DOI: 10.1186/1471-2407-9-432. PMID: 20003271. 
  • M. Mathonnet, A. Perraud, N. Christou, H. Akil i inni. Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells. „World J Gastroenterol”. 20 (15), s. 4189–4196, kwiecień 2014. DOI: 10.3748/wjg.v20.i15.4189. PMID: 24764657. 
  • S.J. Winawer. Natural history of colorectal cancer. „Am J Med”. 106 (1A), s. 3S-6S; discussion 50S-51S, styczeń 1999. PMID: 10089106. 
  • S.J. Stryker, B.G. Wolff, C.E. Culp, S.D. Libbe i inni. Natural history of untreated colonic polyps. „Gastroenterology”. 93 (5), s. 1009–1013, listopad 1987. PMID: 3653628. 
  • W.S. Atkin, B.P. Saunders. Surveillance guidelines after removal of colorectal adenomatous polyps. „Gut”. 51 Suppl 5, s. V6-9, październik 2002. PMID: 12221031. 
  • T. Matsui, T. Yao, A. Iwashita. Natural history of early colorectal cancer. „World J Surg”. 24 (9), s. 1022–1028, wrzesień 2000. PMID: 11036277. 
  • R.G. Landmann, M.R. Weiser. Surgical management of locally advanced and locally recurrent colon cancer. „Clin Colon Rectal Surg”. 18 (3), s. 182–189, sierpień 2005. DOI: 10.1055/s-2005-916279. PMID: 20011301. 
  • C. Liebig, G. Ayala, J.A. Wilks, D.H. Berger i inni. Perineural invasion in cancer: a review of the literature. „Cancer”. 115 (15), s. 3379–3391, sierpień 2009. DOI: 10.1002/cncr.24396. PMID: 19484787. 
  • N. Knijn, S.C. Mogk, S. Teerenstra, F. Simmer i inni. Perineural Invasion Is a Strong Prognostic Factor in Colorectal Cancer: A Systematic Review. „Am J Surg Pathol”, wrzesień 2015. DOI: 10.1097/PAS.0000000000000518. PMID: 26426380. 
  • M. Qiu, J. Hu, D. Yang, D.P. Cosgrove i inni. Pattern of distant metastases in colorectal cancer: a SEER based study. „Oncotarget”, październik 2015. DOI: 10.18632/oncotarget.6130. PMID: 26484417. 
  • P. Gervaz, P. Bucher, I. Neyroud-Caspar, C. Soravia i inni. Proximal location of colon cancer is a risk factor for development of metachronous colorectal cancer: a population-based study. „Dis Colon Rectum”. 48 (2), s. 227–232, luty 2005. DOI: 10.1007/s10350-004-0805-7. PMID: 15711864. 
  • J. Kaplan, A. Strongin, D.G. Adler, A.A. Siddiqui. Enteral stents for the management of malignant colorectal obstruction. „World J Gastroenterol”. 20 (37), s. 13239–13245, październik 2014. DOI: 10.3748/wjg.v20.i37.13239. PMID: 25309061. 
  • S.P. Hong, T.I. Kim. Colorectal stenting: an advanced approach to malignant colorectal obstruction. „World J Gastroenterol”. 20 (43), s. 16020–16028, listopad 2014. DOI: 10.3748/wjg.v20.i43.16020. PMID: 25473154. 
  • M. Ogawa, M. Watanabe, K. Eto, T. Omachi i inni. Clinicopathological features of perforated colorectal cancer. „Anticancer Res”. 29 (5), s. 1681–1684, maj 2009. PMID: 19443386. 
  • X.F. Yang, K. Pan. Diagnosis and management of acute complications in patients with colon cancer: bleeding, obstruction, and perforation. „Chin J Cancer Res”. 26 (3), s. 331–340, czerwiec 2014. DOI: 10.3978/j.issn.1000-9604.2014.06.11. PMID: 25035661. 
  • M. Świderska, B. Choromańska, E. Dąbrowska, E. Konarzewska-Duchnowska i inni. The diagnostics of colorectal cancer. „Contemp Oncol (Pozn)”. 18 (1), s. 1–6, 2014. DOI: 10.5114/wo.2013.39995. PMID: 24876814. 
  • D.A. Fisher, A.K. Shergill, D.S. Early, R.D. Acosta i inni. Role of endoscopy in the staging and management of colorectal cancer. „Gastrointest Endosc”. 78 (1), s. 8–12, lipiec 2013. DOI: 10.1016/j.gie.2013.04.163. PMID: 23664162. 
  • R.J. Loffeld, M. Flens, G. Fransen, F.C. den Boer i inni. The localisation of cancer in the sigmoid, rectum or rectosigmoid junction using endoscopy or radiology-What is the most accurate method?. „J Gastrointest Oncol”. 5 (6), s. 469–473, grudzień 2014. DOI: 10.3978/j.issn.2078-6891.2014.087. PMID: 25436127. 
  • S.E. Araujo, P.R. Alves, A. Habr-Gama. Role of colonoscopy in colorectal cancer. „Rev Hosp Clin Fac Med Sao Paulo”. 56 (1). s. 25–35. PMID: 11378680. 
  • A. Laghi. Computed tomography colonography in 2014: an update on technique and indications. „World J Gastroenterol”. 20 (45), s. 16858–16867, grudzień 2014. DOI: 10.3748/wjg.v20.i45.16858. PMID: 25492999. 
  • S. Bipat, A.S. Glas, F.J. Slors, A.H. Zwinderman i inni. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. „Radiology”. 232 (3), s. 773–783, wrzesień 2004. DOI: 10.1148/radiol.2323031368. PMID: 15273331. 
  • S.R. Puli, M.L. Bechtold, J.B. Reddy, A. Choudhary i inni. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. „Dig Dis Sci”. 55 (5), s. 1221–1229, maj 2010. DOI: 10.1007/s10620-009-0862-9. PMID: 19517233. 
  • S.R. Puli, M.L. Bechtold, J.B. Reddy, A. Choudhary i inni. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. „Ann Surg Oncol”. 16 (2), s. 254–265, luty 2009. DOI: 10.1245/s10434-008-0231-5. PMID: 19018597. 
  • M.J. Lahaye, S.M. Engelen, P.J. Nelemans, G.L. Beets i inni. Imaging for predicting the risk factors--the circumferential resection margin and nodal disease-of local recurrence in rectal cancer: a meta-analysis. „Semin Ultrasound CT MR”. 26 (4), s. 259–268, sierpień 2005. PMID: 16152740. 
  • M.E. Riccioni, R. Urgesi, R. Cianci, A. Bizzotto i inni. Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?. „World J Gastrointest Endosc”. 4 (4), s. 99–107, kwiecień 2012. DOI: 10.4253/wjge.v4.i4.99. PMID: 22523610. 
  • C. Spada, F. Barbaro, G. Andrisani, L. Minelli Grazioli i inni. Colon capsule endoscopy: What we know and what we would like to know. „World J Gastroenterol”. 20 (45), s. 16948–16955, grudzień 2014. DOI: 10.3748/wjg.v20.i45.16948. PMID: 25493007. 
  • M.F. Hale, R. Sidhu, M.E. McAlindon. Capsule endoscopy: current practice and future directions. „World J Gastroenterol”. 20 (24), s. 7752–7759, czerwiec 2014. DOI: 10.3748/wjg.v20.i24.7752. PMID: 24976712. 
  • R. Eliakim, K. Yassin, Y. Niv, Y. Metzger i inni. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. „Endoscopy”. 41 (12), s. 1026–1031, grudzień 2009. DOI: 10.1055/s-0029-1215360. PMID: 19967618. 
  • C. Spada, C. Hassan, M. Munoz-Navas, H. Neuhaus i inni. Second-generation colon capsule endoscopy compared with colonoscopy. „Gastrointest Endosc”. 74 (3), s. 581–589.e1, wrzesień 2011. DOI: 10.1016/j.gie.2011.03.1125. PMID: 21601200. 
  • C. Spada, C. Hassan, J.P. Galmiche, H. Neuhaus i inni. Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. „Endoscopy”. 44 (5), s. 527–536, maj 2012. DOI: 10.1055/s-0031-1291717. PMID: 22389230. 
  • L. Sun, H. Wu, Y.S. Guan. Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging. „World J Gastroenterol”. 14 (6), s. 853–863, luty 2008. PMID: 18240342. 
  • P.J. Pickhardt, C. Hassan, S. Halligan, R. Marmo. Colorectal cancer: CT colonography and colonoscopy for detection-systematic review and meta-analysis. „Radiology”. 259 (2), s. 393–405, maj 2011. DOI: 10.1148/radiol.11101887. PMID: 21415247. 
  • M. Kekelidze, L. D’Errico, M. Pansini, A. Tyndall i inni. Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. „World J Gastroenterol”. 19 (46), s. 8502–8514, grudzień 2013. DOI: 10.3748/wjg.v19.i46.8502. PMID: 24379567. 
  • S. Bipat, M.C. Niekel, E.F. Comans, C.Y. Nio i inni. Imaging modalities for the staging of patients with colorectal cancer. „Neth J Med”. 70 (1), s. 26–34, styczeń 2012. PMID: 22271811. 
  • F.M. Zijta, S. Bipat, J. Stoker. Magnetic resonance (MR) colonography in the detection of colorectal lesions: a systematic review of prospective studies. „Eur Radiol”. 20 (5), s. 1031–1046, maj 2010. DOI: 10.1007/s00330-009-1663-4. PMID: 19936754. 
  • M. Mulla, R. Deb, R. Singh. MRI in T staging of rectal cancer: How effective is it?. „Indian J Radiol Imaging”. 20 (2), s. 118–121, maj 2010. DOI: 10.4103/0971-3026.63055. PMID: 20607023. 
  • U. Tapan, M. Ozbayrak, S. Tatlı. MRI in local staging of rectal cancer: an update. „Diagn Interv Radiol”. 20 (5). s. 390–398. DOI: 10.5152/dir.2014.13265. PMID: 25010367. 
  • C. Klessen, P. Rogalla, M. Taupitz. Local staging of rectal cancer: the current role of MRI. „Eur Radiol”. 17 (2), s. 379–389, luty 2007. DOI: 10.1007/s00330-006-0388-x. PMID: 17008990. 
  • M.C. Niekel, S. Bipat, J. Stoker. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. „Radiology”. 257 (3), s. 674–684, grudzień 2010. DOI: 10.1148/radiol.10100729. PMID: 20829538. 
  • D. Delbeke, W.H. Martin. FDG PET and PET/CT for colorectal cancer. „Methods Mol Biol”. 727, s. 77–103, 2011. DOI: 10.1007/978-1-61779-062-1_6. PMID: 21331930. 
  • F.U. Chowdhury, N. Shah, A.F. Scarsbrook, K.M. Bradley. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. „Postgrad Med J”. 86 (1013), s. 174–182, marzec 2010. DOI: 10.1136/pgmj.2009.079087. PMID: 20237012. 
  • L.F. de Geus-Oei, T.J. Ruers, C.J. Punt, J.W. Leer i inni. FDG-PET in colorectal cancer. „Cancer Imaging”. 6, s. S71-81, 2006. DOI: 10.1102/1470-7330.2006.9014. PMID: 17114081. 
  • A.I. Filiz, I. Sucullu, Y. Kurt, D.O. Karakas i inni. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients--is it important?. „Clinics (Sao Paulo)”. 64 (4), s. 287–294, 2009. PMID: 19488584. 
  • T. Allende, J.L. García Muñiz, F. Vizoso, J.M. Del Casar i inni. Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer. „Rev Esp Med Nucl”. 20 (5), s. 358–364, sierpień 2001. PMID: 11470069. 
  • S. Wiratkapun, M. Kraemer, F. Seow-Choen, Y.H. Ho i inni. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. „Dis Colon Rectum”. 44 (2), s. 231–235, luty 2001. PMID: 11227940. 
  • M.J. Duffy. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. „Clin Chem”. 47 (4), s. 624–630, kwiecień 2001. PMID: 11274010. 
  • L.A. Carriquiry, A. Piñeyro. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer?. „Dis Colon Rectum”. 42 (7), s. 921–929, lipiec 1999. PMID: 10411440. 
  • S.Y. Zhang, M. Lin, H.B. Zhang. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma. „Int J Clin Exp Pathol”. 8 (8), s. 9404–9409, 2015. PMID: 26464695. 
  • R. Partyka, A. Sandelewski, I. Łobejko, J. Kocot i inni. Usefulness of evaluation of soluble fragment cytokeratin 18, carcinoembryonic antigen and gastrointestinal carcinoma-associated antigen in diagnostic of patients with colorectal cancer. „Pol Merkur Lekarski”. 29 (170), s. 128–130, sierpień 2010. PMID: 20842828. 
  • Z. Vukobrat-Bijedic, A. Husic-Selimovic, A. Sofic, N. Bijedic i inni. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. „Med Arch”. 67 (6), s. 397–401, grudzień 2013. DOI: 10.5455/medarh.2013.67.397-401. PMID: 25568506. 
  • S.G. Yeo, D.Y. Kim, T.H. Kim, S.Y. Kim i inni. Carbohydrate antigen 19-9 levels associated with pathological responses to preoperative chemoradiotherapy in rectal cancer. „Asian Pac J Cancer Prev”. 15 (13), s. 5383–5387, 2014. PMID: 25041006. 
  • J. Stiksma, D.C. Grootendorst, P.W. van der Linden. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. „Clin Colorectal Cancer”. 13 (4), s. 239–244, grudzień 2014. DOI: 10.1016/j.clcc.2014.09.004. PMID: 25442815. 
  • Y. Narita, H. Taniguchi, A. Komori, S. Nitta i inni. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. „Cancer Chemother Pharmacol”. 73 (2), s. 409–416, luty 2014. DOI: 10.1007/s00280-013-2367-7. PMID: 24322376. 
  • J.B. Lopez, G.P. Royan, M.N. Lakhwani, M. Mahadaven i inni. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies. „Int J Biol Markers”. 14 (3). s. 172–177. PMID: 10569140. 
  • G. Lindmark, U. Kressner, R. Bergström, B. Glimelius. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer. „Anticancer Res”. 16 (2). s. 895–898. PMID: 8687147. 
  • J. Louhimo, M. Carpelan-Holmström, H. Alfthan, U.H. Stenman i inni. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. „Int J Cancer”. 101 (6), s. 545–548, październik 2002. DOI: 10.1002/ijc.90009. PMID: 12237895. 
  • D. Ayude, F.J. Rodríguez-Berrocal, J. Ayude, S. Blanco-Prieto i inni. Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer. „BMC Cancer”. 13, s. 543, 2013. DOI: 10.1186/1471-2407-13-543. PMID: 24215576. 
  • M. Mishaeli, B. Klein, E. Sadikov, I. Bayer i inni. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. „Anticancer Res”. 18 (3B). s. 2101–2105. PMID: 9677475. 
  • H.Y. Kim, S.J. Lee, G. Lee, L. Song i inni. Should preoperative chest CT be recommended to all colon cancer patients?. „Ann Surg”. 259 (2), s. 323–328, luty 2014. DOI: 10.1097/SLA.0b013e3182865080. PMID: 23426347. 
  • I. Zlobec, A. Lugli. Prognostic and predictive factors in colorectal cancer. „Postgrad Med J”. 84 (994), s. 403–411, sierpień 2008. DOI: 10.1136/jcp.2007.054858. PMID: 18832400. 
  • O. Marzouk, J. Schofield. Review of histopathological and molecular prognostic features in colorectal cance. „Cancers (Basel)”. 3 (2), s. 2767–2810, 2011. DOI: 10.3390/cancers3022767. PMID: 24212832. 
  • H. Ueno, H. Mochizuki, Y. Hashiguchi, H. Shimazaki i inni. Risk factors for an adverse outcome in early invasive colorectal carcinoma. „Gastroenterology”. 127 (2), s. 385–394, sierpień 2004. PMID: 15300569. 
  • C.C. Compton. Colorectal carcinoma: diagnostic, prognostic, and molecular features. „Mod Pathol”. 16 (4), s. 376–388, kwiecień 2003. DOI: 10.1097/01.MP.0000062859.46942.93. PMID: 12692203. 
  • C. Compton, C.M. Fenoglio-Preiser, N. Pettigrew, L.P. Fielding. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. „Cancer”. 88 (7), s. 1739–1757, kwiecień 2000. PMID: 10738234. 
  • C.C. Compton, L.P. Fielding, L.J. Burgart, B. Conley i inni. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. „Arch Pathol Lab Med”. 124 (7), s. 979–994, lipiec 2000. DOI: <0979:PFICC>2.0.CO;2 10.1043/0003-9985(2000)124<0979:PFICC>2.0.CO;2. PMID: 10888773. 
  • H. Ueno, A.B. Price, K.H. Wilkinson, J.R. Jass i inni. A new prognostic staging system for rectal cancer. „Ann Surg”. 240 (5), s. 832–839, listopad 2004. PMID: 15492565. 
  • V.H. Koelzer, A. Lugli. The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. „Front Oncol”. 4, s. 29, 2014. DOI: 10.3389/fonc.2014.00029. PMID: 24600585. 
  • R.C. Newland, O.F. Dent, M.N. Lyttle, P.H. Chapuis i inni. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. „Cancer”. 73 (8), s. 2076–2082, kwiecień 1994. PMID: 8156513. 
  • L. Roncucci, R. Fante, L. Losi, C. Di Gregorio i inni. Survival for colon and rectal cancer in a population-based cancer registry. „Eur J Cancer”. 32A (2), s. 295–302, luty 1996. PMID: 8664045. 
  • J. Betge, M.J. Pollheimer, R.A. Lindtner, P. Kornprat i inni. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. „Cancer”. 118 (3), s. 628–638, luty 2012. DOI: 10.1002/cncr.26310. PMID: 21751188. 
  • C. Liebig, G. Ayala, J. Wilks, G. Verstovsek i inni. Perineural invasion is an independent predictor of outcome in colorectal cancer. „J Clin Oncol”. 27 (31), s. 5131–5137, listopad 2009. DOI: 10.1200/JCO.2009.22.4949. PMID: 19738119. 
  • T. Sakamoto, G. Mori, M. Yamada, Y. Kinjo i inni. Endoscopic submucosal dissection for colorectal neoplasms: a review. „World J Gastroenterol”. 20 (43), s. 16153–16158, listopad 2014. DOI: 10.3748/wjg.v20.i43.16153. PMID: 25473168. 
  • S.L. Bosch, S. Teerenstra, J.H. de Wilt, C. Cunningham i inni. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. „Endoscopy”. 45 (10), s. 827–834, październik 2013. DOI: 10.1055/s-0033-1344238. PMID: 23884793. 
  • C.G. Willett, C.C. Compton, P.C. Shellito, J.T. Efird. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. „Cancer”. 73 (11), s. 2716–2720, czerwiec 1994. PMID: 8194011. 
  • T.A. Heafner, S.C. Glasgow. A critical review of the role of local excision in the treatment of early (T1 and T2) rectal tumors. „J Gastrointest Oncol”. 5 (5), s. 345–352, październik 2014. DOI: 10.3978/j.issn.2078-6891.2014.066. PMID: 25276407. 
  • D. Hahnloser, B.G. Wolff, D.W. Larson, J. Ping i inni. Immediate radical resection after local excision of rectal cancer: an oncologic compromise?. „Dis Colon Rectum”. 48 (3), s. 429–437, marzec 2005. DOI: 10.1007/s10350-004-0900-9. PMID: 15747069. 
  • D.J. Bentrem, S. Okabe, W.D. Wong, J.G. Guillem i inni. T1 adenocarcinoma of the rectum: transanal excision or radical surgery?. „Ann Surg”. 242 (4), s. 472–477; discussion 477-9, październik 2005. PMID: 16192807. 
  • R. Nascimbeni, L.J. Burgart, S. Nivatvongs, D.R. Larson. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. „Dis Colon Rectum”. 45 (2), s. 200–206, luty 2002. PMID: 11852333. 
  • Y.N. You, N.N. Baxter, A. Stewart, H. Nelson. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. „Ann Surg”. 245 (5), s. 726–733, maj 2007. DOI: 10.1097/01.sla.0000252590.95116.4f. PMID: 17457165. 
  • G.M. Nash, M.R. Weiser, J.G. Guillem, L.K. Temple i inni. Long-term survival after transanal excision of T1 rectal cancer. „Dis Colon Rectum”. 52 (4), s. 577–582, kwiecień 2009. DOI: 10.1007/DCR.0b013e3181a0adbd. PMID: 19404055. 
  • K.B. Stitzenberg, H.K. Sanoff, D.C. Penn, M.O. Meyers i inni. Practice patterns and long-term survival for early-stage rectal cancer. „J Clin Oncol”. 31 (34), s. 4276–4282, grudzień 2013. DOI: 10.1200/JCO.2013.49.1860. PMID: 24166526. 
  • E. Tiret, B. Poupardin, D. McNamara, N. Dehni i inni. Ultralow anterior resection with intersphincteric dissection-what is the limit of safe sphincter preservation?. „Colorectal Dis”. 5 (5), s. 454–457, wrzesień 2003. PMID: 12925080. 
  • M. den Dulk, H. Putter, L. Collette, C.A. Marijnen i inni. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. „Eur J Cancer”. 45 (7), s. 1175–1183, maj 2009. DOI: 10.1016/j.ejca.2008.11.039. PMID: 19128956. 
  • L. Påhlman, M. Bohe, B. Cedermark, M. Dahlberg i inni. The Swedish rectal cancer registry. „Br J Surg”. 94 (10), s. 1285–1292, październik 2007. DOI: 10.1002/bjs.5679. PMID: 17661309. 
  • R.O. Lindsetmo, Y.G. Joh, C.P. Delaney. Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. „World J Gastroenterol”. 14 (21), s. 3281–3289, czerwiec 2008. PMID: 18528924. 
  • A. Martling, T. Holm, L.E. Rutqvist, H. Johansson i inni. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. „Br J Surg”. 92 (2), s. 225–229, luty 2005. DOI: 10.1002/bjs.4834. PMID: 15609382. 
  • N. Scott, P. Jackson, T. al-Jaberi, M.F. Dixon i inni. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. „Br J Surg”. 82 (8), s. 1031–1033, sierpień 1995. PMID: 7648142. 
  • P.T. Phang. Total mesorectal excision: technical aspects. „Can J Surg”. 47 (2), s. 130–137, kwiecień 2004. PMID: 15132469. 
  • W.E. Enker, H.T. Thaler, M.L. Cranor, T. Polyak. Total mesorectal excision in the operative treatment of carcinoma of the rectum. „J Am Coll Surg”. 181 (4), s. 335–346, październik 1995. PMID: 7551328. 
  • A.M. Lacy, J.C. García-Valdecasas, S. Delgado, A. Castells i inni. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. „Lancet”. 359 (9325), s. 2224–2229, czerwiec 2002. DOI: 10.1016/S0140-6736(02)09290-5. PMID: 12103285. 
  • M. Buunen, R. Veldkamp, W.C. Hop, E. Kuhry i inni. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. „Lancet Oncol”. 10 (1), s. 44–52, styczeń 2009. DOI: 10.1016/S1470-2045(08)70310-3. PMID: 19071061. 
  • B.L. Green, H.C. Marshall, F. Collinson, P. Quirke i inni. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. „Br J Surg”. 100 (1), s. 75–82, styczeń 2013. DOI: 10.1002/bjs.8945. PMID: 23132548. 
  • H. Ohtani, Y. Tamamori, Y. Arimoto, Y. Nishiguchi i inni. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and open colectomy for colon cancer. „J Cancer”. 3, s. 49–57, 2012. DOI: 10.7150/jca.3621. PMID: 22315650. 
  • B. Di, Y. Li, K. Wei, X. Xiao i inni. Laparoscopic versus open surgery for colon cancer: a meta-analysis of 5-year follow-up outcomes. „Surg Oncol”. 22 (3), s. e39-43, wrzesień 2013. DOI: 10.1016/j.suronc.2013.03.002. PMID: 23643698. 
  • E. Kuhry, W. Schwenk, R. Gaupset, U. Romild i inni. Long-term outcome of laparoscopic surgery for colorectal cancer: a cochrane systematic review of randomised controlled trials. „Cancer Treat Rev”. 34 (6), s. 498–504, październik 2008. DOI: 10.1016/j.ctrv.2008.03.011. PMID: 18468803. 
  • F. Rondelli, S. Trastulli, N. Avenia, G. Schillaci i inni. Is laparoscopic right colectomy more effective than open resection? A meta-analysis of randomized and nonrandomized studies. „Colorectal Dis”. 14 (8), s. e447-69, sierpień 2012. DOI: 10.1111/j.1463-1318.2012.03054.x. PMID: 22540533. 
  • D.G. Jayne, H.C. Thorpe, J. Copeland, P. Quirke i inni. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. „Br J Surg”. 97 (11), s. 1638–1645, listopad 2010. DOI: 10.1002/bjs.7160. PMID: 20629110. 
  • D.G. Jayne, P.J. Guillou, H. Thorpe, P. Quirke i inni. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. „J Clin Oncol”. 25 (21), s. 3061–3068, lipiec 2007. DOI: 10.1200/JCO.2006.09.7758. PMID: 17634484. 
  • D.P. Nussbaum, P.J. Speicher, A.M. Ganapathi, B.R. Englum i inni. Laparoscopic versus open low anterior resection for rectal cancer: results from the national cancer data base. „J Gastrointest Surg”. 19 (1), s. 124–131; discussion 131-2, styczeń 2015. DOI: 10.1007/s11605-014-2614-1. PMID: 25091847. 
  • S. Gill, C.L. Loprinzi, D.J. Sargent, S.D. Thomé i inni. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. „J Clin Oncol”. 22 (10), s. 1797–1806, maj 2004. DOI: 10.1200/JCO.2004.09.059. PMID: 15067028. 
  • R. Gray, J. Barnwell, C. McConkey, R.K. Hills i inni. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. „Lancet”. 370 (9604), s. 2020–2029, grudzień 2007. DOI: 10.1016/S0140-6736(07)61866-2. PMID: 18083404. 
  • X. Wu, J. Zhang, X. He, C. Wang i inni. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. „J Gastrointest Surg”. 16 (3), s. 646–655, marzec 2012. DOI: 10.1007/s11605-011-1682-8. PMID: 22194062. 
  • E.S. O’Connor, D.Y. Greenblatt, N.K. LoConte, R.E. Gangnon i inni. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. „J Clin Oncol”. 29 (25), s. 3381–3388, wrzesień 2011. DOI: 10.1200/JCO.2010.34.3426. PMID: 21788561. 
  • J.J. Biagi, M.J. Raphael, W.J. Mackillop, W. Kong i inni. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. „JAMA”. 305 (22), s. 2335–2342, czerwiec 2011. DOI: 10.1001/jama.2011.749. PMID: 21642686. 
  • T. André, C. Boni, M. Navarro, J. Tabernero i inni. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. „J Clin Oncol”. 27 (19), s. 3109–3116, lipiec 2009. DOI: 10.1200/JCO.2008.20.6771. PMID: 19451431. 
  • H.K. Sanoff, W.R. Carpenter, C.F. Martin, D.J. Sargent i inni. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. „J Natl Cancer Inst”. 104 (3), s. 211–227, luty 2012. DOI: 10.1093/jnci/djr524. PMID: 22266473. 
  • H.K. Sanoff, W.R. Carpenter, J. Freburger, L. Li i inni. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. „Cancer”. 118 (17), s. 4309–4320, wrzesień 2012. DOI: 10.1002/cncr.27422. PMID: 22294436. 
  • J.P. Kuebler, H.S. Wieand, M.J. O’Connell, R.E. Smith i inni. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. „J Clin Oncol”. 25 (16), s. 2198–2204, czerwiec 2007. DOI: 10.1200/JCO.2006.08.2974. PMID: 17470851. 
  • G. Yothers, M.J. O’Connell, C.J. Allegra, J.P. Kuebler i inni. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. „J Clin Oncol”. 29 (28), s. 3768–3774, październik 2011. DOI: 10.1200/JCO.2011.36.4539. PMID: 21859995. 
  • S. Sharif, M.J. O’Connell, G. Yothers, S. Lopa i inni. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. „Cancer Invest”. 26 (9), s. 956–963, listopad 2008. DOI: 10.1080/07357900802132550. PMID: 18798075. 
  • C. Twelves, A. Wong, M.P. Nowacki, M. Abt i inni. Capecitabine as adjuvant treatment for stage III colon cancer. „N Engl J Med”. 352 (26), s. 2696–2704, czerwiec 2005. DOI: 10.1056/NEJMoa043116. PMID: 15987918. 
  • C. Twelves, W. Scheithauer, J. McKendrick, J.F. Seitz i inni. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. „Ann Oncol”. 23 (5), s. 1190–1197, maj 2012. DOI: 10.1093/annonc/mdr366. PMID: 21896539. 
  • D.G. Haller, J. Tabernero, J. Maroun, F. de Braud i inni. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. „J Clin Oncol”. 29 (11), s. 1465–1471, kwiecień 2011. DOI: 10.1200/JCO.2010.33.6297. PMID: 21383294. 
  • L.L. Gunderson, D.J. Sargent, J.E. Tepper, N. Wolmark i inni. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. „J Clin Oncol”. 22 (10), s. 1785–1796, maj 2004. DOI: 10.1200/JCO.2004.08.173. PMID: 15067027. 
  • R. Sauer, H. Becker, W. Hohenberger, C. Rödel i inni. Preoperative versus postoperative chemoradiotherapy for rectal cancer. „N Engl J Med”. 351 (17), s. 1731–1740, październik 2004. DOI: 10.1056/NEJMoa040694. PMID: 15496622. 
  • R. Wagman, B.D. Minsky, A.M. Cohen, J.G. Guillem i inni. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. „Int J Radiat Oncol Biol Phys”. 42 (1), s. 51–57, sierpień 1998. PMID: 9747819. 
  • R. Sauer, T. Liersch, S. Merkel, R. Fietkau i inni. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. „J Clin Oncol”. 30 (16), s. 1926–1933, czerwiec 2012. DOI: 10.1200/JCO.2011.40.1836. PMID: 22529255. 
  • L.C. Peng, J. Milsom, K. Garrett, G. Nandakumar i inni. Surveillance, epidemiology, and end results-based analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes for T3N0 rectal cancer. „Cancer Epidemiol”. 38 (1), s. 73–78, luty 2014. DOI: 10.1016/j.canep.2013.12.008. PMID: 24491755. 
  • J.P. Gérard, T. Conroy, F. Bonnetain, O. Bouché i inni. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. „J Clin Oncol”. 24 (28), s. 4620–4625, październik 2006. DOI: 10.1200/JCO.2006.06.7629. PMID: 17008704. 
  • J.F. Bosset, G. Calais, L. Mineur, P. Maingon i inni. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. „J Clin Oncol”. 23 (24), s. 5620–5627, sierpień 2005. DOI: 10.1200/JCO.2005.02.113. PMID: 16009958. 
  • J.F. Bosset, L. Collette, G. Calais, L. Mineur i inni. Chemotherapy with preoperative radiotherapy in rectal cancer. „N Engl J Med”. 355 (11), s. 1114–1123, wrzesień 2006. DOI: 10.1056/NEJMoa060829. PMID: 16971718. 
  • W.P. Ceelen, Y. Van Nieuwenhove, K. Fierens. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. „Cochrane Database Syst Rev”, s. CD006041, 2009. DOI: 10.1002/14651858.CD006041.pub2. PMID: 19160264. 
  • K. McCarthy, K. Pearson, R. Fulton, J. Hewitt. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. „Cochrane Database Syst Rev”. 12, s. CD008368, 2012. DOI: 10.1002/14651858.CD008368.pub2. PMID: 23235660. 
  • N.N. Rahbari, H. Elbers, V. Askoxylakis, E. Motschall i inni. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. „Ann Surg Oncol”. 20 (13), s. 4169–4182, grudzień 2013. DOI: 10.1245/s10434-013-3198-9. PMID: 24002536. 
  • M.J. O’Connell, L.H. Colangelo, R.W. Beart, N.J. Petrelli i inni. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. „J Clin Oncol”. 32 (18), s. 1927–1934, czerwiec 2014. DOI: 10.1200/JCO.2013.53.7753. PMID: 24799484. 
  • R.D. Hofheinz, F. Wenz, S. Post, A. Matzdorff i inni. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. „Lancet Oncol”. 13 (6), s. 579–588, czerwiec 2012. DOI: 10.1016/S1470-2045(12)70116-X. PMID: 22503032. 
  • C. Aschele, L. Cionini, S. Lonardi, C. Pinto i inni. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. „J Clin Oncol”. 29 (20), s. 2773–2780, lipiec 2011. DOI: 10.1200/JCO.2010.34.4911. PMID: 21606427. 
  • C. Rödel, T. Liersch, H. Becker, R. Fietkau i inni. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. „Lancet Oncol”. 13 (7), s. 679–687, lipiec 2012. DOI: 10.1016/S1470-2045(12)70187-0. PMID: 22627104. 
  • J.P. Gérard, D. Azria, S. Gourgou-Bourgade, I. Martel-Lafay i inni. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. „J Clin Oncol”. 30 (36), s. 4558–4565, grudzień 2012. DOI: 10.1200/JCO.2012.42.8771. PMID: 23109696. 
  • K. Bujko, M.P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski i inni. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. „Br J Surg”. 93 (10), s. 1215–1223, październik 2006. DOI: 10.1002/bjs.5506. PMID: 16983741. 
  • S.Y. Ngan, B. Burmeister, R.J. Fisher, M. Solomon i inni. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. „J Clin Oncol”. 30 (31), s. 3827–3833, listopad 2012. DOI: 10.1200/JCO.2012.42.9597. PMID: 23008301. 
  • T. Latkauskas, H. Pauzas, I. Gineikiene, R. Janciauskiene i inni. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery. „Colorectal Dis”. 14 (3), s. 294–298, marzec 2012. DOI: 10.1111/j.1463-1318.2011.02815.x. PMID: 21899712. 
  • C. Fernández-Martos, C. Pericay, J. Aparicio, A. Salud i inni. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. „J Clin Oncol”. 28 (5), s. 859–865, luty 2010. DOI: 10.1200/JCO.2009.25.8541. PMID: 20065174. 
  • R. Maréchal, B. Vos, M. Polus, T. Delaunoit i inni. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. „Ann Oncol”. 23 (6), s. 1525–1530, czerwiec 2012. DOI: 10.1093/annonc/mdr473. PMID: 22039087. 
  • J.F. Bosset, G. Calais, L. Mineur, P. Maingon i inni. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. „Lancet Oncol”. 15 (2), s. 184–190, luty 2014. DOI: 10.1016/S1470-2045(13)70599-0. PMID: 24440473. 
  • S.H. Petersen, H. Harling, L.T. Kirkeby, P. Wille-Jørgensen i inni. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. „Cochrane Database Syst Rev”. 3, s. CD004078, 2012. DOI: 10.1002/14651858.CD004078.pub2. PMID: 22419291. 
  • Y.S. Hong, B.H. Nam, K.P. Kim, J.E. Kim i inni. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. „Lancet Oncol”. 15 (11), s. 1245–1253, październik 2014. DOI: 10.1016/S1470-2045(14)70377-8. PMID: 25201358. 
  • M.D. Hellinger, C.A. Santiago. Reoperation for recurrent colorectal cancer. „Clin Colon Rectal Surg”. 19 (4), s. 228–236, listopad 2006. DOI: 10.1055/s-2006-956445. PMID: 20011326. 
  • K.F. Birbeck, C.P. Macklin, N.J. Tiffin, W. Parsons i inni. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. „Ann Surg”. 235 (4), s. 449–457, kwiecień 2002. PMID: 11923599. 
  • D. Sargent, A. Sobrero, A. Grothey, M.J. O’Connell i inni. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. „J Clin Oncol”. 27 (6), s. 872–877, luty 2009. DOI: 10.1200/JCO.2008.19.5362. PMID: 19124803. 
  • S. Galandiuk, H.S. Wieand, C.G. Moertel, S.S. Cha i inni. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. „Surg Gynecol Obstet”. 174 (1), s. 27–32, styczeń 1992. PMID: 1729745. 
  • D.J. Sargent, H.S. Wieand, D.G. Haller, R. Gray i inni. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. „J Clin Oncol”. 23 (34), s. 8664–8670, grudzień 2005. DOI: 10.1200/JCO.2005.01.6071. PMID: 16260700. 
  • Ö. Akgül, E. Çetinkaya, Ş. Ersöz, M. Tez. Role of surgery in colorectal cancer liver metastases. „World J Gastroenterol”. 20 (20), s. 6113–6122, maj 2014. DOI: 10.3748/wjg.v20.i20.6113. PMID: 24876733. 
  • F.I. Macedo, T. Makarawo. Colorectal hepatic metastasis: Evolving therapies. „World J Hepatol”. 6 (7), s. 453–463, lipiec 2014. DOI: 10.4254/wjh.v6.i7.453. PMID: 25067997. 
  • S. Vatandoust, T.J. Price, C.S. Karapetis. Colorectal cancer: Metastases to a single organ. „World J Gastroenterol”. 21 (41), s. 11767–11776, listopad 2015. DOI: 10.3748/wjg.v21.i41.11767. PMID: 26557001. 
  • G.P. Kanas, A. Taylor, J.N. Primrose, W.J. Langeberg i inni. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. „Clin Epidemiol”. 4, s. 283–301, 2012. DOI: 10.2147/CLEP.S34285. PMID: 23152705. 
  • M.A. Choti, J.V. Sitzmann, M.F. Tiburi, W. Sumetchotimetha i inni. Trends in long-term survival following liver resection for hepatic colorectal metastases. „Ann Surg”. 235 (6), s. 759–766, czerwiec 2002. PMID: 12035031. 
  • T.M. Pawlik, C.R. Scoggins, D. Zorzi, E.K. Abdalla i inni. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. „Ann Surg”. 241 (5), s. 715–722, discussion 722-4, maj 2005. PMID: 15849507. 
  • T.A. Aloia, J.N. Vauthey, E.M. Loyer, D. Ribero i inni. Solitary colorectal liver metastasis: resection determines outcome. „Arch Surg”. 141 (5), s. 460–466; discussion 466-7, maj 2006. DOI: 10.1001/archsurg.141.5.460. PMID: 16702517. 
  • W.S. Lee, S.H. Yun, H.K. Chun, W.Y. Lee i inni. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. „J Clin Gastroenterol”. 42 (8), s. 945–949, wrzesień 2008. DOI: 10.1097/MCG.0b013e318064e752. PMID: 18438208. 
  • H. Hur, Y.T. Ko, B.S. Min, K.S. Kim i inni. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. „Am J Surg”. 197 (6), s. 728–736, czerwiec 2009. DOI: 10.1016/j.amjsurg.2008.04.013. PMID: 18789428. 
  • H.K. Kim, J.H. Cho, H.Y. Lee, J. Lee i inni. Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times?. „World J Gastroenterol”. 20 (20), s. 6133–6145, maj 2014. DOI: 10.3748/wjg.v20.i20.6133. PMID: 24876735. 
  • T. Treasure. Pulmonary Metastasectomy for Colorectal Cancer: Recent Reports Prompt a Review of the Available Evidence. „Curr Colorectal Cancer Rep”. 10 (3), s. 296–302, 2014. DOI: 10.1007/s11888-014-0234-5. PMID: 25191154. 
  • C. Pulitanò, M. Bodingbauer, L. Aldrighetti, M.C. de Jong i inni. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. „Ann Surg Oncol”. 18 (5), s. 1380–1388, maj 2011. DOI: 10.1245/s10434-010-1459-4. PMID: 21136180. 
  • T.C. Chua, A. Saxena, W. Liauw, F. Chu i inni. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases-a systematic review. „Eur J Cancer”. 48 (12), s. 1757–1765, sierpień 2012. DOI: 10.1016/j.ejca.2011.10.034. PMID: 22153217. 
  • D.R. Carpizo, M. D’Angelica. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. „Ann Surg Oncol”. 16 (9), s. 2411–2421, wrzesień 2009. DOI: 10.1245/s10434-009-0493-6. PMID: 19554376. 
  • D.R. Carpizo, C. Are, W. Jarnagin, R. Dematteo i inni. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. „Ann Surg Oncol”. 16 (8), s. 2138–2146, sierpień 2009. DOI: 10.1245/s10434-009-0521-6. PMID: 19495884. 
  • S.R. Alberts, W.L. Horvath, W.C. Sternfeld, R.M. Goldberg i inni. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. „J Clin Oncol”. 23 (36), s. 9243–9249, grudzień 2005. DOI: 10.1200/JCO.2005.07.740. PMID: 16230673. 
  • R. Adam, V. Delvart, G. Pascal, A. Valeanu i inni. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. „Ann Surg”. 240 (4), s. 644–657; discussion 657-8, październik 2004. PMID: 15383792. 
  • A. Falcone, S. Ricci, I. Brunetti, E. Pfanner i inni. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. „J Clin Oncol”. 25 (13), s. 1670–1676, maj 2007. DOI: 10.1200/JCO.2006.09.0928. PMID: 17470860. 
  • J. Souglakos, N. Androulakis, K. Syrigos, A. Polyzos i inni. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). „Br J Cancer”. 94 (6), s. 798–805, marzec 2006. DOI: 10.1038/sj.bjc.6603011. PMID: 16508637. 
  • G. Masi, E. Vasile, F. Loupakis, S. Cupini i inni. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. „J Natl Cancer Inst”. 103 (1), s. 21–30, styczeń 2011. DOI: 10.1093/jnci/djq456. PMID: 21123833. 
  • G. Folprecht, T. Gruenberger, W.O. Bechstein, H.R. Raab i inni. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. „Lancet Oncol”. 11 (1), s. 38–47, styczeń 2010. DOI: 10.1016/S1470-2045(09)70330-4. PMID: 19942479. 
  • G. Folprecht, T. Gruenberger, W. Bechstein, H.R. Raab i inni. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). „Ann Oncol”. 25 (5), s. 1018–1025, maj 2014. DOI: 10.1093/annonc/mdu088. PMID: 24585720. 
  • L.C. Ye, T.S. Liu, L. Ren, Y. Wei i inni. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. „J Clin Oncol”. 31 (16), s. 1931–1938, czerwiec 2013. DOI: 10.1200/JCO.2012.44.8308. PMID: 23569301. 
  • F. Petrelli, S. Barni. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. „Int J Colorectal Dis”. 27 (8), s. 997–1004, sierpień 2012. DOI: 10.1007/s00384-012-1438-2. PMID: 22358385. 
  • C.S. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki i inni. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. „J Clin Oncol”. 25 (30), s. 4779–4786, październik 2007. DOI: 10.1200/JCO.2007.11.3357. PMID: 17947725. 
  • H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright i inni. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. „N Engl J Med”. 350 (23), s. 2335–2342, czerwiec 2004. DOI: 10.1056/NEJMoa032691. PMID: 15175435. 
  • L.B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. „J Clin Oncol”. 26 (12), s. 2013–2019, kwiecień 2008. DOI: 10.1200/JCO.2007.14.9930. PMID: 18421054. 
  • S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail i inni. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. „J Clin Oncol”. 18 (1), s. 136–147, styczeń 2000. PMID: 10623704. 
  • T. André, M.A. Bensmaine, C. Louvet, E. François i inni. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. „J Clin Oncol”. 17 (11), s. 3560–3568, listopad 1999. PMID: 10550155. 
  • A. de Gramont, A. Figer, M. Seymour, M. Homerin i inni. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. „J Clin Oncol”. 18 (16), s. 2938–2947, sierpień 2000. PMID: 10944126. 
  • B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston i inni. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. „Lancet”. 371 (9617), s. 1007–1016, marzec 2008. DOI: 10.1016/S0140-6736(08)60455-9. PMID: 18358928. 
  • B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston i inni. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. „Lancet Oncol”. 14 (12), s. 1208–1215, listopad 2013. DOI: 10.1016/S1470-2045(13)70447-9. PMID: 24120480. 
  • J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. „J Clin Oncol”. 26 (12), s. 2006–2012, kwiecień 2008. DOI: 10.1200/JCO.2007.14.9898. PMID: 18421053. 
  • J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer i inni. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. „Br J Cancer”. 105 (1), s. 58–64, czerwiec 2011. DOI: 10.1038/bjc.2011.201. PMID: 21673685. 
  • C. Zhang, J. Wang, H. Gu, D. Zhu i inni. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. „Oncol Lett”. 3 (4), s. 831–838, kwiecień 2012. DOI: 10.3892/ol.2012.567. PMID: 22741002. 
  • C. Tournigand, T. André, E. Achille, G. Lledo i inni. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. „J Clin Oncol”. 22 (2), s. 229–237, styczeń 2004. DOI: 10.1200/JCO.2004.05.113. PMID: 14657227. 
  • G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani i inni. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. „J Clin Oncol”. 23 (22), s. 4866–4875, sierpień 2005. DOI: 10.1200/JCO.2005.07.113. PMID: 15939922. 
  • E. Mitry, A.L. Fields, H. Bleiberg, R. Labianca i inni. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. „J Clin Oncol”. 26 (30), s. 4906–4911, październik 2008. DOI: 10.1200/JCO.2008.17.3781. PMID: 18794541. 
  • D. Cunningham, I. Lang, E. Marcuello, V. Lorusso i inni. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. „Lancet Oncol”. 14 (11), s. 1077–1085, październik 2013. DOI: 10.1016/S1470-2045(13)70154-2. PMID: 24028813. 
  • P.L. McCormack, S.J. Keam. Bevacizumab: a review of its use in metastatic colorectal cancer. „Drugs”. 68 (4), s. 487–506, 2008. PMID: 18318567. 
  • F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol i inni. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. „J Clin Oncol”. 21 (1), s. 60–65, styczeń 2003. PMID: 12506171. 
  • F.F. Kabbinavar, J. Schulz, M. McCleod, T. Patel i inni. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. „J Clin Oncol”. 23 (16), s. 3697–3705, czerwiec 2005. DOI: 10.1200/JCO.2005.05.112. PMID: 15738537. 
  • F.F. Kabbinavar, J. Hambleton, R.D. Mass, H.I. Hurwitz i inni. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. „J Clin Oncol”. 23 (16), s. 3706–3712, czerwiec 2005. DOI: 10.1200/JCO.2005.00.232. PMID: 15867200. 
  • F. Petrelli, K. Borgonovo, M. Cabiddu, M. Ghilardi i inni. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. „Clin Colorectal Cancer”. 12 (3), s. 145–151, wrzesień 2013. DOI: 10.1016/j.clcc.2013.04.006. PMID: 23763824. 
  • L.T. Macedo, A.B. da Costa Lima, A.D. Sasse. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. „BMC Cancer”. 12, s. 89, 2012. DOI: 10.1186/1471-2407-12-89. PMID: 22414244. 
  • J.A. Meyerhardt, L. Li, H.K. Sanoff, W. Carpenter i inni. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. „J Clin Oncol”. 30 (6), s. 608–615, luty 2012. DOI: 10.1200/JCO.2011.38.9650. PMID: 22253466. 
  • H.I. Hurwitz, N.C. Tebbutt, F. Kabbinavar, B.J. Giantonio i inni. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. „Oncologist”. 18 (9), s. 1004–1012, 2013. DOI: 10.1634/theoncologist.2013-0107. PMID: 23881988. 
  • Y. Cao, A. Tan, F. Gao, L. Liu i inni. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. „Int J Colorectal Dis”. 24 (6), s. 677–685, czerwiec 2009. DOI: 10.1007/s00384-009-0655-9. PMID: 19184059. 
  • S. Welch, K. Spithoff, R.B. Rumble, J. Maroun. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. „Ann Oncol”. 21 (6), s. 1152–1162, czerwiec 2010. DOI: 10.1093/annonc/mdp533. PMID: 19942597. 
  • V. Ranpura, S. Hapani, S. Wu. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. „JAMA”. 305 (5), s. 487–494, luty 2011. DOI: 10.1001/jama.2011.51. PMID: 21285426. 
  • D. Miles, N. Harbeck, B. Escudier, H. Hurwitz i inni. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. „J Clin Oncol”. 29 (1), s. 83–88, styczeń 2011. DOI: 10.1200/JCO.2010.30.2794. PMID: 21098326. 
  • D. Cunningham, Y. Humblet, S. Siena, D. Khayat i inni. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. „N Engl J Med”. 351 (4), s. 337–345, lipiec 2004. DOI: 10.1056/NEJMoa033025. PMID: 15269313. 
  • E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet i inni. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. „J Clin Oncol”. 25 (13), s. 1658–1664, maj 2007. DOI: 10.1200/JCO.2006.08.1620. PMID: 17470858. 
  • J.A. McKay, L.J. Murray, S. Curran, V.G. Ross i inni. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. „Eur J Cancer”. 38 (17), s. 2258–2264, listopad 2002. PMID: 12441262. 
  • J.P. Spano, C. Lagorce, D. Atlan, G. Milano i inni. Impact of EGFR expression on colorectal cancer patient prognosis and survival. „Ann Oncol”. 16 (1), s. 102–108, styczeń 2005. DOI: 10.1093/annonc/mdi006. PMID: 15598946. 
  • J.R. Hecht, E. Mitchell, M.A. Neubauer, H.A. Burris i inni. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. „Clin Cancer Res”. 16 (7), s. 2205–2213, kwiecień 2010. DOI: 10.1158/1078-0432.CCR-09-2017. PMID: 20332321. 
  • K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah i inni. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. „J Clin Oncol”. 23 (9), s. 1803–1810, marzec 2005. DOI: 10.1200/JCO.2005.08.037. PMID: 15677699. 
  • H.O. Al-Shamsi, W. Alhazzani, R.A. Wolff. Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. „J Gastrointest Oncol”. 6 (3), s. 314–321, czerwiec 2015. DOI: 10.3978/j.issn.2078-6891.2015.016. PMID: 26029459. 
  • C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann i inni. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. „J Clin Oncol”. 27 (5), s. 663–671, luty 2009. DOI: 10.1200/JCO.2008.20.8397. PMID: 19114683. 
  • T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade i inni. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. „Lancet”. 377 (9783), s. 2103–2114, czerwiec 2011. DOI: 10.1016/S0140-6736(11)60613-2. PMID: 21641636. 
  • E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski i inni. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. „N Engl J Med”. 360 (14), s. 1408–1417, kwiecień 2009. DOI: 10.1056/NEJMoa0805019. PMID: 19339720. 
  • I. Láng, C.H. Köhne, G. Folprecht, P. Rougier i inni. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. „Eur J Cancer”. 49 (2), s. 439–448, styczeń 2013. DOI: 10.1016/j.ejca.2012.08.023. PMID: 23116683. 
  • V. Heinemann, L.F. von Weikersthal, T. Decker, A. Kiani i inni. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. „Lancet Oncol”. 15 (10), s. 1065–1075, wrzesień 2014. DOI: 10.1016/S1470-2045(14)70330-4. PMID: 25088940. 
  • J.Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero i inni. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. „N Engl J Med”. 369 (11), s. 1023–1034, wrzesień 2013. DOI: 10.1056/NEJMoa1305275. PMID: 24024839. 
  • L.S. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola i inni. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. „J Clin Oncol”. 32 (21), s. 2240–2247, lipiec 2014. DOI: 10.1200/JCO.2013.53.2473. PMID: 24687833. 
  • E.P. Mitchell, B. Piperdi, M.E. Lacouture, H. Shearer i inni. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. „Clin Colorectal Cancer”. 10 (4), s. 333–339, grudzień 2011. DOI: 10.1016/j.clcc.2011.06.004. PMID: 22000810. 
  • P. Rougier, E. Van Cutsem, E. Bajetta, N. Niederle i inni. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. „Lancet”. 352 (9138), s. 1407–1412, październik 1998. DOI: 10.1016/S0140-6736(98)03085-2. PMID: 9807986. 
  • G.P. Kim, D.J. Sargent, M.R. Mahoney, K.M. Rowland i inni. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. „J Clin Oncol”. 27 (17), s. 2848–2854, czerwiec 2009. DOI: 10.1200/JCO.2008.20.4552. PMID: 19380443. 
  • E. Segelov, D. Chan, J. Shapiro, T.J. Price i inni. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. „Br J Cancer”. 111 (6), s. 1122–1131, wrzesień 2014. DOI: 10.1038/bjc.2014.404. PMID: 25072258. 
  • M. Peeters, T.J. Price, A. Cervantes, A.F. Sobrero i inni. Final results from a randomized phase 3 study of FOLFIRI {±} panitumumab for second-line treatment of metastatic colorectal cancer. „Ann Oncol”. 25 (1), s. 107–116, styczeń 2014. DOI: 10.1093/annonc/mdt523. PMID: 24356622. 
  • D.J. Jonker, C.J. O’Callaghan, C.S. Karapetis, J.R. Zalcberg i inni. Cetuximab for the treatment of colorectal cancer. „N Engl J Med”. 357 (20), s. 2040–2048, listopad 2007. DOI: 10.1056/NEJMoa071834. PMID: 18003960. 
  • J. Bennouna, J. Sastre, D. Arnold, P. Österlund i inni. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. „Lancet Oncol”. 14 (1), s. 29–37, styczeń 2013. DOI: 10.1016/S1470-2045(12)70477-1. PMID: 23168366. 
  • S. Kubicka, R. Greil, T. André, J. Bennouna i inni. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. „Ann Oncol”. 24 (9), s. 2342–2349, wrzesień 2013. DOI: 10.1093/annonc/mdt231. PMID: 23852309. 
  • T.H. Cartwright, Y.M. Yim, E. Yu, H. Chung i inni. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. „Clin Colorectal Cancer”. 11 (4), s. 238–246, grudzień 2012. DOI: 10.1016/j.clcc.2012.05.005. PMID: 22658457. 
  • A. Patel, W. Sun. Ziv-aflibercept in metastatic colorectal cancer. „Biologics”. 8, s. 13–25, 2014. DOI: 10.2147/BTT.S39360. PMID: 24368879. 
  • E. Van Cutsem, J. Tabernero, R. Lakomy, H. Prenen i inni. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. „J Clin Oncol”. 30 (28), s. 3499–3506, październik 2012. DOI: 10.1200/JCO.2012.42.8201. PMID: 22949147. 
  • G. Goel, W. Sun. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting-its impact on clinical practice. „J Hematol Oncol”. 8, s. 92, 2015. DOI: 10.1186/s13045-015-0183-8. PMID: 26215324. 
  • J. Tabernero, T. Yoshino, A.L. Cohn, R. Obermannova i inni. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. „Lancet Oncol”. 16 (5), s. 499–508, maj 2015. DOI: 10.1016/S1470-2045(15)70127-0. PMID: 25877855. 
  • S.M. Ronnekleiv-Kelly, G.D. Kennedy. Management of stage IV rectal cancer: palliative options. „World J Gastroenterol”. 17 (7), s. 835–847, luty 2011. DOI: 10.3748/wjg.v17.i7.835. PMID: 21412493. 
  • R. Costi, F. Leonardi, D. Zanoni, V. Violi i inni. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. „World J Gastroenterol”. 20 (24), s. 7602–7621, czerwiec 2014. DOI: 10.3748/wjg.v20.i24.7602. PMID: 24976699. 
  • A. Tuca, E. Guell, E. Martinez-Losada, N. Codorniu. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. „Cancer Manag Res”. 4, s. 159–169, 2012. DOI: 10.2147/CMAR.S29297. PMID: 22904637. 
  • M. Winner, S.J. Mooney, D.L. Hershman, D.L. Feingold i inni. Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. „JAMA Surg”. 148 (8), s. 715–722, sierpień 2013. DOI: 10.1001/jamasurg.2013.1. PMID: 23740130. 
  • M.A. Mohd Suan, W.L. Tan, S.A. Soelar, I. Ismail i inni. Intestinal obstruction: predictor of poor prognosis in colorectal carcinoma?. „Epidemiol Health”. 37, s. e2015017, 2015. DOI: 10.4178/epih/e2015017. PMID: 25868638. 
  • L. Ansaloni, R.E. Andersson, F. Bazzoli, F. Catena i inni. Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. „World J Emerg Surg”. 5, s. 29, 2010. DOI: 10.1186/1749-7922-5-29. PMID: 21189148. 
  • A.M. Watt, I.G. Faragher, T.T. Griffin, N.A. Rieger i inni. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. „Ann Surg”. 246 (1), s. 24–30, lipiec 2007. DOI: 10.1097/01.sla.0000261124.72687.72. PMID: 17592286. 
  • X.D. Zhao, B.B. Cai, R.S. Cao, R.H. Shi. Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis. „World J Gastroenterol”. 19 (33), s. 5565–5574, wrzesień 2013. DOI: 10.3748/wjg.v19.i33.5565. PMID: 24023502. 
  • H. Ptok, F. Marusch, R. Steinert, L. Meyer i inni. Incurable stenosing colorectal carcinoma: endoscopic stent implantation or palliative surgery?. „World J Surg”. 30 (8), s. 1481–1487, sierpień 2006. DOI: 10.1007/s00268-005-0513-z. PMID: 16850152. 
  • H. Huhtinen, P. Varpe, J. Karvonen, A. Rantala i inni. Late complications related to palliative stenting in patients with obstructing colorectal cancer. „Minim Invasive Ther Allied Technol”. 22 (6), s. 352–358, grudzień 2013. DOI: 10.3109/13645706.2013.797911. PMID: 23758091. 
  • F. Bozzetti, L. Cozzaglio, E. Biganzoli, G. Chiavenna i inni. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. „Clin Nutr”. 21 (4), s. 281–288, sierpień 2002. PMID: 12135587. 
  • B.G. Fan. Parenteral nutrition prolongs the survival of patients associated with malignant gastrointestinal obstruction. „JPEN J Parenter Enteral Nutr”. 31 (6). s. 508–510. PMID: 17947608. 
  • N. Mandava, S. Kumar, W.F. Pizzi, I.J. Aprile. Perforated colorectal carcinomas. „Am J Surg”. 172 (3), s. 236–238, wrzesień 1996. PMID: 8862074. 
  • R.K. Portenoy, J. Miransky, H.T. Thaler, J. Hornung i inni. Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. „Cancer”. 70 (6), s. 1616–1624, wrzesień 1992. PMID: 1516015. 
  • R. Plancarte, O.A. de Leon-Casasola, M. El-Helaly, S. Allende i inni. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. „Reg Anesth”. 22 (6). s. 562–568. PMID: 9425974. 
  • A.M. Nitschke, C.E. Ray. Percutaneous neurolytic celiac plexus block. „Semin Intervent Radiol”. 30 (3), s. 318–321, wrzesień 2013. DOI: 10.1055/s-0033-1353485. PMID: 24436554. 
  • D.P. Seamans, G.Y. Wong, J.L. Wilson. Interventional pain therapy for intractable abdominal cancer pain. „J Clin Oncol”. 21 (9 Suppl), s. 92s-94s, maj 2003. DOI: 10.1200/JCO.2003.01.184. PMID: 12743207. 
  • C. Granda-Cameron, D. DeMille, M.P. Lynch, C. Huntzinger i inni. An interdisciplinary approach to manage cancer cachexia. „Clin J Oncol Nurs”. 14 (1), s. 72–80, luty 2010. DOI: 10.1188/10.CJON.72-80. PMID: 20118029. 
  • W.D. Dewys, C. Begg, P.T. Lavin, P.R. Band i inni. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. „Am J Med”. 69 (4), s. 491–497, październik 1980. PMID: 7424938. 
  • J.N. Gordon, S.R. Green, P.M. Goggin. Cancer cachexia. „QJM”. 98 (11), s. 779–788, listopad 2005. DOI: 10.1093/qjmed/hci127. PMID: 16214835. 
  • R. Dhanapal, T. Saraswathi, R.N. Govind. Cancer cachexia. „J Oral Maxillofac Pathol”. 15 (3), s. 257–260, wrzesień 2011. DOI: 10.4103/0973-029X.86670. PMID: 22144825. 
  • N.B. Kumar, A. Kazi, T. Smith, T. Crocker i inni. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. „Curr Treat Options Oncol”. 11 (3–4), s. 107–117, grudzień 2010. DOI: 10.1007/s11864-010-0127-z. PMID: 21128029. 
  • C.L. Donohoe, A.M. Ryan, J.V. Reynolds. Cancer cachexia: mechanisms and clinical implications. „Gastroenterol Res Pract”. 2011, s. 601434, 2011. DOI: 10.1155/2011/601434. PMID: 21760776. 
  • T. Aoyagi, K.P. Terracina, A. Raza, H. Matsubara i inni. Cancer cachexia, mechanism and treatment. „World J Gastrointest Oncol”. 7 (4), s. 17–29, kwiecień 2015. DOI: 10.4251/wjgo.v7.i4.17. PMID: 25897346. 
  • A. Inui. Cancer anorexia-cachexia syndrome: current issues in research and management. „CA Cancer J Clin”. 52 (2). s. 72–91. PMID: 11929007. 
  • D.C. McMillan, S.J. Wigmore, K.C. Fearon, P. O’Gorman i inni. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. „Br J Cancer”. 79 (3–4), s. 495–500, luty 1999. DOI: 10.1038/sj.bjc.6690077. PMID: 10027319. 
  • K. Lundholm, J. Gelin, A. Hyltander, C. Lönnroth i inni. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. „Cancer Res”. 54 (21), s. 5602–5606, listopad 1994. PMID: 7923204. 
  • L.C. Cerchietti, A.H. Navigante, M.A. Castro. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. „Nutr Cancer”. 59 (1), s. 14–20, 2007. DOI: 10.1080/01635580701365068. PMID: 17927497. 
  • C. Gridelli, C. Gallo, A. Ceribelli, V. Gebbia i inni. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. „Lancet Oncol”. 8 (6), s. 500–512, czerwiec 2007. DOI: 10.1016/S1470-2045(07)70146-8. PMID: 17513173. 
  • J. Reid, C.M. Hughes, L.J. Murray, C. Parsons i inni. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. „Palliat Med”. 27 (4), s. 295–303, kwiecień 2013. DOI: 10.1177/0269216312441382. PMID: 22450159. 
  • N. Nagaya, M. Kojima, K. Kangawa. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. „Intern Med”. 45 (3), s. 127–134, 2006. PMID: 16508225. 
  • M.D. DeBoer, D.L. Marks. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. „Nat Clin Pract Endocrinol Metab”. 2 (8), s. 459–466, sierpień 2006. DOI: 10.1038/ncpendmet0221. PMID: 16932335. 
  • J.M. Scarlett, D.L. Marks. The use of melanocortin antagonists in cachexia of chronic disease. „Expert Opin Investig Drugs”. 14 (10), s. 1233–1239, październik 2005. DOI: 10.1517/13543784.14.10.1233. PMID: 16185165. 
  • S. Busquets, M.T. Figueras, G. Fuster, V. Almendro i inni. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. „Cancer Res”. 64 (18), s. 6725–6731, wrzesień 2004. DOI: 10.1158/0008-5472.CAN-04-0425. PMID: 15374990. 
  • J.N. Gordon, T.M. Trebble, R.D. Ellis, H.D. Duncan i inni. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. „Gut”. 54 (4), s. 540–545, kwiecień 2005. DOI: 10.1136/gut.2004.047563. PMID: 15753541. 
  • F.G. Campos, A. Habr-Gama, S.C. Nahas, R.O. Perez i inni. Abdominoperineal excision: evolution of a centenary operation. „Dis Colon Rectum”. 55 (8), s. 844–853, sierpień 2012. DOI: 10.1097/DCR.0b013e31825ab0f7. PMID: 22810469. 
  • W.C. Hargrove, M.H. Gertner, W.T. Fitts, P. Kraske. The Kraske operation for carcinoma of the rectum. „Surg Gynecol Obstet”. 148 (6), s. 931–933, czerwiec 1979. PMID: 377528. 
  • R.J. Heald, E.M. Husband, R.D. Ryall. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?. „Br J Surg”. 69 (10), s. 613–616, październik 1982. PMID: 6751457. 
  • J. Yoo. Laparoscopic colorectal surgery. „Perm J”. 12 (1), s. 27–31, 2008. PMID: 21369509. 
  • J.R. Bertino. Chemotherapy of colorectal cancer: history and new themes. „Semin Oncol”. 24 (5 Suppl 18), s. S18-3-S18-7, październik 1997. PMID: 9420015. 
  • P. Seifert, L.H. Baker, M.L. Reed, V.K. Vaitkevicius. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. „Cancer”. 36 (1), s. 123–128, lipiec 1975. PMID: 1203840. 
  • J. Lokich. Infusional 5-FU: historical evolution, rationale, and clinical experience. „Oncology (Williston Park)”. 12 (10 Suppl 7), s. 19–22, październik 1998. PMID: 9830620. 
  • B.G. Czito, C.G. Willett. Thirty years of rectal cancer research: a brief history. „Oncology (Williston Park)”. 22 (12), s. 1441–1442, 1444, listopad 2008. PMID: 19322951. 
  • B. Gustavsson, G. Carlsson, D. Machover, N. Petrelli i inni. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. „Clin Colorectal Cancer”. 14 (1), s. 1–10, marzec 2015. DOI: 10.1016/j.clcc.2014.11.002. PMID: 25579803. 
  • E. Mini, F. Trave, Y.M. Rustum, J.R. Bertino. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. „Pharmacol Ther”. 47 (1), s. 1–19, 1990. PMID: 2195551. 
  • L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen i inni. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. „N Engl J Med”. 343 (13), s. 905–914, wrzesień 2000. DOI: 10.1056/NEJM200009283431302. PMID: 11006366. 
  • R.M. Goldberg, D.J. Sargent, R.F. Morton, C.S. Fuchs i inni. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. „J Clin Oncol”. 22 (1), s. 23–30, styczeń 2004. DOI: 10.1200/JCO.2004.09.046. PMID: 14665611. 
  • R.L. Johnson, J.C. Fleet. Animal models of colorectal cancer. „Cancer Metastasis Rev”. 32 (1–2), s. 39–61, czerwiec 2013. DOI: 10.1007/s10555-012-9404-6. PMID: 23076650. 
  • A. Velcich, W. Yang, J. Heyer, A. Fragale i inni. Colorectal cancer in mice genetically deficient in the mucin Muc2. „Science”. 295 (5560), s. 1726–1729, marzec 2002. DOI: 10.1126/science.1069094. PMID: 11872843. 
  • S.D. Taylor, N. Pusterla, B. Vaughan, M.B. Whitcomb i inni. Intestinal neoplasia in horses. „J Vet Intern Med”. 20 (6). s. 1429–1436. PMID: 17186861. 

onkologia.org.pl

oup.com

academic.oup.com

pharmacopola.pl

phie.pl

researchgate.net

sciencedirect.com

springer.com

link.springer.com

termedia.pl

vetpol.org.pl

viamedica.pl

journals.viamedica.pl

wcrf.org

web.archive.org

who.int

wiley.com

onlinelibrary.wiley.com

zalecenia.med.pl

onkologia.zalecenia.med.pl

  • Roman Herman, Jarosław Reguła, Jakub Pałucki, Wojciech Polkowski, Piotr Potemski: Rak okrężnicy. 2014.
  • Roman Herman, Jarosław Reguła, Jakub Pałucki, Wojciech Polkowski, Piotr Potemski: Rak odbytnicy. 2014.